



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmjjournals.com>).

If you have any questions on BMJ Open's open peer review process please email
info.bmjopen@bmj.com

BMJ Open

Screening Instruments for Mental Disorders in Primary Health Care: A Scoping Review (SCREENING-MD)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-084612
Article Type:	Protocol
Date Submitted by the Author:	23-Jan-2024
Complete List of Authors:	Lopes, Luis; Universidade da Sorocaba, Santos, Danielle Maria; University of Sorocaba; Federal University of Rio de Janeiro Silva, Jéssica Cumpian; University of Sorocaba Bergamaschi, Cristiane; University of Sorocaba, Pharmaceutical Science Moura, Mariana ; University of Sorocaba, Department of Pharmaceutical Sciences Okuyama, Julia; Universidade de Sorocaba, Post-Graduate Program of Pharmaceutical Science Lopes, Luciane; Universidade de Sorocaba, Pharmaceutical Science
Keywords:	Primary Health Care, MENTAL HEALTH, Mass Screening

SCHOLARONE™
Manuscripts

1 1 **Screening Instruments for Mental Disorders in Primary Health Care: a**
2 2 **scoping review (SCREENING-MD)**

3 3 **Luis Phillippe Nagem Lopes**

4 4 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
5 5 Sorocaba, São Paulo, Brazil
6 6 Email: luis.pharma20161@gmail.com

7 7 **Danielle Maria de Souza Serio dos Santos, PhD**

8 8 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
9 9 Sorocaba, São Paulo, Brazil
10 10 Institute of Pharmaceutical Sciences, Multidisciplinary Center. Federal
11 11 University of Rio de Janeiro, Macaé, Rio de Janeiro, Brazil.
12 12 Email: dani.farma84@gmail.com

13 13 **Jéssica Cumpian Silva, PhD**

14 14 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
15 15 Sorocaba, São Paulo, Brazil
16 16 Email: jesscumpian@gmail.com

17 17 **Mariana Del Grossi, PhD**

18 18 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
19 19 Sorocaba, São Paulo, Brazil
20 20 Email: maridelgrossi@gmail.com

21 21 **Cristiane de Cássia Bergamaschi, PhD**

22 22 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
23 23 Sorocaba, São Paulo, Brazil
24 24 E-mail: cristiane.motta@prof.uniso.br

25 25 **Julia Hiromi Hori Okuyama, PhD**

26 26 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
27 27 Sorocaba, São Paulo, Brazil
28 28 Email: jhhokuyama@gmail.com

29 29 **Luciane Cruz Lopes, PhD**

30 30 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
31 31 Sorocaba, São Paulo, Brazil

33 33 ***Corresponding author:**

34 34 Luciane Cruz Lopes – luciane.lopes@prof.uniso.br; luslopesbr@gmail.com
35 35 Graduate Course in Pharmaceutical Sciences, University of Sorocaba, UNISO,
36 36 Brazil
37 37 Rodovia Raposo Tavares, KM 92,5 - Sorocaba, São Paulo, Brazil
38 38 ZIP Code: 18023-000
39 39 Phone: 55 19 99781-8441 Fax: 55 15 2101-7074

ABSTRACT

Introduction: When mental disorders go undetected until later stages, they can result in poorer health outcomes for patients. Primary Health Care (PHC) stands as a strategic setting for the early identification and management of these mental disorders, given its role as the primary care environment for health service users. This scoping review has the objective is mapping and assessing screening instruments validated for mental disorders that are applicable in PHC, particularly regarding their measurement properties.

Methods and Analysis: This scoping review will include studies that have developed and validated screening instruments for mental disorders applicable within PHC, irrespective of the age group. Searches will be conducted in Medline, Embase, Lilacs, CINAHL, and PsycINFO, without imposing restrictions on publication status, publication year, or language. Additionally, we will explore the gray literature through Google Scholar and scrutinize the references cited in the selected studies. Our inclusion criteria encompass studies examining any measurement property recommended by the Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) taxonomy. The selection process, data extraction, and quality assessment of studies will be performed independently by pairs of reviewers. To evaluate the risk of bias within the selected studies, we will employ the COSMIN Risk of Bias 2 tools. The collected data will undergo analysis using descriptive statistics and will be presented in an evidence gap map format for each specific mental disorder.

Ethics and dissemination: The findings from this review will be discussed through deliberative dialogue with stakeholders and disseminated through peer-reviewed publications and conference presentations. The project was approved by the Ethics Committee for Research at the University of Sorocaba (number: 66993323.9.0000.5500).

Protocol Registration: Open Science Framework – 10.17605/OSF.IO/Z6T5M

Keywords: Mental Disorders. Primary Health Care. Screening. Scoping Review.

1 2 70 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 3
4 71 • This scoping review is the first to map and analyze screening instruments
5 72 validated for Mental Disorders in Primary Health Care;
6
7 73 • The findings of this study will be with relevant stakeholders through a
8 74 deliberative dialogue;
9
10 75 • The study follows important guidelines like the Consensus-based
11 76 Standards for the selection of health Measurement Instruments (COSMIN)
12 77 initiative and Joanna Briggs, to ensure robust methodology;
13
14 78 • Significant gaps will be identified to establish a comprehensive research
15 79 agenda regarding screening instruments for mental disorders;
16
17 80 • Heterogeneous reporting in psychometric studies and instances of missing
18 81 data might restrict the outcomes of this study.

1 2 82 INTRODUCTION 3 4

5 83 One out of every eight individuals worldwide has received a diagnosis of a mental
6 84 disorder, amounting to 970 million people [1]. In 2020, the estimates surged by
7 85 over 20%, primarily for anxiety and depressive disorders, due to the impact of the
8 86 COVID-19 pandemic [1]. Despite the existence of treatment options for various
9 87 mental disorders, their recognition remains challenging, primarily due to stigma,
10 88 insufficient professional training, and a shortage of validated screening
11 89 instruments [2].
12

13 90 Primary Health Care (PHC) serves as the primary entry point into health systems,
14 91 typically where patients seek care most often, playing a crucial role in ensuring
15 92 universal healthcare, accessible, and equitable for the population [3]. When it
16 93 comes to mental health, PHC has been instrumental in reducing the stigma and
17 94 discrimination associated with mental disorders, enhancing healthcare access,
18 95 reducing the long-term impact of mental disorders, and promoting social
19 96 integration [4]. As a result, PHC stands as a vital setting for the implementation
20 97 of mental disorder screening.
21

22 98 Screening for mental disorders in PHC has been encouraged because late
23 99 identification leads to poorer health outcomes [5]. It's important to note, however,
24 100 that PHC lacks systematic methods for tracking mental disorders, leading to
25 101 inaccuracies in results primarily due to missed or incorrect diagnoses, owing to
26 102 the complexity of mental disorders [6,7]. Therefore, implementing suitable
27 103 instruments is the initial step towards integrating mental disorder screening into
28 104 the existing PHC services.
29

30 105 Instruments that are validated and consistent are crucial for the implementation
31 106 of screening in PHC. In recent years, many screening instruments for mental
32 107 disorders have been developed, but little is known about the measurement
33 108 properties that have been evaluated [8]. Moreover, when it comes to low- and
34 109 middle-income countries, there are concerns about whether the development
35 110 process of these instruments is suitable for this population. A recent systematic
36 111 review revealed that the instruments designed for screening mental disorders are
37 112 validated in local contexts, and these validations leave gaps in the applicability of
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

113 these instruments in other countries, particularly those with low and middle
114 incomes [9].

115 This scoping review has the objective of both mapping and assessing screening
116 instruments for mental disorders that are applicable in PHC, particularly regarding
117 their measurement properties.

118 **METHODS**

119 **Study design and registry**

120 **Figure 1** illustrates the steps to be undertaken in this scoping review. Our scoping
121 review will adhere to the guidelines by Joanna Briggs and the Consensus-based
122 Standards for the selection of health Measurement Instruments (COSMIN)
123 systematic reviews manual [10,11]. The study's protocol is accessible on the
124 Open Science Framework [12]. The protocol was documented following the
125 Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension
126 for Scoping Reviews (PRISMA-ScR) Checklist (adapted for protocol)
127 (**Supplementary Material 1**) [13].

128 [Figure 1. Flow of conducting the scoping review]

129 **Eligibility criteria**

130 The research question was structured following the key components typically
131 used in reviews of health measurement instruments [11], including:

132 **Construct**

133 We will consider studies that primarily focus on the screening of specific mental
134 disorders, including eating disorders (ICD F50), anxiety disorders (ICD F40-41),
135 mood disorders (ICD F30-39), substance use disorders (ICD F10-19), and
136 psychotic disorders (ICD F20-29). These disorders were selected due to their
137 higher prevalence.

138 **Population**

139 We will include studies involving individuals of various age groups, genders, and
140 geographic locations who exhibit one or more risk factors for mental disorders,
141 including eating disorders (ICD F50), anxiety disorders (ICD F40-41), mood

1
2
3 142 disorders (ICD F30-39), substance use disorders (ICD F10-19), and psychotic
4 143 disorders (ICD F20-29).
5
6

7 144 **Types of Instruments and Measurement Properties of Interest**
8
9

10 145 Studies will be considered without restrictions on the specific measurement
11 146 property under examination or the method of administration. Multidimensional
12 147 instruments will also be eligible for inclusion.
13
14

15 148 **Context**
16
17

18 149 Studies conducted in primary care settings or those that do not specify the care
19 150 context will be incorporated. As a result, instruments developed and validated for
20 151 specialized care or psychiatric inpatient settings will be excluded.
21
22

23 152 **Information Sources**
24
25

26 153 The consulted databases will be MEDLINE (via PubMed), Embase, Lilacs (via
27 154 Virtual Health Library Portal), PsycINFO, and CINAHL. Other information sources
28 155 will also be consulted, including gray literature from Google Scholar and the
29 156 reference lists of included studies. No restrictions on language or year of
30 157 publication will be applied. If necessary, specialized translation services will be
31 158 consulted for languages that are not readable by the team.
32
33

34 159 **Search Strategy**
35
36

37 160 To validate the search strategy, double-checking will be conducted using Peer
38 161 Review of Electronic Search Strategies (PRESS) [14]. A specialized librarian will
39 162 validate it, and modifications will be made if necessary. **Supplementary Material**
40 163 1 describes the search strategy for each information source. Given the substantial
41 164 volume of studies on screening instruments for mental disorders, we applied a
42 165 developed and validated methodological filter to identify instruments [15].
43
44

45 166 **Study selection and data extraction**
46
47

48 167 The selection process will involve pairs of reviewers, resolving any
49 168 disagreements through consensus. This process will occur in two stages: initially
50 169 screening based on title and abstract, followed by the assessment of full-text
51 170 articles using Rayyan software (Step 1) and Microsoft Excel 2016 (Step 2) [16].
52 171 Reviewer calibration will precede the selection process, which includes the initial
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

172 assessment of 50 randomly chosen titles and abstracts in the first stage, followed
173 by 10 full-text articles. A reviewer will be considered qualified if they accurately
174 select at least 75% of the calibration set, as recommended in the manuals [10].

175 The data extraction process will similarly involve two independent reviewers, and
176 the calibration will follow a process akin to that previously described for selection.
177 At this stage, within an Excel spreadsheet, reviewers will extract the following
178 information:

179 Part 1. Study characteristics: author, year, number of participants; number and
180 percentage of female participants; average or median age; and whether the
181 instrument was designed for use in primary care (yes/no);

182 Part 2. Characteristics of the instruments: name of the instrument; acronym or
183 abbreviation of the instrument; method of administration; administration time;
184 number of items; number of dimensions; whether cross-cultural adaptation was
185 performed (yes/no), if yes, specify the culture.

186 Part 3. Measurement properties: Studies will be categorized based on the
187 measurement properties outlined in the COSMIN taxonomy [17]. This taxonomy
188 categorizes studies according to the following properties: reliability, validity,
189 responsiveness, and interpretability.

190 **Risk of bias**

191 The risk of bias assessment will be conducted using the COSMIN Risk of Bias
192 checklist tool, which evaluates instruments based on their measurement
193 properties [18]. The COSMIN Risk of Bias checklist tool assesses instruments
194 based on the methodological quality of the psychometric steps conducted in the
195 studies. In other words, when we utilize the COSMIN Risk of Bias checklist tool
196 to assess studies, we inherently appraise the psychometric properties of the
197 instrument. While it was primarily developed for Patient-Reported Outcome
198 Measures (PROM), it can also be employed for other psychometric instruments
199 [18]. Two reviewers will independently conduct the assessment, and any
200 discrepancies will be resolved through consensus.

201 **Data synthesis**

1
2
3 202 The data will be analyzed using descriptive statistics via Stata (version 14.2)
4 203 software. For better visualization, the results will be presented in bubble and heat
5 204 maps, categorizing them based on the methodological quality of instrument
6 205 development and the assessed measurement properties.
7
8
9

10 206 **Patient and public involvement: deliberative dialogue**
11
12

13 207 We will conduct a deliberative dialogue with stakeholders to discuss barriers and
14 208 facilitators for implementing screening in PHC. A convenience sample of health
15 209 professionals working in primary care, representatives from the Brazilian Ministry
16 210 of Health, and researchers will be recruited via email. The deliberative dialogue
17 211 will be held virtually, following the recommendations outlined in the SUPPORT
18 212 tools [19].
19
20
21
22

23 213 A plain language summary of the scoping review will be disseminated to
24 214 interested parties 15 days before the dialogue. The organization of the
25 215 deliberative dialogue will be as follows: the initial 15 minutes of the dialogue will
26 216 focus on presenting a thorough overview of the scoping review findings.
27 217 Subsequently, discussions will revolve around barriers, facilitators, and the
28 218 utilization of screening instruments in PHC in Brazil. After the deliberative
29 219 dialogue, interested parties will evaluate the scoping review using a checklist
30 220 developed by Lavis (2009) [19].
31
32
33
34
35
36
37

38 221 **Ethical aspects**
39
40

41 222 The project was approved by the Ethics Committee for Research at the University
42 223 of Sorocaba (number: 66993323.9.0000.5500). As the deliberative dialogue will
43 224 involve human participants, a free and informed consent form will be provided in
44 225 advance and completed by the research participants.
45
46
47

48 226 **DISCUSSION**
49
50

51 227 This is the first scoping review to chart screening instruments for mental disorders
52 228 in PHC, involving their measurement properties and assessing bias risks. In this
53 229 context, this work, employing an innovative knowledge translation methodology
54 230 involving deliberative dialogue, holds the potential to assist healthcare
55 231 professionals, managers, and researchers in making evidence-informed
56 232 decisions regarding the implementation of validated screening instruments within
57
58
59
60

1
2
3 PHC. Furthermore, our findings will facilitate the identification of limitations in the
4 developed instruments, enabling the proposal of research agendas that prioritize
5 robust psychometric studies on screening instruments for mental disorders,
6 aiming to create instruments beneficial for clinical practice.
7
8

9
10 Although our work adhered to all methodological guidelines, potential limitations
11 may arise due to the heterogeneity in reporting concerning the development of
12 screening instruments for mental disorders. Consequently, reviewers may need
13 to conduct subjective assessments to evaluate the risk of bias and categorize
14 instruments, aligning with the guidelines outlined in the COSMIN Manual [11].
15 Furthermore, incomplete data, particularly concerning contextual information
16 about these instruments within care settings, can present challenges in data
17 extraction.
18
19

20 Therefore, the methodological rigor of our scoping review, combined with the
21 knowledge translation strategy employing deliberative dialogue, can promote the
22 integration of scientific evidence into clinical practice and the screening of mental
23 disorders in PHC. Moreover, the identified research gaps can serve as a
24 foundation for new studies on these instruments. Additionally, utilizing COSMIN's
25 international taxonomy and methodological recommendations can raise
26 awareness among researchers about the effective utilization of these validated
27 instruments for measuring outcomes in the healthcare domain [17].
28
29

30 253 AUTHOR CONTRIBUTIONS 31

32 LPNL is the principal investigator, responsible for drafting the protocol and final
33 version. The other authors (DMSSS, JCS, MDG, CCB, JHHO and LCL) reviewed
34 the content and provided significant edits to the final version. LCL serves as the
35 review guarantor, offering advice on the background, contributing to protocol
36 drafting, and revising the manuscript.
37
38

39 259 ACKNOWLEDGEMENTS 40

41 The authors wish to express their gratitude to the health evidence team at the
42 Department of Science and Technology for their invaluable assistance in
43 formulating the research question and devising the search strategy. Additionally,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3 263 librarian Mabel Figueiró deserves appreciation for validating the search strategy
4 264 and making necessary corrections.
5
6
7 265 **FUNDING**
8
9
10 266 Our research was supported by funding from the Ministry of Health of Brazil
11 267 (MoH) and the National Council for Scientific and Technological Development
12 268 (CNPq), under grant number 408237/2022-8. Additionally, this project received
13 269 funding from the Coordination for the Improvement of Higher Education
14 270 Personnel (CAPES)—PROSUC—CAPES/UNISO. Unfortunately, no specific
15 271 grant number is applicable for this support.
16
17
18
19

20 272 **COMPETING INTERESTS**
21
22
23 273 None to declare.
24
25
26 274 **WORD COUNT**
27
28 275 1,723.
29
30
31 276 **References**
32
33 277 1 Mental disorders. <https://www.who.int/news-room/fact-sheets/detail/mental-disorders> (accessed 23 November 2023)
34
35
36 279 2 Wakida EK, Talib ZM, Akena D, et al. Barriers and facilitators to the
37 280 integration of mental health services into primary health care: a systematic
38 281 review. *Syst Rev.* 2018;7:211.
39
40
41 282 3 Hall JJ, Taylor R. Health for all beyond 2000: the demise of the Alma-Ata
42 283 Declaration and primary health care in developing countries. *Med J Aust.*
43 284 2003;178:17–20.
44
45 285 4 Mulvaney-Day N, Marshall T, Downey Piscopo K, et al. Screening for
46 286 Behavioral Health Conditions in Primary Care Settings: A Systematic Review of
47 287 the Literature. *J Gen Intern Med.* 2018;33:335–46.
48
49
50 288 5 AACAP. Mental Health Screening in Primary Care.
51 289 [https://www.aacap.org/AACAP/Policy_Statements/2019/Mental-Health-](https://www.aacap.org/AACAP/Policy_Statements/2019/Mental-Health-Screening-Primary-Care.aspx)
52 290 [Screening-Primary-Care.aspx](https://www.aacap.org/AACAP/Policy_Statements/2019/Mental-Health-Screening-Primary-Care.aspx) (accessed 23 November 2023)
53
54
55 291 6 Loeb DF, Bayliss EA, Binswanger IA, et al. Primary care physician
56 292 perceptions on caring for complex patients with medical and mental illness. *J Gen Intern Med.* 2012;27:945–52.
57
58
59 294 7 Rogers R, Hartigan SE, Sanders CE. Identifying Mental Disorders in
60 295 Primary Care: Diagnostic Accuracy of the Connected Mind Fast Check (CMFC)
296 Electronic Screen. *J Clin Psychol Med Settings.* 2021;28:882–96.

- 1
2
3 297 8 Fotheringham L, Paddick S-M, Barron Millar E, et al. Screening tools for
4 common mental disorders in older adults in South Asia: a systematic scoping
5 review. *Int Psychogeriatr.* 2022;34:427–38.
6
7 300 9 Ali G-C, Ryan G, De Silva MJ. Validated Screening Tools for Common
8 Mental Disorders in Low and Middle Income Countries: A Systematic Review.
9 *PLoS One.* 2016;11:e0156939.
10
11 303 10 Chapter 11: Scoping reviews - JBI Manual for Evidence Synthesis - JBI
12 Global Wiki. [https://jbi-global-](https://jbi-global-wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews)
13 [wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews](https://jbi-global-wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews)
14 (accessed 4 January 2023)
15
16
17 307 11 Guideline for Systematic Reviews of Outcome Measurement Instruments
18 • COSMIN. COSMIN. [https://www.cosmin.nl/tools/guideline-conducting-](https://www.cosmin.nl/tools/guideline-conducting-systematic-review-outcome-measures/)
19 [systematic-review-outcome-measures/](https://www.cosmin.nl/tools/guideline-conducting-systematic-review-outcome-measures/) (accessed 24 November 2023)
20
21 310 12 Lopes LPN. SCREENING MD Study: protocol. Published Online First: 24
22 November 2023.
23
24
25 312 13 Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping
26 Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.*
27 2018;169:467–73.
28
29 315 14 McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of
30 Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical*
31 *Epidemiology.* 2016;75:40–6.
32
33
34 318 15 Terwee CB, Jansma EP, Riphagen II, et al. Development of a
35 methodological PubMed search filter for finding studies on measurement
36 properties of measurement instruments. *Qual Life Res.* 2009;18:1115–23.
37
38 321 16 Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and
39 mobile app for systematic reviews. *Systematic Reviews.* 2016;5:210.
40
41 323 17 Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached
42 international consensus on taxonomy, terminology, and definitions of
43 measurement properties for health-related patient-reported outcomes. *J Clin*
44 *Epidemiol.* 2010;63:737–45.
45
46
47 327 18 Mokkink LB, de Vet HCW, Prinsen C a. C, et al. COSMIN Risk of Bias
48 checklist for systematic reviews of Patient-Reported Outcome Measures. *Qual*
49 *Life Res.* 2018;27:1171–9.
50
51
52 330 19 Lavis JN, Oxman AD, Lewin S, et al. SUPPORT Tools for evidence-
53 informed health Policymaking (STP). *Health Res Policy Syst.* 2009;7 Suppl 1:1.
54
55
56
57
58
59
60

1
2
3 335
4
5 336
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Supplementary Material 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

Adapted to protocol

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	5-6
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	6
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	6-7
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	7 and Supplementary Material 2
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	8
Critical appraisal of individual	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe	8



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
sources of evidence§		the methods used and how this information was used in any data synthesis (if appropriate).	
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	9

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850).



1
2
3
4
5
6
Supplementary Material 2: Search strategies employed in each consulted
7 database.
8

9
MEDLINE (Via Pubmed)
10

- 11 1. "Mental Disorder*"
12 2. "Psychiatric Illness**"
13 3. "Psychiatric* Disease"
14 4. "Mental Illness"
15 5. "Mental Illnesses"
16 6. "Psychiatric Disorder**"
17 7. "Behavior Disorders"
18 8. "Psychiatric Diagnosis"
19 9. "Severe Mental Disorder**"
20 10. "Psychotic Disorder**"
21 11. Psychos*
22 12. "Schizoaffective Disorder***"
23 13. "Schizophreniform Disorder**"
24 14. "Brief Reactive Psychos*"
25 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
26 16. "Schizophrenia, Paranoid"
27 17. "Paranoid Schizophrenias"
28 18. "Schizophrenias, Paranoid"
29 19. "Paranoid Schizophrenia"
30 20. "Delusional Disorder"
31 21. "Delusional Disorders"
32 22. "Disorder, Delusional"
33 23. "Disorders, Delusional"
34 24. "Schizophrenia, Disorganized"
35 25. "Disorganized Schizophrenia"
36 26. "Disorganized Schizophrenias"
37 27. "Schizophrenias, Disorganized"
38 28. "Hebephrenic Schizophrenia"
39 29. "Hebephrenic Schizophrenias"
40 30. "Schizophrenias, Hebephrenic"
41 31. "Schizophrenia, Hebephrenic"
42 32. "Schizophrenia, Catatonic"
43 33. "Catatonic Schizophrenia"
44 34. "Catatonic Schizophrenias"
45 35. "Schizophrenias, Catatonic***"
46 36. "Mood Disorder*"
47 37. "Disorder, Mood"
48 38. "Disorders, Mood"
49 39. "Affective Disorder**"
50 40. "Disorder, Affective"
51 41. "Disorders, Affective"
52 42. Mania*
53 43. "Manic State"
54 44. "Hypomanic Episode"
55 45. "Hypomanic Episodes"
56 46. Hypomania*
57 47. "Manic Episode"
58 48. "Episode, Manic"
59
60

- 1
2
3 49. "Manic Episodes"
4 50. "Bipolar Disorder"
5 51. "Bipolar Disorders"
6 52. "Psychosis, Manic-Depressive"
7 53. "Psychosis, Manic Depressive"
8 54. "Psychoses, Manic-Depressive"
9 55. "Psychoses, Manic Depressive"
10 56. "Manic-Depressive Psychosis"
11 57. "Manic Depressive Psychosis"
12 58. "Bipolar Mood Disorder"
13 59. "Bipolar Mood Disorders"
14 60. "Disorder, Bipolar Mood"
15 61. "Mood Disorder, Bipolar"
16 62. "Affective Psychosis, Bipolar"
17 63. "Bipolar Affective Psychosis"
18 64. "Psychoses, Bipolar Affective"
19 65. "Psychosis, Bipolar Affective"
20 66. "Bipolar Disorder Type 1"
21 67. "Type 1 Bipolar Disorder"
22 68. "Manic Depression"
23 69. "Depression, Manic"
24 70. "Depressions, Manic"
25 71. "Depression, Bipolar"
26 72. "Bipolar Depression"
27 73. "Bipolar Disorder Type 2"
28 74. "Type 2 Bipolar Disorder" OR
29 75. "Manic Disorder"
30 76. "Disorder, Manic"
31 77. "Manic Disorders"
32 78. "Anxiety Disorder**"
33 79. "Disorder, Anxiety"
34 80. "Disorders, Anxiety"
35 81. "Neuroses, Anxiety"
36 82. "Anxiety Neuroses"
37 83. "Anxiety States, Neurotic"
38 84. "Anxiety State, Neurotic"
39 85. "Neurotic Anxiety State"
40 86. "Neurotic Anxiety States"
41 87. "State, Neurotic Anxiety"
42 88. "States, Neurotic Anxiety"
43 89. "Phobia, Social" OR "Social Phobia**"
44 90. "Social Evaluation Phobia"
45 91. "Phobia, Social Evaluation"
46 92. "Social Evaluation Phobias"
47 93. "Social Anxiety Disorder"
48 94. "Anxiety Disorder, Social"
49 95. "Disorder, Social Anxiety"
50 96. "Social Anxiety Disorders"
51 97. "Sociophobia*"
52 98. "Fear of Social Evaluation"
53 99. "Evaluation Fear, Social"
54 100. "Social Evaluation Fear"
55 101. "Feeding and Eating Disorders"
56 102. "Eating and Feeding Disorders"
57 103. "Feeding Disorders"
58 104. "Disorder, Feeding"

- 1
2
3 105. "Disorders, Feeding"
4 106. "Feeding Disorder"
5 107. "Eating Disorders"
6 108. "Disorder, Eating"
7 109. "Disorders, Eating"
8 110. "Eating Disorder"
9 111. "Appetite Disorders"
10 112. "Appetite Disorder"
11 113. "Anorexia Nervosa"
12 114. "Anorexia Nervosas"
13 115. "Nervosa, Anorexia"
14 116. "Nervosas, Anorexia"
15 117. "Bulimia Nervosa"
16 118. "Nervosa, Bulimia"
17 119. "Substance-Related Disorder*"
18 120. "Disorder, Substance Related"
19 121. "Disorders, Substance Related"
20 122. "Related Disorder, Substance"
21 123. "Related Disorders, Substance"
22 124. "Drug Use Disorders"
23 125. "Drug Use Disorder"
24 126. "Disorder, Drug Use"
25 127. "Organic Mental Disorders, Substance-Induced"
26 128. "Organic Mental Disorders, Substance Induced"
27 129. "Substance Abuse"
28 130. "Abuse, Substance"
29 131. "Substance Abuses"
30 132. "Substance Dependence"
31 133. "Dependence, Substance"
32 134. "Substance Addiction"
33 135. "Addiction, Substance"
34 136. "Chemical Dependence"
35 137. "Chemical Dependences"
36 138. "Dependence, Chemical"
37 139. "Dependences, Chemical"
38 140. "Drug Dependence"
39 141. "Dependence, Drug"
40 142. "Drug Addiction"
41 143. "Addiction, Drug"
42 144. "Prescription Drug Abuse"
43 145. "Abuse, Prescription Drug"
44 146. "Drug Abuse, Prescription"
45 147. "Substance Use"
46 148. "Substance Uses"
47 149. "Use, Substance"
48 150. "Drug Abuse"
49 151. "Abuse, Drug"
50 152. "Drug Habituation"
51 153. "Habituation, Drug"
52 154. "Substance Use Disorders"
53 155. "Disorder, Substance Use"
54 156. "Substance Use Disorder"
55 157. or/1-157
56 158. "Mass Screening"
57 159. "Mass Screenings"
58 160. "Screening, Mass"

- 1
2
3 161. "Screenings, Mass"
4 162. Screening*
5 163. "Diagnostic Screening Programs"
6 164. "Diagnostic Screening Program"
7 165. "Program, Diagnostic Screening"
8 166. "Programs, Diagnostic Screening"
9 167. "Screening Program, Diagnostic"
10 168. "Screening Programs, Diagnostic"
11 169. or/158-168
12 170. COSMIN filter for identifying studies on the development of health measurement
13 instruments
14 171. #157 OR #169 OR 170
15

16 **EMBASE**
17

- 18 1. 'Mental Disorder*'
19 2. 'Psychiatric Illness*'
20 3. 'Psychiatric* Disease'
21 4. 'Mental Illness'
22 5. 'Mental Illnesses'
23 6. 'Psychiatric Disorder*'
24 7. 'Behavior Disorders'
25 8. 'Psychiatric Diagnosis'
26 9. 'Severe Mental Disorder*'
27 10. 'Psychotic Disorder**'
28 11. Psychos*
29 12. 'Schizoaffective Disorder***'
30 13. 'Schizophreniform Disorder*'
31 14. 'Brief Reactive Psychos*'
32 15. 'Schizophrenia Spectrum and Other Psychotic Disorders'
33 16. 'Schizophrenia, Paranoid'
34 17. 'Paranoid Schizophrenias'
35 18. 'Schizophrenias, Paranoid'
36 19. 'Paranoid Schizophrenia'
37 20. 'Delusional Disorder'
38 21. 'Delusional Disorders'
39 22. 'Disorder, Delusional'
40 23. 'Disorders, Delusional'
41 24. 'Schizophrenia, Disorganized'
42 25. 'Disorganized Schizophrenia'
43 26. 'Disorganized Schizophrenias'
44 27. 'Schizophrenias, Disorganized'
45 28. 'Hebephrenic Schizophrenia'
46 29. 'Hebephrenic Schizophrenias'
47 30. 'Schizophrenias, Hebephrenic'
48 31. 'Schizophrenia, Hebephrenic'
49 32. 'Schizophrenia, Catatonic'
50 33. 'Catatonic Schizophrenia'
51 34. 'Catatonic Schizophrenias'
52 35. 'Schizophrenias, Catatonic"
53 36. 'Mood Disorder*'
54 37. 'Disorder, Mood'
55 38. 'Disorders, Mood'
56 39. 'Affective Disorder*'
57 40. 'Disorder, Affective'
58 41. 'Disorders, Affective'
59 42. Mania*
60

- 1
2
3 43. 'Manic State'
4 44. 'Hypomanic Episode'
5 45. 'Hypomanic Episodes'
6 46. Hypomania*
7 47. 'Manic Episode'
8 48. 'Episode, Manic'
9 49. 'Manic Episodes'
10 50. 'Bipolar Disorder'
11 51. 'Bipolar Disorders'
12 52. 'Psychosis, Manic-Depressive'
13 53. 'Psychosis, Manic Depressive'
14 54. 'Psychoses, Manic-Depressive'
15 55. 'Psychoses, Manic Depressive'
16 56. 'Manic-Depressive Psychosis'
17 57. 'Manic Depressive Psychosis'
18 58. 'Bipolar Mood Disorder'
19 59. 'Bipolar Mood Disorders'
20 60. 'Disorder, Bipolar Mood'
21 61. 'Mood Disorder, Bipolar'
22 62. 'Affective Psychosis, Bipolar'
23 63. 'Bipolar Affective Psychosis'
24 64. 'Psychoses, Bipolar Affective'
25 65. 'Psychosis, Bipolar Affective'
26 66. 'Bipolar Disorder Type 1'
27 67. 'Type 1 Bipolar Disorder'
28 68. 'Manic Depression'
29 69. 'Depression, Manic'
30 70. 'Depressions, Manic'
31 71. 'Depression, Bipolar'
32 72. 'Bipolar Depression'
33 73. 'Bipolar Disorder Type 2'
34 74. 'Type 2 Bipolar Disorder' OR
35 75. 'Manic Disorder'
36 76. 'Disorder, Manic'
37 77. 'Manic Disorders'
38 78. 'Anxiety Disorder**'
39 79. 'Disorder, Anxiety'
40 80. 'Disorders, Anxiety'
41 81. 'Neuroses, Anxiety'
42 82. 'Anxiety Neuroses'
43 83. 'Anxiety States, Neurotic'
44 84. 'Anxiety State, Neurotic'
45 85. 'Neurotic Anxiety State'
46 86. 'Neurotic Anxiety States'
47 87. 'State, Neurotic Anxiety'
48 88. 'States, Neurotic Anxiety'
49 89. 'Phobia, Social' OR 'Social Phobia*'
50 90. 'Social Evaluation Phobia'
51 91. 'Phobia, Social Evaluation'
52 92. 'Social Evaluation Phobias'
53 93. 'Social Anxiety Disorder'
54 94. 'Anxiety Disorder, Social'
55 95. 'Disorder, Social Anxiety'
56 96. 'Social Anxiety Disorders'
57 97. 'Sociophobia*'
58 98. 'Fear of Social Evaluation'

- 1
2
3 99. 'Evaluation Fear, Social'
4 100. 'Social Evaluation Fear'
5 101. 'Feeding and Eating Disorders'
6 102. 'Eating and Feeding Disorders'
7 103. 'Feeding Disorders'
8 104. 'Disorder, Feeding'
9 105. 'Disorders, Feeding'
10 106. 'Feeding Disorder'
11 107. 'Eating Disorders'
12 108. 'Disorder, Eating'
13 109. 'Disorders, Eating'
14 110. 'Eating Disorder'
15 111. 'Appetite Disorders'
16 112. 'Appetite Disorder'
17 113. 'Anorexia Nervosa'
18 114. 'Anorexia Nervosas'
19 115. 'Nervosa, Anorexia'
20 116. 'Nervosas, Anorexia'
21 117. 'Bulimia Nervosa'
22 118. 'Nervosa, Bulimia'
23 119. 'Substance-Related Disorder*'
24 120. 'Disorder, Substance Related'
25 121. 'Disorders, Substance Related'
26 122. 'Related Disorder, Substance'
27 123. 'Related Disorders, Substance'
28 124. 'Drug Use Disorders'
29 125. 'Drug Use Disorder'
30 126. 'Disorder, Drug Use'
31 127. 'Organic Mental Disorders, Substance-Induced'
32 128. 'Organic Mental Disorders, Substance Induced'
33 129. 'Substance Abuse'
34 130. 'Abuse, Substance'
35 131. 'Substance Abuses'
36 132. 'Substance Dependence'
37 133. 'Dependence, Substance'
38 134. 'Substance Addiction'
39 135. 'Addiction, Substance'
40 136. 'Chemical Dependence'
41 137. 'Chemical Dependences'
42 138. 'Dependence, Chemical'
43 139. 'Dependences, Chemical'
44 140. 'Drug Dependence'
45 141. 'Dependence, Drug'
46 142. 'Drug Addiction'
47 143. 'Addiction, Drug'
48 144. 'Prescription Drug Abuse'
49 145. 'Abuse, Prescription Drug'
50 146. 'Drug Abuse, Prescription'
51 147. 'Substance Use'
52 148. 'Substance Uses'
53 149. 'Use, Substance'
54 150. 'Drug Abuse'
55 151. 'Abuse, Drug'
56 152. 'Drug Habituation'
57 153. 'Habituation, Drug'
58 154. 'Substance Use Disorders'

- 1
2
3 155. 'Disorder, Substance Use'
4 156. 'Substance Use Disorder'
5 157. or/1-157
6 158. 'Mass Screening'
7 159. 'Mass Screenings'
8 160. 'Screening, Mass'
9 161. 'Screenings, Mass'
10 162. Screening*
11 163. 'Diagnostic Screening Programs'
12 164. 'Diagnostic Screening Program'
13 165. 'Program, Diagnostic Screening'
14 166. 'Programs, Diagnostic Screening'
15 167. 'Screening Program, Diagnostic'
16 168. 'Screening Programs, Diagnostic'
17 169. or/158-168
18 170. COSMIN filter for identifying studies on the development of health measurement
19 instruments
20 171. #157 OR #169 OR 170
21
22

PsycINFO

- 24 1. "Mental Disorder**"
25 2. "Psychiatric Illness**"
26 3. "Psychiatric* Disease"
27 4. "Mental Illness"
28 5. "Mental Illnesses"
29 6. "Psychiatric Disorder**"
30 7. "Behavior Disorders"
31 8. "Psychiatric Diagnosis"
32 9. "Severe Mental Disorder**"
33 10. "Psychotic Disorder**"
34 11. Psychos*
35 12. "Schizoaffective Disorder****"
36 13. "Schizophreniform Disorder**"
37 14. "Brief Reactive Psychos**"
38 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
39 16. "Schizophrenia, Paranoid"
40 17. "Paranoid Schizophrenias"
41 18. "Schizophrenias, Paranoid"
42 19. "Paranoid Schizophrenia"
43 20. "Delusional Disorder"
44 21. "Delusional Disorders"
45 22. "Disorder, Delusional"
46 23. "Disorders, Delusional"
47 24. "Schizophrenia, Disorganized"
48 25. "Disorganized Schizophrenia"
49 26. "Disorganized Schizophrenias"
50 27. "Schizophrenias, Disorganized"
51 28. "Hebephrenic Schizophrenia"
52 29. "Hebephrenic Schizophrenias"
53 30. "Schizophrenias, Hebephrenic"
54 31. "Schizophrenia, Hebephrenic"
55 32. "Schizophrenia, Catatonic"
56 33. "Catatonic Schizophrenia"
57 34. "Catatonic Schizophrenias"
58 35. "Schizophrenias, Catatonic***"
59 36. "Mood Disorder**"
60

- 1
2
3 37. "Disorder, Mood"
4 38. "Disorders, Mood"
5 39. "Affective Disorder**"
6 40. "Disorder, Affective"
7 41. "Disorders, Affective"
8 42. Mania*
9 43. "Manic State"
10 44. "Hypomanic Episode"
11 45. "Hypomanic Episodes"
12 46. Hypomania*
13 47. "Manic Episode"
14 48. "Episode, Manic"
15 49. "Manic Episodes"
16 50. "Bipolar Disorder"
17 51. "Bipolar Disorders"
18 52. "Psychosis, Manic-Depressive"
19 53. "Psychosis, Manic Depressive"
20 54. "Psychoses, Manic-Depressive"
21 55. "Psychoses, Manic Depressive"
22 56. "Manic-Depressive Psychosis"
23 57. "Manic Depressive Psychosis"
24 58. "Bipolar Mood Disorder"
25 59. "Bipolar Mood Disorders"
26 60. "Disorder, Bipolar Mood"
27 61. "Mood Disorder, Bipolar"
28 62. "Affective Psychosis, Bipolar"
29 63. "Bipolar Affective Psychosis"
30 64. "Psychoses, Bipolar Affective"
31 65. "Psychosis, Bipolar Affective"
32 66. "Bipolar Disorder Type 1"
33 67. "Type 1 Bipolar Disorder"
34 68. "Manic Depression"
35 69. "Depression, Manic"
36 70. "Depressions, Manic"
37 71. "Depression, Bipolar"
38 72. "Bipolar Depression"
39 73. "Bipolar Disorder Type 2"
40 74. "Type 2 Bipolar Disorder" OR
41 75. "Manic Disorder"
42 76. "Disorder, Manic"
43 77. "Manic Disorders"
44 78. "Anxiety Disorder**"
45 79. "Disorder, Anxiety"
46 80. "Disorders, Anxiety"
47 81. "Neuroses, Anxiety"
48 82. "Anxiety Neuroses"
49 83. "Anxiety States, Neurotic"
50 84. "Anxiety State, Neurotic"
51 85. "Neurotic Anxiety State"
52 86. "Neurotic Anxiety States"
53 87. "State, Neurotic Anxiety"
54 88. "States, Neurotic Anxiety"
55 89. "Phobia, Social" OR "Social Phobia**"
56 90. "Social Evaluation Phobia"
57 91. "Phobia, Social Evaluation"
58 92. "Social Evaluation Phobias"

- 1
2
3 93. "Social Anxiety Disorder"
4 94. "Anxiety Disorder, Social"
5 95. "Disorder, Social Anxiety"
6 96. "Social Anxiety Disorders"
7 97. Sociophobia*
8 98. "Fear of Social Evaluation"
9 99. "Evaluation Fear, Social"
10 100. "Social Evaluation Fear"
11 101. "Feeding and Eating Disorders"
12 102. "Eating and Feeding Disorders"
13 103. "Feeding Disorders"
14 104. "Disorder, Feeding"
15 105. "Disorders, Feeding"
16 106. "Feeding Disorder"
17 107. "Eating Disorders"
18 108. "Disorder, Eating"
19 109. "Disorders, Eating"
20 110. "Eating Disorder"
21 111. "Appetite Disorders"
22 112. "Appetite Disorder"
23 113. "Anorexia Nervosa"
24 114. "Anorexia Nervosas"
25 115. "Nervosa, Anorexia"
26 116. "Nervosas, Anorexia"
27 117. "Bulimia Nervosa"
28 118. "Nervosa, Bulimia"
29 119. "Substance-Related Disorder*"
30 120. "Disorder, Substance Related"
31 121. "Disorders, Substance Related"
32 122. "Related Disorder, Substance"
33 123. "Related Disorders, Substance"
34 124. "Drug Use Disorders"
35 125. "Drug Use Disorder"
36 126. "Disorder, Drug Use"
37 127. "Organic Mental Disorders, Substance-Induced"
38 128. "Organic Mental Disorders, Substance Induced"
39 129. "Substance Abuse"
40 130. "Abuse, Substance"
41 131. "Substance Abuses"
42 132. "Substance Dependence"
43 133. "Dependence, Substance"
44 134. "Substance Addiction"
45 135. "Addiction, Substance"
46 136. "Chemical Dependence"
47 137. "Chemical Dependences"
48 138. "Dependence, Chemical"
49 139. "Dependences, Chemical"
50 140. "Drug Dependence"
51 141. "Dependence, Drug"
52 142. "Drug Addiction"
53 143. "Addiction, Drug"
54 144. "Prescription Drug Abuse"
55 145. "Abuse, Prescription Drug"
56 146. "Drug Abuse, Prescription"
57 147. "Substance Use"
58 148. "Substance Uses"

- 1
2
3 149. "Use, Substance"
4 150. "Drug Abuse"
5 151. "Abuse, Drug"
6 152. "Drug Habituation"
7 153. "Habituation, Drug"
8 154. "Substance Use Disorders"
9 155. "Disorder, Substance Use"
10 156. "Substance Use Disorder"
11 157. or/1-157
12 158. "Mass Screening"
13 159. "Mass Screenings"
14 160. "Screening, Mass"
15 161. "Screenings, Mass"
16 162. Screening*
17 163. "Diagnostic Screening Programs"
18 164. "Diagnostic Screening Program"
19 165. "Program, Diagnostic Screening"
20 166. "Programs, Diagnostic Screening"
21 167. "Screening Program, Diagnostic"
22 168. "Screening Programs, Diagnostic"
23 169. or/158-168
24 170. COSMIN filter for identifying studies on the development of health measurement
25 instruments
26 171. #157 OR #169 OR 170
27
28
29

LILACS

- 30 1. "Transtornos Mentais"
31 2. "Diagnóstico Psiquiátrico"
32 3. "Distúrbios Psiquiátricos"
33 4. "Doença Mental"
34 5. "Doença Psiquiátrica"
35 6. "Doenças Psiquiátricas"
36 7. Insanidade
37 8. "Transtorno do Comportamento"
38 9. "Transtornos do Comportamento"
39 10. "Transtornos Mentais Graves"
40 11. "Transtornos Mentais Severos"
41 12. "Transtornos Psiquiátricos"
42 13. "Trastornos Mentales"
43 14. "Enfermedad Mental"
44 15. "Enfermedad Psiquiátrica"
45 16. "Enfermedades Psiquiátricas"
46 17. Insanidad
47 18. "Transtornos Mentales Severos"
48 19. "Trastorno del Comportamiento"
49 20. "Trastorno Mental"
50 21. "Trastornos del Comportamiento"
51 22. "Trastornos Mentales Graves"
52 23. "Trastornos Psiquiátricos"
53 24. "Mental Disorder**"
54 25. "Psychiatric Illness**"
55 26. "Psychiatric* Disease"
56 27. "Mental Illness"
57 28. "Mental Illnesses"
58 29. "Psychiatric Disorder**"
59 30. "Behavior Disorders"

- 1
2
3 31. "Psychiatric Diagnosis"
4 32. "Severe Mental Disorder*"
5 33. "Psychotic Disorder**"
6 34. Psychos*
7 35. "Schizoaffective Disorder***"
8 36. "Schizophreniform Disorder**"
9 37. "Brief Reactive Psychos**"
10 38. "Schizophrenia Spectrum and Other Psychotic Disorders"
11 39. "Schizophrenia, Paranoid"
12 40. "Paranoid Schizophrenias"
13 41. "Schizophrenias, Paranoid"
14 42. "Paranoid Schizophrenia"
15 43. "Delusional Disorder"
16 44. "Delusional Disorders"
17 45. "Disorder, Delusional"
18 46. "Disorders, Delusional"
19 47. "Schizophrenia, Disorganized"
20 48. "Disorganized Schizophrenia"
21 49. "Disorganized Schizophrenias"
22 50. "Schizophrenias, Disorganized"
23 51. "Hebephrenic Schizophrenia"
24 52. "Hebephrenic Schizophrenias"
25 53. "Schizophrenias, Hebephrenic"
26 54. "Schizophrenia, Hebephrenic"
27 55. "Schizophrenia, Catatonic"
28 56. "Catatonic Schizophrenia"
29 57. "Catatonic Schizophrenias"
30 58. "Schizophrenias, Catatonic""
31 59. "Transtornos Psicóticos"
32 60. "Psicose Reativa Breve"
33 61. Psicoses
34 62. "Transtorno Esquizoafetivo"
35 63. "Transtornos Esquizofreniformes"
36 64. "Espectro da Esquizofrenia e Outros Transtornos Psicóticos"
37 65. "Esquizofrenia e Transtornos com Características Psicóticas"
38 66. "Esquizofrenia Paranoide"
39 67. "Transtorno Delirante"
40 68. "Esquizofrenia Hebefrênica"
41 69. "Esquizofrenia Catatônica"
42 70. "Trastornos Psicóticos"
43 71. Psicosis OR "Psicosis Reactiva Breve"
44 72. "Trastorno Esquizoafectivo"
45 73. "Trastornos Esquizofreniformes"
46 74. "Esquizofrenia Hebefrénica"
47 75. "Esquizofrenia Catatónica"
48 76. "Mood Disorder**"
49 77. "Disorder, Mood"
50 78. "Disorders, Mood"
51 79. "Affective Disorder**"
52 80. "Disorder, Affective"
53 81. "Disorders, Affective"
54 82. Mania*
55 83. "Manic State"
56 84. "Hypomanic Episode"
57 85. "Hypomanic Episodes"
58 86. Hypomania*

- 1
2
3 87. "Manic Episode"
4 88. "Episode, Manic"
5 89. "Manic Episodes"
6 90. "Bipolar Disorder"
7 91. "Bipolar Disorders"
8 92. "Psychosis, Manic-Depressive"
9 93. "Psychosis, Manic Depressive"
10 94. "Psychoses, Manic-Depressive"
11 95. "Psychoses, Manic Depressive"
12 96. "Manic-Depressive Psychosis"
13 97. "Manic Depressive Psychosis"
14 98. "Bipolar Mood Disorder"
15 99. "Bipolar Mood Disorders"
16 100. "Disorder, Bipolar Mood"
17 101. "Mood Disorder, Bipolar"
18 102. "Affective Psychosis, Bipolar"
19 103. "Bipolar Affective Psychosis"
20 104. "Psychoses, Bipolar Affective"
21 105. "Psychosis, Bipolar Affective"
22 106. "Bipolar Disorder Type 1"
23 107. "Type 1 Bipolar Disorder"
24 108. "Manic Depression"
25 109. "Depression, Manic"
26 110. "Depressions, Manic"
27 111. "Depression, Bipolar"
28 112. "Bipolar Depression"
29 113. "Bipolar Disorder Type 2"
30 114. "Type 2 Bipolar Disorder" OR
31 115. "Manic Disorder"
32 116. "Disorder, Manic"
33 117. "Manic Disorders"
34 118. "Transtornos do Humor"
35 119. "Transtornos Afetivos"
36 120. "Trastornos del Humor"
37 121. Mania
38 122. "Episódio Hipomaníaco"
39 123. "Episódio Maníaco"
40 124. "Estado Maníaco"
41 125. "Estado de Loucura"
42 126. hipomania
43 127. "episodio hipomaníaco"
44 128. "episodio maníaco"
45 129. "estado maníaco"
46 130. "hipomanía"
47 131. "Anxiety Disorder**"
48 132. "Disorder, Anxiety"
49 133. "Disorders, Anxiety"
50 134. "Neuroses, Anxiety"
51 135. "Anxiety Neuroses"
52 136. "Anxiety States, Neurotic"
53 137. "Anxiety State, Neurotic"
54 138. "Neurotic Anxiety State"
55 139. "Neurotic Anxiety States"
56 140. "State, Neurotic Anxiety"
57 141. "States, Neurotic Anxiety"
58 142. "Phobia, Social" OR "Social Phobia**"

- 1
2
3 143. "Social Evaluation Phobia"
4 144. "Phobia, Social Evaluation"
5 145. "Social Evaluation Phobias"
6 146. "Social Anxiety Disorder"
7 147. "Anxiety Disorder, Social"
8 148. "Disorder, Social Anxiety"
9 149. "Social Anxiety Disorders"
10 150. Sociophobia*
11 151. "Transtornos de Ansiedade"
12 152. "Distúrbios de Ansiedade"
13 153. "Estados de Ansiedade Neurótica"
14 154. "Neurose de Ansiedade"
15 155. "Transtornos Ansiosos"
16 156. "Transtornos de Angústia"
17 157. Agorafobia
18 158. Demofobia
19 159. Enoclofobia
20 160. "Fobia de Espaços Abertos"
21 161. "Fobia de Multidão"
22 162. "Fobia de Multidões"
23 163. Oclofobia*
24 164. "Transtorno de Pânico"
25 165. "Ataques de Pânico"
26 166. "trastornos de ansiedad"
27 167. "estados de ansiedad neuróticos"
28 168. "neurosis de ansiedad"
29 169. "fobia a las multitudes"
30 170. "fobia a los espacios abiertos"
31 171. "trastorno de pánico"
32 172. "ataques de pánico"
33 173. "Fear of Social Evaluation"
34 174. "Evaluation Fear, Social"
35 175. "Social Evaluation Fear"
36 176. "Feeding and Eating Disorders"
37 177. "Eating and Feeding Disorders"
38 178. "Feeding Disorders"
39 179. "Disorder, Feeding"
40 180. "Disorders, Feeding"
41 181. "Feeding Disorder"
42 182. "Eating Disorders"
43 183. "Disorder, Eating"
44 184. "Disorders, Eating"
45 185. "Eating Disorder"
46 186. "Appetite Disorders"
47 187. "Appetite Disorder"
48 188. "Anorexia Nervosa"
49 189. "Anorexia Nervosas"
50 190. "Nervosa, Anorexia"
51 191. "Nervosas, Anorexia"
52 192. "Bulimia Nervosa"
53 193. "Nervosa, Bulimia"
54 194. "Transtornos da Alimentação"
55 195. "Transtornos da Ingestão de Alimentos"
56 196. "Transtornos do Apetite"
57 197. "Transtorno da Compulsão Alimentar"
58 198. "Compulsão Alimentar"

- 1
2
3 199. "Anorexia Nervosa"
4 200. "Bulimia Nervosa"
5 201. "Trastornos de Alimentación y de la Ingestión de Alimentos"
6 202. "Trastorno Alimentario"
7 203. "Trastornos Alimentarios"
8 204. "Trastornos Alimentarios y de la Ingestión de Alimentos"
9 205. "Trastornos de Alimentación"
10 206. "Trastornos de la Conducta Alimentaria"
11 207. "Trastornos de la Ingesta de Alimentos"
12 208. "Trastornos de la Ingestión de Alimentos"
13 209. "Trastornos del Apetito"
14 210. "Trastorno por Atracón"
15 211. "trastorno de hiperfagia compulsiva"
16 212. "trastorno de atracones"
17 213. "Anorexia Nerviosa"
18 214. "anorexia nerviosa"
19 215. "Bulimia Nerviosa"
20 216. "Substance-Related Disorder*"
21 217. "Disorder, Substance Related"
22 218. "Disorders, Substance Related"
23 219. "Related Disorder, Substance"
24 220. "Related Disorders, Substance"
25 221. "Drug Use Disorders"
26 222. "Drug Use Disorder"
27 223. "Disorder, Drug Use"
28 224. "Organic Mental Disorders, Substance-Induced"
29 225. "Organic Mental Disorders, Substance Induced"
30 226. "Substance Abuse"
31 227. "Abuse, Substance"
32 228. "Substance Abuses"
33 229. "Substance Dependence"
34 230. "Dependence, Substance"
35 231. "Substance Addiction"
36 232. "Addiction, Substance"
37 233. "Chemical Dependence"
38 234. "Chemical Dependences"
39 235. "Dependence, Chemical"
40 236. "Dependences, Chemical"
41 237. "Drug Dependence"
42 238. "Dependence, Drug"
43 239. "Drug Addiction"
44 240. "Addiction, Drug"
45 241. "Prescription Drug Abuse"
46 242. "Abuse, Prescription Drug"
47 243. "Drug Abuse, Prescription"
48 244. "Substance Use"
49 245. "Substance Uses"
50 246. "Use, Substance"
51 247. "Drug Abuse"
52 248. "Abuse, Drug"
53 249. "Drug Habituation"
54 250. "Habituation, Drug"
55 251. "Substance Use Disorders"
56 252. "Disorder, Substance Use"
57 253. "Substance Use Disorder"
58 254. "Transtornos Relacionados ao Uso de Substâncias"

- 1
2
3 255. "Abuso de Drogas"
4 256. "Abuso de Medicamentos sob Prescrição"
5 257. "Abuso de Substâncias"
6 258. "Abuso de Substâncias Psicoativas"
7 259. "Abuso de Substâncias que Produzem Dependência"
8 260. "Abuso de Substâncias que não Produzem Dependência"
9 261. "Adição a Drogas"
10 262. "Dependência Física de Substâncias"
11 263. "Dependência Psíquica de Substâncias"
12 264. "Dependência Química"
13 265. "Dependência de Agentes Químicos"
14 266. "Dependência de Drogas"
15 267. "Dependência de Substâncias"
16 268. "Dependência de Substâncias Psicoativas"
17 269. Drogadicção
18 270. Drogadição
19 271. Farmacodependência
20 272. "Habituação a Drogas"
21 273. Toxicomania
22 274. "Transtorno Relacionado ao Uso de Substâncias"
23 275. "Transtornos Induzidos por Uso de Substâncias"
24 276. "Transtornos Mentais Orgânicos Induzidos por Substâncias"
25 277. "Transtornos Mentais Orgânicos Induzidos por Substâncias Psicoativas"
26 278. "Transtornos Relacionados ao Uso de Substâncias Psicoativas"
27 279. "Transtornos por Uso de Drogas"
28 280. "Transtornos por Uso de Substâncias"
29 281. "Transtornos por Uso de Substâncias Psicoativas"
30 282. "Uso Indevido de Drogas"
31 283. "Uso Indevido de Substâncias"
32 284. "Uso de Substâncias"
33 285. "Trastornos Relacionados con Sustancias"
34 286. "adicción a sustancias"
35 287. drogadicción
36 288. drogodependencia
37 289. "habituación a drogas"
38 290. "habituación a sustancias"
39 291. "trastorno por consumo de sustancias"
40 292. "trastorno relacionado con sustancias"
41 293. "trastornos inducidos por consumo de sustancias"
42 294. "trastornos inducidos por uso de sustancias"
43 295. "trastornos mentales orgánicos inducidos por sustancias"
44 296. "trastornos por consumo de drogas"
45 297. "trastornos por consumo de sustancias"
46 298. "trastornos por consumo de sustancias psicoactivas"
47 299. "trastornos por uso de drogas"
48 300. "trastornos por uso de sustancias"
49 301. "trastornos por uso de sustancias psicoactivas"
50 302. "trastornos relacionados con el consumo de sustancias psicoactivas"
51 303. "trastornos relacionados con el uso de sustancias psicoactivas"
52 304. or/1-303
53 305. "Mass Screening"
54 306. "Mass Screenings"
55 307. "Screening, Mass"
56 308. "Screenings, Mass"
57 309. Screening*
58 310. "Diagnostic Screening Programs"

- 1
2
3 311. "Diagnostic Screening Program"
4 312. "Program, Diagnostic Screening"
5 313. "Programs, Diagnostic Screening"
6 314. "Screening Program, Diagnostic"
7 315. "Screening Programs, Diagnostic"
8 316. "Programas de Rastreamento"
9 317. "Exame Coletivo"
10 318. "Identificação Sistemática"
11 319. "Programas de Triagem Diagnóstica"
12 320. Rastreamento
13 321. Rastreio
14 322. "Triagem de Massa"
15 323. "Tamizaje Masivo"
16 324. "cribado sistemático"
17 325. cribado "cribado masivo"
18 326. "detección selectiva"
19 327. "detección sistemática"
20 328. "examen colectivo"
21 329. "identificación sistemática"
22 330. screening OR "screening masivo"
23 331. "Programas de Detección Diagnóstica"
24 332. "programas de cribado diagnóstico"
25 333. "programa de cribado diagnóstico"
26 334. or/305-333
27 335. COSMIN filter for identifying studies on the development of health measurement
28 instruments
29 336. #304 OR #334 OR 335
30
31
32

CINAHL

- 33 1. "Mental Disorder**"
34 2. "Psychiatric Illness**"
35 3. "Psychiatric* Disease"
36 4. "Mental Illness"
37 5. "Mental Illnesses"
38 6. "Psychiatric Disorder**"
39 7. "Behavior Disorders"
40 8. "Psychiatric Diagnosis"
41 9. "Severe Mental Disorder**"
42 10. "Psychotic Disorder**"
43 11. Psychos*
44 12. "Schizoaffective Disorder****"
45 13. "Schizophreniform Disorder**"
46 14. "Brief Reactive Psychos**"
47 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
48 16. "Schizophrenia, Paranoid"
49 17. "Paranoid Schizophrenias"
50 18. "Schizophrenias, Paranoid"
51 19. "Paranoid Schizophrenia"
52 20. "Delusional Disorder"
53 21. "Delusional Disorders"
54 22. "Disorder, Delusional"
55 23. "Disorders, Delusional"
56 24. "Schizophrenia, Disorganized"
57 25. "Disorganized Schizophrenia"
58 26. "Disorganized Schizophrenias"
59 27. "Schizophrenias, Disorganized"

- 1
2
3 28. "Hebephrenic Schizophrenia"
4 29. "Hebephrenic Schizophrenias"
5 30. "Schizophrenias, Hebephrenic"
6 31. "Schizophrenia, Hebephrenic"
7 32. "Schizophrenia, Catatonic"
8 33. "Catatonic Schizophrenia"
9 34. "Catatonic Schizophrenias"
10 35. "Schizophrenias, Catatonic""
11 36. "Mood Disorder**"
12 37. "Disorder, Mood"
13 38. "Disorders, Mood"
14 39. "Affective Disorder**"
15 40. "Disorder, Affective"
16 41. "Disorders, Affective"
17 42. Mania*
18 43. "Manic State"
19 44. "Hypomanic Episode"
20 45. "Hypomanic Episodes"
21 46. Hypomania*
22 47. "Manic Episode"
23 48. "Episode, Manic"
24 49. "Manic Episodes"
25 50. "Bipolar Disorder"
26 51. "Bipolar Disorders"
27 52. "Psychosis, Manic-Depressive"
28 53. "Psychosis, Manic Depressive"
29 54. "Psychoses, Manic-Depressive"
30 55. "Psychoses, Manic Depressive"
31 56. "Manic-Depressive Psychosis"
32 57. "Manic Depressive Psychosis"
33 58. "Bipolar Mood Disorder"
34 59. "Bipolar Mood Disorders"
35 60. "Disorder, Bipolar Mood"
36 61. "Mood Disorder, Bipolar"
37 62. "Affective Psychosis, Bipolar"
38 63. "Bipolar Affective Psychosis"
39 64. "Psychoses, Bipolar Affective"
40 65. "Psychosis, Bipolar Affective"
41 66. "Bipolar Disorder Type 1"
42 67. "Type 1 Bipolar Disorder"
43 68. "Manic Depression"
44 69. "Depression, Manic"
45 70. "Depressions, Manic"
46 71. "Depression, Bipolar"
47 72. "Bipolar Depression"
48 73. "Bipolar Disorder Type 2"
49 74. "Type 2 Bipolar Disorder" OR
50 75. "Manic Disorder"
51 76. "Disorder, Manic"
52 77. "Manic Disorders"
53 78. "Anxiety Disorder**"
54 79. "Disorder, Anxiety"
55 80. "Disorders, Anxiety"
56 81. "Neuroses, Anxiety"
57 82. "Anxiety Neuroses"
58 83. "Anxiety States, Neurotic"

- 1
2
3 84. "Anxiety State, Neurotic"
4 85. "Neurotic Anxiety State"
5 86. "Neurotic Anxiety States"
6 87. "State, Neurotic Anxiety"
7 88. "States, Neurotic Anxiety"
8 89. "Phobia, Social" OR "Social Phobia**"
9 90. "Social Evaluation Phobia"
10 91. "Phobia, Social Evaluation"
11 92. "Social Evaluation Phobias"
12 93. "Social Anxiety Disorder"
13 94. "Anxiety Disorder, Social"
14 95. "Disorder, Social Anxiety"
15 96. "Social Anxiety Disorders"
16 97. Sociophobia*
17 98. "Fear of Social Evaluation"
18 99. "Evaluation Fear, Social"
19 100. "Social Evaluation Fear"
20 101. "Feeding and Eating Disorders"
21 102. "Eating and Feeding Disorders"
22 103. "Feeding Disorders"
23 104. "Disorder, Feeding"
24 105. "Disorders, Feeding"
25 106. "Feeding Disorder"
26 107. "Eating Disorders"
27 108. "Disorder, Eating"
28 109. "Disorders, Eating"
29 110. "Eating Disorder"
30 111. "Appetite Disorders"
31 112. "Appetite Disorder"
32 113. "Anorexia Nervosa"
33 114. "Anorexia Nervosas"
34 115. "Nervosa, Anorexia"
35 116. "Nervosas, Anorexia"
36 117. "Bulimia Nervosa"
37 118. "Nervosa, Bulimia"
38 119. "Substance-Related Disorder**"
39 120. "Disorder, Substance Related"
40 121. "Disorders, Substance Related"
41 122. "Related Disorder, Substance"
42 123. "Related Disorders, Substance"
43 124. "Drug Use Disorders"
44 125. "Drug Use Disorder"
45 126. "Disorder, Drug Use"
46 127. "Organic Mental Disorders, Substance-Induced"
47 128. "Organic Mental Disorders, Substance Induced"
48 129. "Substance Abuse"
49 130. "Abuse, Substance"
50 131. "Substance Abuses"
51 132. "Substance Dependence"
52 133. "Dependence, Substance"
53 134. "Substance Addiction"
54 135. "Addiction, Substance"
55 136. "Chemical Dependence"
56 137. "Chemical Dependences"
57 138. "Dependence, Chemical"
58 139. "Dependences, Chemical"

1
2
3 140. "Drug Dependence"
4 141. "Dependence, Drug"
5 142. "Drug Addiction"
6 143. "Addiction, Drug"
7 144. "Prescription Drug Abuse"
8 145. "Abuse, Prescription Drug"
9 146. "Drug Abuse, Prescription"
10 147. "Substance Use"
11 148. "Substance Uses"
12 149. "Use, Substance"
13 150. "Drug Abuse"
14 151. "Abuse, Drug"
15 152. "Drug Habituation"
16 153. "Habituation, Drug"
17 154. "Substance Use Disorders"
18 155. "Disorder, Substance Use"
19 156. "Substance Use Disorder"
20 157. or/1-157
21 158. "Mass Screening"
22 159. "Mass Screenings"
23 160. "Screening, Mass"
24 161. "Screenings, Mass"
25 162. Screening*
26 163. "Diagnostic Screening Programs"
27 164. "Diagnostic Screening Program"
28 165. "Program, Diagnostic Screening"
29 166. "Programs, Diagnostic Screening"
30 167. "Screening Program, Diagnostic"
31 168. "Screening Programs, Diagnostic"
32 169. or/158-168
33 170. COSMIN filter for identifying studies on the development of health measurement
34 instruments
35 171. #157 OR #169 OR 170
36
37

38 Google Scholar

39 1. "Mental Disorder"
40 2. "Psychotic Disorder"
41 3. "Mood Disorder"
42 4. "Anxiety Disorder"
43 5. "Feeding and Eating Disorders"
44 6. "Substance-Related Disorder"
45 7. or/1-6
46 8. "Mass Screening"
47 9. Screening
48 10. or/8-9
49 11. Instrument
50 12. #07 AND 10 AND 11
51 13. #Limit_page 5
52
53
54

55 COSMIN filter

56
57 (instrumentation[sh] OR methods[sh] OR "Validation Studies"[pt] OR "Comparative Study"[pt]
58 OR "psychometrics"[MeSH] OR psychometr*[tiab] OR clinimetr*[tw] OR clinometr*[tw] OR
59 "outcome assessment (health care)"[MeSH] OR "outcome assessment"[tiab] OR "outcome
60 measure*[tw] OR "observer variation"[MeSH] OR "observer variation"[tiab] OR "Health Status

1
2
3 Indicators"[Mesh] OR "reproducibility of results"[MeSH] OR reproducib*[tiab] OR "discriminant
4 analysis"[MeSH] OR reliab*[tiab] OR unreliab*[tiab] OR valid*[tiab] OR "coefficient of
5 variation"[tiab] OR coefficient[tiab] OR homogeneity[tiab] OR homogeneous[tiab] OR "internal
6 consistency"[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND
7 (correlation*[tiab] OR selection*[tiab] OR reduction*[tiab])) OR agreement[tw] OR precision[tw]
8 OR imprecision[tw] OR "precise values"[tw] OR test-retest[tiab] OR (test[tiab] AND retest[tiab])
9 OR (reliab*[tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-
10 rater[tiab] OR intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR
11 intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer[tiab] OR
12 intraobserver[tiab] OR intra-observer[tiab] OR intertechnician[tiab] OR inter-technician[tiab] OR
13 intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-examiner[tiab] OR
14 intraexaminer[tiab] OR intra-examiner[tiab] OR interassay[tiab] OR inter-assay[tiab] OR
15 intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-individual[tiab] OR
16 intraindividual[tiab] OR intra-individual[tiab] OR interparticipant[tiab] OR inter-participant[tiab]
17 OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa's[tiab] OR
18 kappas[tiab] OR repeatab*[tw] OR ((replicab*[tw] OR repeated[tw]) AND (measure[tw] OR
19 measures[tw] OR findings[tw] OR result[tw] OR results[tw] OR test[tw] OR tests[tw])) OR
20 generaliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND
21 correlation*[tiab]) OR discriminative[tiab] OR "known group"[tiab] OR "factor analysis"[tiab] OR
22 "factor analyses"[tiab] OR "factor structure"[tiab] OR "factor structures"[tiab] OR dimension*[tiab]
23 OR subscale*[tiab] OR (multitrait[tiab] AND scaling[tiab] AND (analysis[tiab] OR analyses[tiab]))
24 OR "item discriminant"[tiab] OR "interscale correlation*[tiab] OR error[tiab] OR errors[tiab] OR
25 "individual variability"[tiab] OR "interval variability"[tiab] OR "rate variability"[tiab] OR
26 (variability[tiab] AND (analysis[tiab] OR values[tiab])) OR (uncertainty[tiab] AND
27 (measurement[tiab] OR measuring[tiab])) OR "standard error of measurement"[tiab] OR
28 sensitiv*[tiab] OR responsive*[tiab] OR (limit[tiab] AND detection[tiab]) OR "minimal detectable
29 concentration"[tiab] OR interpretab*[tiab] OR ((minimal[tiab] OR minimally[tiab] OR clinical[tiab]
30 OR clinically[tiab]) AND (important[tiab] OR significant[tiab] OR detectable[tiab]) AND
31 (change[tiab] OR difference[tiab])) OR (small*[tiab] AND (real[tiab] OR detectable[tiab])) AND
32 (change[tiab] OR difference[tiab])) OR "meaningful change"[tiab] OR "ceiling effect"[tiab] OR
33 "floor effect"[tiab] OR "Item response model"[tiab] OR IRT[tiab] OR Rasch[tiab] OR "Differential
34 item functioning"[tiab] OR DIF[tiab] OR "computer adaptive testing"[tiab] OR "item bank"[tiab]
35 OR "cross-cultural equivalence"[tiab])
36
37

38 #4 exclusie

39 NOT ('delphi-technique'[ti] OR cross-sectional[ti] OR "addresses"[Publication Type] OR
40 "biography"[Publication Type] OR "case reports"[Publication Type] OR "comment"[Publication
41 Type] OR "directory"[Publication Type] OR "editorial"[Publication Type] OR
42 "festschrift"[Publication Type] OR "interview"[Publication Type] OR "lectures"[Publication Type]
43 OR "legal cases"[Publication Type] OR "legislation"[Publication Type] OR "letter"[Publication
44 Type] OR "news"[Publication Type] OR "newspaper article"[Publication Type] OR "patient
45 education handout"[Publication Type] OR "popular works"[Publication Type] OR
46 "congresses"[Publication Type] OR "consensus development conference"[Publication Type] OR
47 "consensus development conference, nih"[Publication Type] OR "practice guideline"[Publication
48 Type]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])

BMJ Open

Screening Instruments for Mental Disorders in Primary Health Care: a scoping review protocol (SCREENING-MD)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-084612.R1
Article Type:	Protocol
Date Submitted by the Author:	01-May-2024
Complete List of Authors:	Lopes, Luis; Universidade da Sorocaba, Santos, Danielle Maria; University of Sorocaba; Federal University of Rio de Janeiro Silva, Jéssica Cumpian; University of Sorocaba Bergamaschi, Cristiane; University of Sorocaba, Pharmaceutical Science Moura, Mariana ; University of Sorocaba, Department of Pharmaceutical Sciences Okuyama, Julia; Universidade de Sorocaba, Post-Graduate Program of Pharmaceutical Science Lopes, Luciane; Universidade de Sorocaba, Pharmaceutical Science
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Primary Health Care, MENTAL HEALTH, Mass Screening

SCHOLARONE™
Manuscripts

1 1 **Screening Instruments for Mental Disorders in Primary Health Care: a**
2 2 **scoping review protocol (SCREENING-MD)**

3 3 **Luis Phillippe Nagem Lopes**

4 4 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
5 5 Sorocaba, São Paulo, Brazil
6 6 Email: luis.pharma20161@gmail.com

7 7 **Danielle Maria de Souza Serio dos Santos, PhD**

8 8 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
9 9 Sorocaba, São Paulo, Brazil
10 10 Institute of Pharmaceutical Sciences, Multidisciplinary Center. Federal
11 11 University of Rio de Janeiro, Macaé, Rio de Janeiro, Brazil.
12 12 Email: dani.farma84@gmail.com

13 13 **Jéssica Cumpian Silva, PhD**

14 14 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
15 15 Sorocaba, São Paulo, Brazil
16 16 Email: jesscumpian@gmail.com

17 17 **Mariana Del Grossi, PhD**

18 18 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
19 19 Sorocaba, São Paulo, Brazil
20 20 Email: maridelgrossi@gmail.com

21 21 **Cristiane de Cássia Bergamaschi, PhD**

22 22 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
23 23 Sorocaba, São Paulo, Brazil
24 24 E-mail: cristiane.motta@prof.uniso.br

25 25 **Julia Hiromi Hori Okuyama, PhD**

26 26 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
27 27 Sorocaba, São Paulo, Brazil
28 28 Email: jhhokuyama@gmail.com

29 29 **Luciane Cruz Lopes, PhD**

30 30 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
31 31 Sorocaba, São Paulo, Brazil

33 33 ***Corresponding author:**

34 34 Luciane Cruz Lopes – luciane.lopes@prof.uniso.br; luslopesbr@gmail.com
35 35 Graduate Course in Pharmaceutical Sciences, University of Sorocaba, UNISO,
36 36 Brazil
37 37 Rodovia Raposo Tavares, KM 92,5 - Sorocaba, São Paulo, Brazil
38 38 ZIP Code: 18023-000
39 39 Phone: 55 19 99781-8441 Fax: 55 15 2101-7074

2

41

ABSTRACT

42 **Introduction:** When mental disorders go undetected until later stages, they can
43 result in poorer health outcomes for patients. Primary Health Care (PHC) stands
44 as a strategic setting for the early identification and management of these mental
45 disorders, given its role as the primary care environment for health service users.
46 This scoping review has the objective of mapping and assessing screening
47 instruments validated for mental disorders that are applicable in PHC, particularly
48 regarding their measurement properties.

49 **Methods and Analysis:** This scoping review will include studies that have
50 developed and validated screening instruments for mental disorders in the PHC
51 context, irrespective of the age group. Searches will be conducted in Medline,
52 Embase, Lilacs, CINAHL, and PsycINFO, without imposing restrictions on
53 publication status, publication year, or language. Additionally, we will explore the
54 gray literature through Google Scholar and scrutinize the references cited in the
55 selected studies. Our inclusion criteria encompass studies examining any
56 measurement property recommended by the Consensus-based Standards for
57 the selection of health Measurement Instruments (COSMIN) taxonomy. The
58 selection process, data extraction, and quality assessment of studies will be
59 performed independently by pairs of reviewers. To evaluate the risk of bias within
60 the selected studies, we will employ the COSMIN Risk of Bias 2 tools. The
61 collected data will undergo analysis using descriptive statistics and will be
62 presented in an evidence gap map format for each specific mental disorder.

63 **Ethics and dissemination:** The findings from this review will be discussed
64 through deliberative dialogue with stakeholders and disseminated through peer-
65 reviewed publications and conference presentations. The project was approved
66 by the Ethics Committee for Research at the University of Sorocaba (number:
67 66993323.9.0000.5500).

68 **Protocol Registration:** Open Science Framework – 10.17605/OSF.IO/Z6T5M

69 **Keywords:** Mental Disorders. Primary Health Care. Screening. Scoping Review.

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This scoping review will employ systematic procedures based on important methodological guidelines such as those provided by the Joanna Briggs Institute and the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN);
- Stakeholders were involved in the development of this study protocol;
- Significant gaps will be identified to establish a comprehensive research agenda regarding screening instruments for mental disorders;
- Heterogeneous reporting in psychometric studies and instances of missing data might restrict the outcomes of this study.

1 2 80 INTRODUCTION 3 4

5
6 81 One out of every eight individuals worldwide has received a diagnosis of a mental
7 82 disorder, amounting to 970 million people [1]. In 2020, the estimates surged by
8 83 over 20%, primarily for anxiety and depressive disorders, due to the impact of the
9 84 COVID-19 pandemic [1]. Currently, even after the pandemic, statistics on mental
10 85 disorders remain high [2]. The significant global prevalence of these and other
11 86 mental disorders, such as eating disorders [3], substance use disorders [4], and
12 87 psychotic disorders [5], has mobilized important research agendas for
13 88 appropriate screening and identification [6]. Despite the existence of treatment
14 89 options for these conditions, their recognition remains challenging, primarily due
15 90 to stigma, insufficient professional training, and a shortage of validated screening
16 91 instruments [7].
17
18

19
20 92 Primary Health Care (PHC) serves as the primary entry point into health systems,
21 93 typically where patients seek care most often, playing a crucial role in ensuring
22 94 universal healthcare, accessible, and equitable for the population [8,9]. When it
23 95 comes to mental health, PHC has been instrumental in reducing the stigma and
24 96 discrimination associated with mental disorders, enhancing healthcare access,
25 97 reducing the long-term impact of mental disorders, and promoting social
26 98 integration [10]. As a result, PHC stands as a vital setting for the implementation
27 99 of mental disorder screening.
28
29

30
31 100 Screening for mental disorders in PHC has been encouraged because late
32 101 identification leads to poorer health outcomes [11]. It's important to note,
33 102 however, that PHC lacks systematic methods for tracking mental disorders,
34 103 leading to inaccuracies in results primarily due to missed or incorrect diagnoses,
35 104 owing to the complexity of mental disorders [12,13]. Screening for mental
36 105 disorders in primary care environments, when conducted, is often done
37 106 subjectively and without a systematic process, lacking the use of validated
38 107 instruments and professional training. This observation was made in a qualitative
39 108 study by Loeb and colleagues, based on the perspective of primary care medical
40 109 professionals. This finding was further corroborated by the study conducted by
41 110 Rogers and collaborators (2021), who also noted the scarcity of systematized
42 111 screening processes incorporating validated strategies [12,13]. Therefore,
43
44

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

112 implementing suitable instruments is the initial step towards integrating mental
113 disorder screening into the existing PHC services.

114 Instruments that are validated and consistent are crucial for the implementation
115 of screening in PHC. In recent years, many screening instruments for mental
116 disorders have been developed, but little is known about the measurement
117 properties that have been evaluated [14]. Moreover, when it comes to low- and
118 middle-income countries, there are concerns about whether the development
119 process of these instruments is suitable for this population. A recent systematic
120 review revealed that the instruments designed for screening mental disorders are
121 validated in local contexts, and these validations leave gaps in the applicability of
122 these instruments in other countries, particularly those with low and middle
123 incomes [15].

124 This scoping review has the objective of both mapping and assessing screening
125 instruments for mental disorders that are applicable in PHC, particularly regarding
126 their measurement properties.

127 **METHODS**

128 **Study design and registry**

129 **Figure 1** illustrates the steps to be undertaken in this scoping review. Our scoping
130 review will adhere to the guidelines by Joanna Briggs and the Consensus-based
131 Standards for the selection of health Measurement Instruments (COSMIN)
132 systematic reviews manual [16,17]. The study's protocol is accessible on the
133 Open Science Framework [18]. The protocol was documented following the
134 Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension
135 for Scoping Reviews (PRISMA-ScR) Checklist (adapted for protocol)
136 (**Supplementary Material 1**) [19]. This study will begin in July 2024 and end in
137 September 2025.

138 **[Figure 1. Flow of conducting the scoping review]**

139 **Eligibility criteria**

140 The research question was structured following the key components typically
141 used in reviews of health measurement instruments [17], including:

1
2 **142 Construct**

3
4
5 143 We will consider studies that primarily focus on the screening of specific mental
6 disorders, including eating disorders (ICD F50), anxiety disorders (ICD F40-41),
7 mood disorders (ICD F30-39), substance use disorders (ICD F10-19), and
8 psychotic disorders (ICD F20-29). These disorders were selected due to their
9 higher prevalence.
10
11
12
13

14
15 **148 Population**
16

17
18 149 We will include studies involving individuals of various age groups, genders, and
19 geographic locations who exhibit one or more risk factors for mental disorders,
20 including eating disorders (ICD F50), anxiety disorders (ICD F40-41), mood
21 disorders (ICD F30-39), substance use disorders (ICD F10-19), and psychotic
22 disorders (ICD F20-29).
23
24
25

26
27 **154 Types of Instruments and Measurement Properties of Interest**
28

29
30 155 Studies will be considered without restrictions on the specific measurement
31 property under examination or the method of administration. We will only include
32 studies focused on instrument development (methodological studies); studies
33 that just utilized the instrument will be excluded. Multidimensional instruments will
34 158 also be eligible for inclusion.
35
36

37
38 **160 Context**
39

40
41 161 Only studies conducted in PHC settings will be included, considering primary care
42 environments and population health levels [20]. As a result, instruments
43 developed and validated for specialized care or psychiatric inpatient settings will
44 be excluded.
45
46

47
48 **165 Information Sources**
49

50
51 166 The consulted databases will be MEDLINE (via PubMed), Embase, Lilacs (via
52 Virtual Health Library Portal), PsycINFO, and CINAHL. Other information sources
53 will also be consulted, including the reference lists of included studies. No
54 restrictions on language or year of publication will be applied. If necessary,
55 specialized translation services will be consulted for languages that are not
56 readable by the team.
57
58
59
60

1
2 **172 Search Strategy**

3
4 173 To validate the search strategy, double-checking will be conducted using Peer
5 174 Review of Electronic Search Strategies (PRESS) [21]. A specialized librarian will
6 175 validate it, and modifications will be made if necessary. **Supplementary Material**
7
8 176 **2** describes the search strategy for each information source. Given the substantial
9 177 volume of studies on screening instruments for mental disorders, we applied a
10 178 developed and validated methodological filter to identify instruments [22].
11
12

13 **179 Study selection and data extraction**

14
15 180 The selection process will involve pairs of reviewers, resolving any
16 181 disagreements through consensus. This process will occur in two stages: initially
17 182 screening based on title and abstract, followed by the assessment of full-text
18 183 articles using Rayyan software (Step 1) and Microsoft Excel 2016 (Step 2) [23].
19 184 Reviewer calibration will precede the selection process, which includes the initial
20 185 assessment of at least 50 randomly chosen titles and abstracts in the first stage,
21 186 followed by at least 10 full-text articles. This process will continue until the
22 187 standardization of included and excluded studies is achieved. The overlapping of
23 188 articles from the calibration exercise between reviewers will be adopted to assess
24 189 the reliability of the team [24,25]. A reviewer will be considered qualified if they
25 190 accurately select at least 75% of the calibration set, as recommended in the
26 191 manuals [16].
27
28

29 192 The data extraction process will similarly involve two independent reviewers, and
30 193 the calibration will follow a process akin to that previously described for selection.
31 194 At this stage, within an Excel spreadsheet, reviewers will extract the following
32 195 information:
33
34

35 196 Part 1. Study characteristics: author, year, country, number of participants;
36 197 number and percentage of female participants; average or median age and age
37 198 range; and whether the instrument was designed for use in primary care (yes/no);
38
39 199 Part 2. Characteristics of the instruments: name of the instrument; acronym or
40 200 abbreviation of the instrument; method of administration; administration time;
41 201 number of items; number of dimensions; whether cross-cultural adaptation was
42 202 performed (yes/no), if yes, specify the culture.
43
44

1
2
3 203 Part 3. Measurement properties: Studies will be categorized based on the
4 measurement properties outlined in the COSMIN taxonomy [26]. This taxonomy
5 categorizes studies according to the following properties: reliability, validity,
6 responsiveness, and interpretability.
7
8 206
9

10 207 **Risk of bias**
11
12

13 208 The risk of bias assessment will be conducted using the COSMIN Risk of Bias
14 checklist tool, which evaluates instruments based on their measurement
15 properties [27, 28]. The COSMIN Risk of Bias checklist tool assesses instruments
16 based on the methodological quality of the psychometric steps conducted in the
17 studies. In other words, when we utilize the COSMIN Risk of Bias checklist tool
18 to assess studies, we inherently appraise the psychometric properties of the
19 instrument. While it was primarily developed for Patient-Reported Outcome
20 Measures (PROM), it can also be employed for other psychometric instruments
21 [27]. Two reviewers will independently conduct the assessment, and any
22 discrepancies will be resolved through consensus.
23
24 217
25
26
27
28
29
30

31 218 **Data synthesis**
32
33

34 219 The data will be analyzed using descriptive statistics via Stata (version 14.2)
35 software. For better visualization, the results will be presented in bubble and heat
36 maps, categorizing them based on the methodological quality of instrument
37 development and the assessed measurement properties.
38
39 222
40
41

42 223 **Patient and public involvement: deliberative dialogue**
43
44

45 224 We will conduct a deliberative dialogue with stakeholders to discuss barriers and
46 facilitators for implementing screening in PHC. A convenience sample of health
47 professionals working in primary care, representatives from the Brazilian Ministry
48 of Health, and researchers will be recruited via email. The deliberative dialogue
49 will be held virtually, following the recommendations outlined in the SUPPORT
50 tools [29].
51
52 229
53

54 230 A plain language summary of the scoping review will be disseminated to
55 interested parties 15 days before the dialogue. The organization of the
56 deliberative dialogue will be as follows: the initial 15 minutes of the dialogue will
57 focus on presenting a thorough overview of the scoping review findings.
58
59 233
60

1
2
3 234 Subsequently, discussions will revolve around barriers, facilitators, and the
4 utilization of screening instruments in PHC in Brazil. After the deliberative
5 dialogue, interested parties will evaluate the scoping review using a checklist
6 developed by Lavis (2009) [29]. This checklist, utilizing both open and closed
7 questions, aims to explore the experience of stakeholders in deliberative
8 dialogue, the knowledge gained, and the insights identified from the evidence
9 synthesis. It also evaluates the participants' level of satisfaction with the
10 deliberative dialogue and the evidence summarized in the scoping review.
11
12
13
14
15
16

17 242 **Ethical aspects**

18

19
20 243 The project was approved by the Ethics Committee for Research at the University
21 of Sorocaba (number: 66993323.9.0000.5500). As the deliberative dialogue will
22 involve human participants, a free and informed consent form will be provided in
23 advance and completed by the research participants.
24
25

26 247 **DISCUSSION**

27

28
29 248 This is the first scoping review to chart screening instruments for mental disorders
30 in PHC, involving their measurement properties and assessing bias risks. In this
31 context, this work, employing an innovative knowledge translation methodology
32 involving deliberative dialogue, holds the potential to assist healthcare
33 professionals, managers, and researchers in making evidence-informed
34 decisions regarding the implementation of validated screening instruments within
35 PHC. Furthermore, our findings will facilitate the identification of limitations in the
36 developed instruments, enabling the proposal of research agendas that prioritize
37 robust psychometric studies on screening instruments for mental disorders,
38 aiming to create instruments beneficial for clinical practice.
39
40

41 258 Although our work adhere to all methodological guidelines, potential limitations
42 may arise due to the heterogeneity in reporting concerning the development of
43 screening instruments for mental disorders. Consequently, reviewers may need
44 to conduct subjective assessments to evaluate the risk of bias and categorize
45 instruments, aligning with the guidelines outlined in the COSMIN Manual [17].
46 Furthermore, incomplete data, particularly concerning contextual information
47 about these instruments within care settings, can present challenges in data
48 extraction.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 266 Therefore, the methodological rigor of our scoping review, combined with the
4 knowledge translation strategy employing deliberative dialogue, can promote the
5 integration of scientific evidence into clinical practice and the screening of mental
6 disorders in PHC. This will be possible through engaging interested parties and
7 the Brazilian government, ensuring that these individuals are sensitized to the
8 process of screening for mental disorders in Brazil's PHC. Moreover, the
9 identified research gaps can serve as a foundation for new studies on these
10 instruments. Additionally, utilizing COSMIN's international taxonomy and
11 methodological recommendations can raise awareness among researchers
12 about the effective utilization of these validated instruments for measuring
13 outcomes in the healthcare domain [26].
14
15
16
17
18
19
20
21

22 277 AUTHOR CONTRIBUTIONS

23
24 278 LPNL is the principal investigator, responsible for drafting the protocol and final
25 version. The other authors (DMSSS, JCS, MDG, CCB, JHHO and LCL) reviewed
26 the content and provided significant edits to the final version. LCL serves as the
27 review guarantor, offering advice on the background, contributing to protocol
28 drafting, and revising the manuscript.
29
30
31
32
33

34 283 ACKNOWLEDGEMENTS

35
36 284 The authors wish to express their gratitude to the health evidence team at the
37 Department of Science and Technology for their invaluable assistance in
38 formulating the research question and devising the search strategy. Additionally,
39 librarian Mabel Figueiró deserves appreciation for validating the search strategy
40 and making necessary corrections.
41
42
43
44

45 289 FUNDING

46
47 290 Our research was supported by funding from the Ministry of Health of Brazil
48 (MoH) and the National Council for Scientific and Technological Development
49 (CNPq), under grant number 408237/2022-8. Additionally, this project received
50 funding from the Coordination for the Improvement of Higher Education
51 Personnel (CAPES)—PROSUC—CAPES/UNISO. Unfortunately, no specific
52 grant number is applicable for this support.
53
54
55
56
57
58


59 296 COMPETING INTERESTS

1
2
3 297 None to declare.
4
5
6 298 WORD COUNT
7
8 299 1,723.
9
10
11 300 References
12
13 301 1 World Health Organization. Mental disorders. <https://www.who.int/news-room/fact-sheets/detail/mental-disorders> (accessed 23 November 2023)
14
15
16 303 2 McGrath JJ, Al-Hamzawi A, Alonso J, et al. Age of onset and cumulative
17 risk of mental disorders: a cross-national analysis of population surveys from 29
18 countries. *Lancet Psychiatry*. 2023;10:668–81.
19
20
21 306 3 Qian J, Wu Y, Liu F, et al. An update on the prevalence of eating
22 disorders in the general population: a systematic review and meta-analysis. *Eat
23 Weight Disord*. 2022;27:415–28.
24
25
26 309 4 Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common
27 mental disorders: a systematic review and meta-analysis 1980-2013. *Int J
28 Epidemiol*. 2014;43:476–93.
29
30
31 312 5 Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders
32 and its association with methodological issues. A systematic review and meta-
33 analyses. *PLoS One*. 2018;13:e0195687.
34
35
36 315 6 Whitton AE, Hardy R, Cope K, et al. Mental Health Screening in General
37 Practices as a Means for Enhancing Uptake of Digital Mental Health
38 Interventions: Observational Cohort Study. *J Med Internet Res*.
39 2021;23:e28369.
40
41
42 319 7 Wakida EK, Talib ZM, Akena D, et al. Barriers and facilitators to the
43 integration of mental health services into primary health care: a systematic
44 review. *Syst Rev*. 2018;7:211.
45
46
47 322 8 Hall JJ, Taylor R. Health for all beyond 2000: the demise of the Alma-Ata
48 Declaration and primary health care in developing countries. *Med J Aust*.
49 2003;178:17–20.
50
51
52 325 9 World Health Organization. Primary health care.
53 https://www.who.int/health-topics/primary-health-care (accessed 28 April 2024)
54
55
56 327 10 Mulvaney-Day N, Marshall T, Downey Piscopo K, et al. Screening for
57 Behavioral Health Conditions in Primary Care Settings: A Systematic Review of
58 the Literature. *J Gen Intern Med*. 2018;33:335–46.
59
60 330 11 AACAP. Mental Health Screening in Primary Care.
61 https://www.aacap.org/AACAP/Policy_Statements/2019/Mental-Health-
62 Screening-Primary-Care.aspx (accessed 23 November 2023)

- 1
2
3 333 12 Loeb DF, Bayliss EA, Binswanger IA, *et al.* Primary care physician
4 334 perceptions on caring for complex patients with medical and mental illness. *J*
5 335 *Gen Intern Med.* 2012;27:945–52.
6
7 336 13 Rogers R, Hartigan SE, Sanders CE. Identifying Mental Disorders in
8 Primary Care: Diagnostic Accuracy of the Connected Mind Fast Check (CMFC)
9 Electronic Screen. *J Clin Psychol Med Settings.* 2021;28:882–96.
10
11 339 14 Fotheringham L, Paddick S-M, Barron Millar E, *et al.* Screening tools for
12 common mental disorders in older adults in South Asia: a systematic scoping
13 review. *Int Psychogeriatr.* 2022;34:427–38.
14
15 342 15 Ali G-C, Ryan G, De Silva MJ. Validated Screening Tools for Common
16 Mental Disorders in Low and Middle Income Countries: A Systematic Review.
17 *PLoS One.* 2016;11:e0156939.
18
19 345 16 Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil, H.
20 Scoping Reviews (2020). Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan
21 Z, editors. JBI Manual for Evidence Synthesis. <https://jbi-global-wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews>
22 (accessed 4 January 2023)
23
24 350 17 Consensus-based Standards for the selection of health Measurement
25 Instruments (COSMIN). Guideline for Systematic Reviews of Outcome
26 Measurement Instruments • COSMIN. COSMIN.
27 <https://www.cosmin.nl/tools/guideline-conducting-systematic-review-outcome-measures/> (accessed 24 November 2023)
28
29 355 18 Lopes LPN. SCREENING MD Study: protocol. Published Online First: 24
30 November 2023. <https://osf.io/z6t5m/> (accessed 5 April 2024)
31
32 357 19 Tricco AC, Lillie E, Zarin W, *et al.* PRISMA Extension for Scoping
33 Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.*
34 2018;169:467–73.
35
36 360 20 Muldoon LK, Hogg WE, Levitt M. Primary Care (PC) and Primary Health
37 Care (PHC). *Can J Public Health.* 2006;97:409–11.
38
39 362 21 McGowan J, Sampson M, Salzwedel DM, *et al.* PRESS Peer Review of
40 Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical*
41 *Epidemiology.* 2016;75:40–6.
42
43 365 22 Terwee CB, Jansma EP, Riphagen II, *et al.* Development of a
44 methodological PubMed search filter for finding studies on measurement
45 properties of measurement instruments. *Qual Life Res.* 2009;18:1115–23.
46
47 368 23 Ouzzani M, Hammady H, Fedorowicz Z, *et al.* Rayyan—a web and
48 mobile app for systematic reviews. *Systematic Reviews.* 2016;5:210.
49
50 370 24 Lopes LPN, Oliveira JC de, Bergamaschi C de C, *et al.* Use of second-
51 generation antipsychotics in autism spectrum disorder: a systematic review and
52 meta-analysis protocol. *BMJ Open.* 2023;13:e069114.
53
54
55
56
57
58
59
60

- 1
2
3 373 25 de Oliveira JC, Alves MR, Lopes LPN, et al. Sex differences and adverse
4 374 events of antiretrovirals in people living with HIV/AIDS: a systematic review and
5 375 meta-analysis protocol. *BMJ Open*. 2022;12:e057094.
6
7 376 26 Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached
8 international consensus on taxonomy, terminology, and definitions of
9 measurement properties for health-related patient-reported outcomes. *J Clin*
10 378 *Epidemiol*. 2010;63:737–45.
11 379
12
13 380 27 Mokkink LB, de Vet HCW, Prinsen C a. C, et al. COSMIN Risk of Bias
14 381 checklist for systematic reviews of Patient-Reported Outcome Measures. *Qual*
15 382 *Life Res*. 2018;27:1171–9.
16
17 383 28 Francis DO, McPheeeters ML, Noud M, et al. Checklist to operationalize
18 384 measurement characteristics of patient-reported outcome measures. *Syst Rev*.
19 385 2016;5:129.
20
21 386 29 Lavis JN, Oxman AD, Lewin S, et al. SUPPORT Tools for evidence-
22 387 informed health Policymaking (STP). *Health Res Policy Syst*. 2009;7 Suppl 1:1.
23
24 388
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Flow of conducting the scoping review



Supplementary Material 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

Adapted to protocol

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	5-6
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	6
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	6-7
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	7 and Supplementary Material 2
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	8
Critical appraisal of individual	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe	8



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
sources of evidence§		the methods used and how this information was used in any data synthesis (if appropriate).	
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	9

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850).



1
2
3 **Supplementary Material 2:** Search strategies employed in each consulted
4 database.
5

6 **MEDLINE (Via Pubmed)**
7

- 8 1. "Mental Disorder*"
9 2. "Psychiatric Illness**"
10 3. "Psychiatric* Disease"
11 4. "Mental Illness"
12 5. "Mental Illnesses"
13 6. "Psychiatric Disorder**"
14 7. "Behavior Disorders"
15 8. "Psychiatric Diagnosis"
16 9. "Severe Mental Disorder**"
17 10. "Psychotic Disorder**"
18 11. Psychos*
19 12. "Schizoaffective Disorder***"
20 13. "Schizophreniform Disorder**"
21 14. "Brief Reactive Psychos**"
22 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
23 16. "Schizophrenia, Paranoid"
24 17. "Paranoid Schizophrenias"
25 18. "Schizophrenias, Paranoid"
26 19. "Paranoid Schizophrenia"
27 20. "Delusional Disorder"
28 21. "Delusional Disorders"
29 22. "Disorder, Delusional"
30 23. "Disorders, Delusional"
31 24. "Schizophrenia, Disorganized"
32 25. "Disorganized Schizophrenia"
33 26. "Disorganized Schizophrenias"
34 27. "Schizophrenias, Disorganized"
35 28. "Hebephrenic Schizophrenia"
36 29. "Hebephrenic Schizophrenias"
37 30. "Schizophrenias, Hebephrenic"
38 31. "Schizophrenia, Hebephrenic"
39 32. "Schizophrenia, Catatonic"
40 33. "Catatonic Schizophrenia"
41 34. "Catatonic Schizophrenias"
42 35. "Schizophrenias, Catatonic""
43 36. "Mood Disorder**"
44 37. "Disorder, Mood"
45 38. "Disorders, Mood"
46 39. "Affective Disorder**"
47 40. "Disorder, Affective"
48 41. "Disorders, Affective"
49 42. Mania*
50 43. "Manic State"
51 44. "Hypomanic Episode"
52 45. "Hypomanic Episodes"
53 46. Hypomania*
54 47. "Manic Episode"
55 48. "Episode, Manic"
56 49. "Manic Episodes"
57 50. "Bipolar Disorder"
58 51. "Bipolar Disorders"

- 1
2
3 52. "Psychosis, Manic-Depressive"
4 53. "Psychosis, Manic Depressive"
5 54. "Psychoses, Manic-Depressive"
6 55. "Psychoses, Manic Depressive"
7 56. "Manic-Depressive Psychosis"
8 57. "Manic Depressive Psychosis"
9 58. "Bipolar Mood Disorder"
10 59. "Bipolar Mood Disorders"
11 60. "Disorder, Bipolar Mood"
12 61. "Mood Disorder, Bipolar"
13 62. "Affective Psychosis, Bipolar"
14 63. "Bipolar Affective Psychosis"
15 64. "Psychoses, Bipolar Affective"
16 65. "Psychosis, Bipolar Affective"
17 66. "Bipolar Disorder Type 1"
18 67. "Type 1 Bipolar Disorder"
19 68. "Manic Depression"
20 69. "Depression, Manic"
21 70. "Depressions, Manic"
22 71. "Depression, Bipolar"
23 72. "Bipolar Depression"
24 73. "Bipolar Disorder Type 2"
25 74. "Type 2 Bipolar Disorder" OR
26 75. "Manic Disorder"
27 76. "Disorder, Manic"
28 77. "Manic Disorders"
29 78. "Anxiety Disorder**"
30 79. "Disorder, Anxiety"
31 80. "Disorders, Anxiety"
32 81. "Neuroses, Anxiety"
33 82. "Anxiety Neuroses"
34 83. "Anxiety States, Neurotic"
35 84. "Anxiety State, Neurotic"
36 85. "Neurotic Anxiety State"
37 86. "Neurotic Anxiety States"
38 87. "State, Neurotic Anxiety"
39 88. "States, Neurotic Anxiety"
40 89. "Phobia, Social" OR "Social Phobia**"
41 90. "Social Evaluation Phobia"
42 91. "Phobia, Social Evaluation"
43 92. "Social Evaluation Phobias"
44 93. "Social Anxiety Disorder"
45 94. "Anxiety Disorder, Social"
46 95. "Disorder, Social Anxiety"
47 96. "Social Anxiety Disorders"
48 97. "Sociophobia"
49 98. "Fear of Social Evaluation"
50 99. "Evaluation Fear, Social"
51 100. "Social Evaluation Fear"
52 101. "Feeding and Eating Disorders"
53 102. "Eating and Feeding Disorders"
54 103. "Feeding Disorders"
55 104. "Disorder, Feeding"
56 105. "Disorders, Feeding"
57 106. "Feeding Disorder"
58 107. "Eating Disorders"

- 1
2
3 108. "Disorder, Eating"
4 109. "Disorders, Eating"
5 110. "Eating Disorder"
6 111. "Appetite Disorders"
7 112. "Appetite Disorder"
8 113. "Anorexia Nervosa"
9 114. "Anorexia Nervosas"
10 115. "Nervosa, Anorexia"
11 116. "Nervosas, Anorexia"
12 117. "Bulimia Nervosa"
13 118. "Nervosa, Bulimia"
14 119. "Substance-Related Disorder*"
15 120. "Disorder, Substance Related"
16 121. "Disorders, Substance Related"
17 122. "Related Disorder, Substance"
18 123. "Related Disorders, Substance"
19 124. "Drug Use Disorders"
20 125. "Drug Use Disorder"
21 126. "Disorder, Drug Use"
22 127. "Organic Mental Disorders, Substance-Induced"
23 128. "Organic Mental Disorders, Substance Induced"
24 129. "Substance Abuse"
25 130. "Abuse, Substance"
26 131. "Substance Abuses"
27 132. "Substance Dependence"
28 133. "Dependence, Substance"
29 134. "Substance Addiction"
30 135. "Addiction, Substance"
31 136. "Chemical Dependence"
32 137. "Chemical Dependences"
33 138. "Dependence, Chemical"
34 139. "Dependences, Chemical"
35 140. "Drug Dependence"
36 141. "Dependence, Drug"
37 142. "Drug Addiction"
38 143. "Addiction, Drug"
39 144. "Prescription Drug Abuse"
40 145. "Abuse, Prescription Drug"
41 146. "Drug Abuse, Prescription"
42 147. "Substance Use"
43 148. "Substance Uses"
44 149. "Use, Substance"
45 150. "Drug Abuse"
46 151. "Abuse, Drug"
47 152. "Drug Habituation"
48 153. "Habituation, Drug"
49 154. "Substance Use Disorders"
50 155. "Disorder, Substance Use"
51 156. "Substance Use Disorder"
52 157. or/1-157
53 158. "Mass Screening"
54 159. "Mass Screenings"
55 160. "Screening, Mass"
56 161. "Screenings, Mass"
57 162. "Screening*"
58 163. "Diagnostic Screening Programs"

- 1
2
3 164. "Diagnostic Screening Program"
4 165. "Program, Diagnostic Screening"
5 166. "Programs, Diagnostic Screening"
6 167. "Screening Program, Diagnostic"
7 168. "Screening Programs, Diagnostic"
8 169. or/158-168
9 170. COSMIN filter for identifying studies on the development of health measurement
10 instruments
11 171. #157 AND #169 AND 170
12

13 **EMBASE**

- 14
15 1. 'Mental Disorder*'
16 2. 'Psychiatric Illness*'
17 3. 'Psychiatric* Disease'
18 4. 'Mental Illness'
19 5. 'Mental Illnesses'
20 6. 'Psychiatric Disorder*'
21 7. 'Behavior Disorders'
22 8. 'Psychiatric Diagnosis'
23 9. 'Severe Mental Disorder*'
24 10. 'Psychotic Disorder**'
25 11. Psychos*
26 12. 'Schizoaffective Disorder***'
27 13. 'Schizophreniform Disorder*'
28 14. 'Brief Reactive Psychos*'
29 15. 'Schizophrenia Spectrum and Other Psychotic Disorders'
30 16. 'Schizophrenia, Paranoid'
31 17. 'Paranoid Schizophrenias'
32 18. 'Schizophrenias, Paranoid'
33 19. 'Paranoid Schizophrenia'
34 20. 'Delusional Disorder'
35 21. 'Delusional Disorders'
36 22. 'Disorder, Delusional'
37 23. 'Disorders, Delusional'
38 24. 'Schizophrenia, Disorganized'
39 25. 'Disorganized Schizophrenia'
40 26. 'Disorganized Schizophrenias'
41 27. 'Schizophrenias, Disorganized'
42 28. 'Hebephrenic Schizophrenia'
43 29. 'Hebephrenic Schizophrenias'
44 30. 'Schizophrenias, Hebephrenic'
45 31. 'Schizophrenia, Hebephrenic'
46 32. 'Schizophrenia, Catatonic'
47 33. 'Catatonic Schizophrenia'
48 34. 'Catatonic Schizophrenias'
49 35. 'Schizophrenias, Catatonic"
50 36. 'Mood Disorder*'
51 37. 'Disorder, Mood'
52 38. 'Disorders, Mood'
53 39. 'Affective Disorder*'
54 40. 'Disorder, Affective'
55 41. 'Disorders, Affective'
56 42. Mania*
57 43. 'Manic State'
58 44. 'Hypomanic Episode'
59 45. 'Hypomanic Episodes'
60

- 1
2
3 46. Hypomania*
4 47. 'Manic Episode'
5 48. 'Episode, Manic'
6 49. 'Manic Episodes'
7 50. 'Bipolar Disorder'
8 51. 'Bipolar Disorders'
9 52. 'Psychosis, Manic-Depressive'
10 53. 'Psychosis, Manic Depressive'
11 54. 'Psychoses, Manic-Depressive'
12 55. 'Psychoses, Manic Depressive'
13 56. 'Manic-Depressive Psychosis'
14 57. 'Manic Depressive Psychosis'
15 58. 'Bipolar Mood Disorder'
16 59. 'Bipolar Mood Disorders'
17 60. 'Disorder, Bipolar Mood'
18 61. 'Mood Disorder, Bipolar'
19 62. 'Affective Psychosis, Bipolar'
20 63. 'Bipolar Affective Psychosis'
21 64. 'Psychoses, Bipolar Affective'
22 65. 'Psychosis, Bipolar Affective'
23 66. 'Bipolar Disorder Type 1'
24 67. 'Type 1 Bipolar Disorder'
25 68. 'Manic Depression'
26 69. 'Depression, Manic'
27 70. 'Depressions, Manic'
28 71. 'Depression, Bipolar'
29 72. 'Bipolar Depression'
30 73. 'Bipolar Disorder Type 2'
31 74. 'Type 2 Bipolar Disorder' OR
32 75. 'Manic Disorder'
33 76. 'Disorder, Manic'
34 77. 'Manic Disorders'
35 78. 'Anxiety Disorder*'
36 79. 'Disorder, Anxiety'
37 80. 'Disorders, Anxiety'
38 81. 'Neuroses, Anxiety'
39 82. 'Anxiety Neuroses'
40 83. 'Anxiety States, Neurotic'
41 84. 'Anxiety State, Neurotic'
42 85. 'Neurotic Anxiety State'
43 86. 'Neurotic Anxiety States'
44 87. 'State, Neurotic Anxiety'
45 88. 'States, Neurotic Anxiety'
46 89. 'Phobia, Social' OR 'Social Phobia*'
47 90. 'Social Evaluation Phobia'
48 91. 'Phobia, Social Evaluation'
49 92. 'Social Evaluation Phobias'
50 93. 'Social Anxiety Disorder'
51 94. 'Anxiety Disorder, Social'
52 95. 'Disorder, Social Anxiety'
53 96. 'Social Anxiety Disorders'
54 97. Sociophobia*
55 98. 'Fear of Social Evaluation'
56 99. 'Evaluation Fear, Social'
57 100. 'Social Evaluation Fear'
58 101. 'Feeding and Eating Disorders'

- 1
2
3 102. 'Eating and Feeding Disorders'
4 103. 'Feeding Disorders'
5 104. 'Disorder, Feeding'
6 105. 'Disorders, Feeding'
7 106. 'Feeding Disorder'
8 107. 'Eating Disorders'
9 108. 'Disorder, Eating'
10 109. 'Disorders, Eating'
11 110. 'Eating Disorder'
12 111. 'Appetite Disorders'
13 112. 'Appetite Disorder'
14 113. 'Anorexia Nervosa'
15 114. 'Anorexia Nervosas'
16 115. 'Nervosa, Anorexia'
17 116. 'Nervosas, Anorexia'
18 117. 'Bulimia Nervosa'
19 118. 'Nervosa, Bulimia'
20 119. 'Substance-Related Disorder*'
21 120. 'Disorder, Substance Related'
22 121. 'Disorders, Substance Related'
23 122. 'Related Disorder, Substance'
24 123. 'Related Disorders, Substance'
25 124. 'Drug Use Disorders'
26 125. 'Drug Use Disorder'
27 126. 'Disorder, Drug Use'
28 127. 'Organic Mental Disorders, Substance-Induced'
29 128. 'Organic Mental Disorders, Substance Induced'
30 129. 'Substance Abuse'
31 130. 'Abuse, Substance'
32 131. 'Substance Abuses'
33 132. 'Substance Dependence'
34 133. 'Dependence, Substance'
35 134. 'Substance Addiction'
36 135. 'Addiction, Substance'
37 136. 'Chemical Dependence'
38 137. 'Chemical Dependences'
39 138. 'Dependence, Chemical'
40 139. 'Dependences, Chemical'
41 140. 'Drug Dependence'
42 141. 'Dependence, Drug'
43 142. 'Drug Addiction'
44 143. 'Addiction, Drug'
45 144. 'Prescription Drug Abuse'
46 145. 'Abuse, Prescription Drug'
47 146. 'Drug Abuse, Prescription'
48 147. 'Substance Use'
49 148. 'Substance Uses'
50 149. 'Use, Substance'
51 150. 'Drug Abuse'
52 151. 'Abuse, Drug'
53 152. 'Drug Habituation'
54 153. 'Habituation, Drug'
55 154. 'Substance Use Disorders'
56 155. 'Disorder, Substance Use'
57 156. 'Substance Use Disorder'
58 157. or/1-157

- 1
2
3 158. 'Mass Screening'
4 159. 'Mass Screenings'
5 160. 'Screening, Mass'
6 161. 'Screenings, Mass'
7 162. Screening*
8 163. 'Diagnostic Screening Programs'
9 164. 'Diagnostic Screening Program'
10 165. 'Program, Diagnostic Screening'
11 166. 'Programs, Diagnostic Screening'
12 167. 'Screening Program, Diagnostic'
13 168. 'Screening Programs, Diagnostic'
14 169. or/158-168
15 170. COSMIN filter for identifying studies on the development of health measurement
16 instruments
17 171. #157 AND #169 AND 170
18

19 **PsycINFO**
20

- 21 1. "Mental Disorder*"
22 2. "Psychiatric Illness**"
23 3. "Psychiatric* Disease"
24 4. "Mental Illness"
25 5. "Mental Illnesses"
26 6. "Psychiatric Disorder*"
27 7. "Behavior Disorders"
28 8. "Psychiatric Diagnosis"
29 9. "Severe Mental Disorder*"
30 10. "Psychotic Disorder*"
31 11. Psychos*
32 12. "Schizoaffective Disorder***"
33 13. "Schizophreniform Disorder*"
34 14. "Brief Reactive Psychos*"
35 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
36 16. "Schizophrenia, Paranoid"
37 17. "Paranoid Schizophrenias"
38 18. "Schizophrenias, Paranoid"
39 19. "Paranoid Schizophrenia"
40 20. "Delusional Disorder"
41 21. "Delusional Disorders"
42 22. "Disorder, Delusional"
43 23. "Disorders, Delusional"
44 24. "Schizophrenia, Disorganized"
45 25. "Disorganized Schizophrenia"
46 26. "Disorganized Schizophrenias"
47 27. "Schizophrenias, Disorganized"
48 28. "Hebephrenic Schizophrenia"
49 29. "Hebephrenic Schizophrenias"
50 30. "Schizophrenias, Hebephrenic"
51 31. "Schizophrenia, Hebephrenic"
52 32. "Schizophrenia, Catatonic"
53 33. "Catatonic Schizophrenia"
54 34. "Catatonic Schizophrenias"
55 35. "Schizophrenias, Catatonic""
56 36. "Mood Disorder*"
57 37. "Disorder, Mood"
58 38. "Disorders, Mood"
59 39. "Affective Disorder**"

- 1
2
3 40. "Disorder, Affective"
4 41. "Disorders, Affective"
5 42. Mania*
6 43. "Manic State"
7 44. "Hypomanic Episode"
8 45. "Hypomanic Episodes"
9 46. Hypomania*
10 47. "Manic Episode"
11 48. "Episode, Manic"
12 49. "Manic Episodes"
13 50. "Bipolar Disorder"
14 51. "Bipolar Disorders"
15 52. "Psychosis, Manic-Depressive"
16 53. "Psychosis, Manic Depressive"
17 54. "Psychoses, Manic-Depressive"
18 55. "Psychoses, Manic Depressive"
19 56. "Manic-Depressive Psychosis"
20 57. "Manic Depressive Psychosis"
21 58. "Bipolar Mood Disorder"
22 59. "Bipolar Mood Disorders"
23 60. "Disorder, Bipolar Mood"
24 61. "Mood Disorder, Bipolar"
25 62. "Affective Psychosis, Bipolar"
26 63. "Bipolar Affective Psychosis"
27 64. "Psychoses, Bipolar Affective"
28 65. "Psychosis, Bipolar Affective"
29 66. "Bipolar Disorder Type 1"
30 67. "Type 1 Bipolar Disorder"
31 68. "Manic Depression"
32 69. "Depression, Manic"
33 70. "Depressions, Manic"
34 71. "Depression, Bipolar"
35 72. "Bipolar Depression"
36 73. "Bipolar Disorder Type 2"
37 74. "Type 2 Bipolar Disorder" OR
38 75. "Manic Disorder"
39 76. "Disorder, Manic"
40 77. "Manic Disorders"
41 78. "Anxiety Disorder**"
42 79. "Disorder, Anxiety"
43 80. "Disorders, Anxiety"
44 81. "Neuroses, Anxiety"
45 82. "Anxiety Neuroses"
46 83. "Anxiety States, Neurotic"
47 84. "Anxiety State, Neurotic"
48 85. "Neurotic Anxiety State"
49 86. "Neurotic Anxiety States"
50 87. "State, Neurotic Anxiety"
51 88. "States, Neurotic Anxiety"
52 89. "Phobia, Social" OR "Social Phobia**"
53 90. "Social Evaluation Phobia"
54 91. "Phobia, Social Evaluation"
55 92. "Social Evaluation Phobias"
56 93. "Social Anxiety Disorder"
57 94. "Anxiety Disorder, Social"
58 95. "Disorder, Social Anxiety"

- 1
2
3 96. "Social Anxiety Disorders"
4 97. Sociophobia*
5 98. "Fear of Social Evaluation"
6 99. "Evaluation Fear, Social"
7 100. "Social Evaluation Fear"
8 101. "Feeding and Eating Disorders"
9 102. "Eating and Feeding Disorders"
10 103. "Feeding Disorders"
11 104. "Disorder, Feeding"
12 105. "Disorders, Feeding"
13 106. "Feeding Disorder"
14 107. "Eating Disorders"
15 108. "Disorder, Eating"
16 109. "Disorders, Eating"
17 110. "Eating Disorder"
18 111. "Appetite Disorders"
19 112. "Appetite Disorder"
20 113. "Anorexia Nervosa"
21 114. "Anorexia Nervosas"
22 115. "Nervosa, Anorexia"
23 116. "Nervosas, Anorexia"
24 117. "Bulimia Nervosa"
25 118. "Nervosa, Bulimia"
26 119. "Substance-Related Disorder*"
27 120. "Disorder, Substance Related"
28 121. "Disorders, Substance Related"
29 122. "Related Disorder, Substance"
30 123. "Related Disorders, Substance"
31 124. "Drug Use Disorders"
32 125. "Drug Use Disorder"
33 126. "Disorder, Drug Use"
34 127. "Organic Mental Disorders, Substance-Induced"
35 128. "Organic Mental Disorders, Substance Induced"
36 129. "Substance Abuse"
37 130. "Abuse, Substance"
38 131. "Substance Abuses"
39 132. "Substance Dependence"
40 133. "Dependence, Substance"
41 134. "Substance Addiction"
42 135. "Addiction, Substance"
43 136. "Chemical Dependence"
44 137. "Chemical Dependences"
45 138. "Dependence, Chemical"
46 139. "Dependences, Chemical"
47 140. "Drug Dependence"
48 141. "Dependence, Drug"
49 142. "Drug Addiction"
50 143. "Addiction, Drug"
51 144. "Prescription Drug Abuse"
52 145. "Abuse, Prescription Drug"
53 146. "Drug Abuse, Prescription"
54 147. "Substance Use"
55 148. "Substance Uses"
56 149. "Use, Substance"
57 150. "Drug Abuse"
58 151. "Abuse, Drug"

- 1
2
3 152. "Drug Habituation"
4 153. "Habituation, Drug"
5 154. "Substance Use Disorders"
6 155. "Disorder, Substance Use"
7 156. "Substance Use Disorder"
8 157. or/1-157
9 158. "Mass Screening"
10 159. "Mass Screenings"
11 160. "Screening, Mass"
12 161. "Screenings, Mass"
13 162. Screening*
14 163. "Diagnostic Screening Programs"
15 164. "Diagnostic Screening Program"
16 165. "Program, Diagnostic Screening"
17 166. "Programs, Diagnostic Screening"
18 167. "Screening Program, Diagnostic"
19 168. "Screening Programs, Diagnostic"
20 169. or/158-168
21 170. COSMIN filter for identifying studies on the development of health measurement
22 instruments
23 171. #157 AND #169 AND 170

24
25 **LILACS**
26

- 27 1. "Transtornos Mentais"
28 2. "Diagnóstico Psiquiátrico"
29 3. "Distúrbios Psiquiátricos"
30 4. "Doença Mental"
31 5. "Doença Psiquiátrica"
32 6. "Doenças Psiquiátricas"
33 7. Insanidade
34 8. "Transtorno do Comportamento"
35 9. "Transtornos do Comportamento"
36 10. "Transtornos Mentais Graves"
37 11. "Transtornos Mentais Severos"
38 12. "Transtornos Psiquiátricos"
39 13. "Trastornos Mentales"
40 14. "Enfermedad Mental"
41 15. "Enfermedad Psiquiátrica"
42 16. "Enfermedades Psiquiátricas"
43 17. Insanidad
44 18. "Transtornos Mentales Severos"
45 19. "Trastorno del Comportamiento"
46 20. "Trastorno Mental"
47 21. "Trastornos del Comportamiento"
48 22. "Trastornos Mentales Graves"
49 23. "Trastornos Psiquiátricos"
50 24. "Mental Disorder**"
51 25. "Psychiatric Illness**"
52 26. "Psychiatric* Disease"
53 27. "Mental Illness"
54 28. "Mental Illnesses"
55 29. "Psychiatric Disorder**"
56 30. "Behavior Disorders"
57 31. "Psychiatric Diagnosis"
58 32. "Severe Mental Disorder**"
59 33. "Psychotic Disorder**"

- 1
2
3 34. Psychos*
4 35. "Schizoaffective Disorder*"
5 36. "Schizophreniform Disorder*"
6 37. "Brief Reactive Psychos*"
7 38. "Schizophrenia Spectrum and Other Psychotic Disorders"
8 39. "Schizophrenia, Paranoid"
9 40. "Paranoid Schizophrenias"
10 41. "Schizophrenias, Paranoid"
11 42. "Paranoid Schizophrenia"
12 43. "Delusional Disorder"
13 44. "Delusional Disorders"
14 45. "Disorder, Delusional"
15 46. "Disorders, Delusional"
16 47. "Schizophrenia, Disorganized"
17 48. "Disorganized Schizophrenia"
18 49. "Disorganized Schizophrenias"
19 50. "Schizophrenias, Disorganized"
20 51. "Hebephrenic Schizophrenia"
21 52. "Hebephrenic Schizophrenias"
22 53. "Schizophrenias, Hebephrenic"
23 54. "Schizophrenia, Hebephrenic"
24 55. "Schizophrenia, Catatonic"
25 56. "Catatonic Schizophrenia"
26 57. "Catatonic Schizophrenias"
27 58. "Schizophrenias, Catatonic"
28 59. "Transtornos Psicóticos"
29 60. "Psicose Reativa Breve"
30 61. Psicoses
31 62. "Transtorno Esquizoafetivo"
32 63. "Transtornos Esquizofreniformes"
33 64. "Espectro da Esquizofrenia e Outros Transtornos Psicóticos"
34 65. "Esquizofrenia e Transtornos com Características Psicóticas"
35 66. "Esquizofrenia Paranoide"
36 67. "Transtorno Delirante"
37 68. "Esquizofrenia Hebefrênica"
38 69. "Esquizofrenia Catatônica"
39 70. "Transtornos Psicóticos"
40 71. Psicosis OR "Psicosis Reactiva Breve"
41 72. "Transtorno Esquizoafetivo"
42 73. "Transtornos Esquizofreniformes"
43 74. "Esquizofrenia Hebefrénica"
44 75. "Esquizofrenia Catatónica"
45 76. "Mood Disorder*"
46 77. "Disorder, Mood"
47 78. "Disorders, Mood"
48 79. "Affective Disorder*"
49 80. "Disorder, Affective"
50 81. "Disorders, Affective"
51 82. Mania*
52 83. "Manic State"
53 84. "Hypomanic Episode"
54 85. "Hypomanic Episodes"
55 86. Hypomania*
56 87. "Manic Episode"
57 88. "Episode, Manic"
58 89. "Manic Episodes"

- 1
2
3 90. "Bipolar Disorder"
4 91. "Bipolar Disorders"
5 92. "Psychosis, Manic-Depressive"
6 93. "Psychosis, Manic Depressive"
7 94. "Psychoses, Manic-Depressive"
8 95. "Psychoses, Manic Depressive"
9 96. "Manic-Depressive Psychosis"
10 97. "Manic Depressive Psychosis"
11 98. "Bipolar Mood Disorder"
12 99. "Bipolar Mood Disorders"
13 100. "Disorder, Bipolar Mood"
14 101. "Mood Disorder, Bipolar"
15 102. "Affective Psychosis, Bipolar"
16 103. "Bipolar Affective Psychosis"
17 104. "Psychoses, Bipolar Affective"
18 105. "Psychosis, Bipolar Affective"
19 106. "Bipolar Disorder Type 1"
20 107. "Type 1 Bipolar Disorder"
21 108. "Manic Depression"
22 109. "Depression, Manic"
23 110. "Depressions, Manic"
24 111. "Depression, Bipolar"
25 112. "Bipolar Depression"
26 113. "Bipolar Disorder Type 2"
27 114. "Type 2 Bipolar Disorder" OR
28 115. "Manic Disorder"
29 116. "Disorder, Manic"
30 117. "Manic Disorders"
31 118. "Transtornos do Humor"
32 119. "Transtornos Afetivos"
33 120. "Trastornos del Humor"
34 121. Mania
35 122. "Episódio Hipomaníaco"
36 123. "Episódio Maníaco"
37 124. "Estado Maníaco"
38 125. "Estado de Loucura"
39 126. hipomania
40 127. "episodio hipomaníaco"
41 128. "episodio maníaco"
42 129. "estado maníaco"
43 130. "hipomanía"
44 131. "Anxiety Disorder*"
45 132. "Disorder, Anxiety"
46 133. "Disorders, Anxiety"
47 134. "Neuroses, Anxiety"
48 135. "Anxiety Neuroses"
49 136. "Anxiety States, Neurotic"
50 137. "Anxiety State, Neurotic"
51 138. "Neurotic Anxiety State"
52 139. "Neurotic Anxiety States"
53 140. "State, Neurotic Anxiety"
54 141. "States, Neurotic Anxiety"
55 142. "Phobia, Social" OR "Social Phobia*"
56 143. "Social Evaluation Phobia"
57 144. "Phobia, Social Evaluation"
58 145. "Social Evaluation Phobias"

- 1
2
3 146. "Social Anxiety Disorder"
4 147. "Anxiety Disorder, Social"
5 148. "Disorder, Social Anxiety"
6 149. "Social Anxiety Disorders"
7 150. Sociophobia*
8 151. "Transtornos de Ansiedade"
9 152. "Distúrbios de Ansiedade"
10 153. "Estados de Ansiedade Neurótica"
11 154. "Neurose de Ansiedade"
12 155. "Transtornos Ansiosos"
13 156. "Transtornos de Angústia"
14 157. Agorafobia
15 158. Demofobia
16 159. Enoclofobia
17 160. "Fobia de Espaços Abertos"
18 161. "Fobia de Multidão"
19 162. "Fobia de Multidões"
20 163. Oclofobia*
21 164. "Transtorno de Pânico"
22 165. "Ataques de Pânico"
23 166. "trastornos de ansiedad"
24 167. "estados de ansiedad neuróticos"
25 168. "neurosis de ansiedad"
26 169. "fobia a las multitudes"
27 170. "fobia a los espacios abiertos"
28 171. "trastorno de pánico"
29 172. "ataques de pánico"
30 173. "Fear of Social Evaluation"
31 174. "Evaluation Fear, Social"
32 175. "Social Evaluation Fear"
33 176. "Feeding and Eating Disorders"
34 177. "Eating and Feeding Disorders"
35 178. "Feeding Disorders"
36 179. "Disorder, Feeding"
37 180. "Disorders, Feeding"
38 181. "Feeding Disorder"
39 182. "Eating Disorders"
40 183. "Disorder, Eating"
41 184. "Disorders, Eating"
42 185. "Eating Disorder"
43 186. "Appetite Disorders"
44 187. "Appetite Disorder"
45 188. "Anorexia Nervosa"
46 189. "Anorexia Nervosas"
47 190. "Nervosa, Anorexia"
48 191. "Nervosas, Anorexia"
49 192. "Bulimia Nervosa"
50 193. "Nervosa, Bulimia"
51 194. "Transtornos da Alimentação"
52 195. "Transtornos da Ingestão de Alimentos"
53 196. "Transtornos do Apetite"
54 197. "Transtorno da Compulsão Alimentar"
55 198. "Compulsão Alimentar"
56 199. "Anorexia Nervosa"
57 200. "Bulimia Nervosa"
58 201. "Trastornos de Alimentación y de la Ingestión de Alimentos"

- 1
2
3 202. "Trastorno Alimentario"
4 203. "Trastornos Alimentarios"
5 204. "Trastornos Alimentarios y de la Ingestión de Alimentos"
6 205. "Trastornos de Alimentación"
7 206. "Trastornos de la Conducta Alimentaria"
8 207. "Trastornos de la Ingesta de Alimentos"
9 208. "Trastornos de la Ingestión de Alimentos"
10 209. "Trastornos del Apetito"
11 210. "Trastorno por Atracón"
12 211. "trastorno de hiperfagia compulsiva"
13 212. "trastorno de atracones"
14 213. "Anorexia Nerviosa"
15 214. "anorexia nerviosa"
16 215. "Bulimia Nerviosa"
17 216. "Substance-Related Disorder*"
18 217. "Disorder, Substance Related"
19 218. "Disorders, Substance Related"
20 219. "Related Disorder, Substance"
21 220. "Related Disorders, Substance"
22 221. "Drug Use Disorders"
23 222. "Drug Use Disorder"
24 223. "Disorder, Drug Use"
25 224. "Organic Mental Disorders, Substance-Induced"
26 225. "Organic Mental Disorders, Substance Induced"
27 226. "Substance Abuse"
28 227. "Abuse, Substance"
29 228. "Substance Abuses"
30 229. "Substance Dependence"
31 230. "Dependence, Substance"
32 231. "Substance Addiction"
33 232. "Addiction, Substance"
34 233. "Chemical Dependence"
35 234. "Chemical Dependences"
36 235. "Dependence, Chemical"
37 236. "Dependences, Chemical"
38 237. "Drug Dependence"
39 238. "Dependence, Drug"
40 239. "Drug Addiction"
41 240. "Addiction, Drug"
42 241. "Prescription Drug Abuse"
43 242. "Abuse, Prescription Drug"
44 243. "Drug Abuse, Prescription"
45 244. "Substance Use"
46 245. "Substance Uses"
47 246. "Use, Substance"
48 247. "Drug Abuse"
49 248. "Abuse, Drug"
50 249. "Drug Habituation"
51 250. "Habituation, Drug"
52 251. "Substance Use Disorders"
53 252. "Disorder, Substance Use"
54 253. "Substance Use Disorder"
55 254. "Transtornos Relacionados ao Uso de Substâncias"
56 255. "Abuso de Drogas"
57 256. "Abuso de Medicamentos sob Prescrição"
58 257. "Abuso de Substâncias"

- 1
2
3 258. "Abuso de Substâncias Psicoativas"
4 259. "Abuso de Substâncias que Produzem Dependência"
5 260. "Abuso de Substâncias que não Produzem Dependência"
6 261. "Adição a Drogas"
7 262. "Dependência Física de Substâncias"
8 263. "Dependência Psíquica de Substâncias"
9 264. "Dependência Química"
10 265. "Dependência de Agentes Químicos"
11 266. "Dependência de Drogas"
12 267. "Dependência de Substâncias"
13 268. "Dependência de Substâncias Psicoativas"
14 269. Drogadicção
15 270. Drogadição
16 271. Farmacodependência
17 272. "Habituação a Drogas"
18 273. Toxicomania
19 274. "Transtorno Relacionado ao Uso de Substâncias"
20 275. "Transtornos Induzidos por Uso de Substâncias"
21 276. "Transtornos Mentais Orgânicos Induzidos por Substâncias"
22 277. "Transtornos Mentais Orgânicos Induzidos por Substâncias Psicoativas"
23 278. "Transtornos Relacionados ao Uso de Substâncias Psicoativas"
24 279. "Transtornos por Uso de Drogas"
25 280. "Transtornos por Uso de Substâncias"
26 281. "Transtornos por Uso de Substâncias Psicoativas"
27 282. "Uso Indevido de Drogas"
28 283. "Uso Indevido de Substâncias"
29 284. "Uso de Substâncias"
30 285. "Trastornos Relacionados con Sustancias"
31 286. "adicción a sustancias"
32 287. drogadicción
33 288. drogodependencia
34 289. "habituación a drogas"
35 290. "habituación a sustancias"
36 291. "trastorno por consumo de sustancias"
37 292. "trastorno relacionado con sustancias"
38 293. "trastornos inducidos por consumo de sustancias"
39 294. "trastornos inducidos por uso de sustancias"
40 295. "trastornos mentales orgánicos inducidos por sustancias"
41 296. "trastornos por consumo de drogas"
42 297. "trastornos por consumo de sustancias"
43 298. "trastornos por consumo de sustancias psicoactivas"
44 299. "trastornos por uso de drogas"
45 300. "trastornos por uso de sustancias"
46 301. "trastornos por uso de sustancias psicoactivas"
47 302. "trastornos relacionados con el consumo de sustancias psicoactivas"
48 303. "trastornos relacionados con el uso de sustancias psicoactivas"
49 304. or/1-303
50 305. "Mass Screening"
51 306. "Mass Screenings"
52 307. "Screening, Mass"
53 308. "Screenings, Mass"
54 309. Screening*
55 310. "Diagnostic Screening Programs"
56 311. "Diagnostic Screening Program"
57 312. "Program, Diagnostic Screening"
58 313. "Programs, Diagnostic Screening"

- 1
2
3 314. "Screening Program, Diagnostic"
4 315. "Screening Programs, Diagnostic"
5 316. "Programas de Rastreamento"
6 317. "Exame Coletivo"
7 318. "Identificação Sistêmica"
8 319. "Programas de Triagem Diagnóstica"
9 320. Rastreamento
10 321. Rastreio
11 322. "Triagem de Massa"
12 323. "Tamizaje Masivo"
13 324. "cribado sistemático"
14 325. cribado "cribado masivo"
15 326. "detección selectiva"
16 327. "detección sistemática"
17 328. "examen colectivo"
18 329. "identificación sistemática"
19 330. screening OR "screening masivo"
20 331. "Programas de Detección Diagnóstica"
21 332. "programas de cribado diagnóstico"
22 333. "programa de cribado diagnóstico"
23 334. or/305-333
24 335. COSMIN filter for identifying studies on the development of health measurement
25 instruments
26 336. #304 AND #334 AND 335
27
28
29

CINAHL

- 30 1. "Mental Disorder**"
31 2. "Psychiatric Illness**"
32 3. "Psychiatric* Disease"
33 4. "Mental Illness"
34 5. "Mental Illnesses"
35 6. "Psychiatric Disorder**"
36 7. "Behavior Disorders"
37 8. "Psychiatric Diagnosis"
38 9. "Severe Mental Disorder**"
39 10. "Psychotic Disorder**"
40 11. Psychos*
41 12. "Schizoaffective Disorder***"
42 13. "Schizophreniform Disorder**"
43 14. "Brief Reactive Psychos**"
44 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
45 16. "Schizophrenia, Paranoid"
46 17. "Paranoid Schizophrenias"
47 18. "Schizophrenias, Paranoid"
48 19. "Paranoid Schizophrenia"
49 20. "Delusional Disorder"
50 21. "Delusional Disorders"
51 22. "Disorder, Delusional"
52 23. "Disorders, Delusional"
53 24. "Schizophrenia, Disorganized"
54 25. "Disorganized Schizophrenia"
55 26. "Disorganized Schizophrenias"
56 27. "Schizophrenias, Disorganized"
57 28. "Hebephrenic Schizophrenia"
58 29. "Hebephrenic Schizophrenias"
59 30. "Schizophrenias, Hebephrenic"
60

- 1
2
3 31. "Schizophrenia, Hebephrenic"
4 32. "Schizophrenia, Catatonic"
5 33. "Catatonic Schizophrenia"
6 34. "Catatonic Schizophrenias"
7 35. "Schizophrenias, Catatonic""
8 36. "Mood Disorder**"
9 37. "Disorder, Mood"
10 38. "Disorders, Mood"
11 39. "Affective Disorder**"
12 40. "Disorder, Affective"
13 41. "Disorders, Affective"
14 42. Mania*
15 43. "Manic State"
16 44. "Hypomanic Episode"
17 45. "Hypomanic Episodes"
18 46. Hypomania*
19 47. "Manic Episode"
20 48. "Episode, Manic"
21 49. "Manic Episodes"
22 50. "Bipolar Disorder"
23 51. "Bipolar Disorders"
24 52. "Psychosis, Manic-Depressive"
25 53. "Psychosis, Manic Depressive"
26 54. "Psychoses, Manic-Depressive"
27 55. "Psychoses, Manic Depressive"
28 56. "Manic-Depressive Psychosis"
29 57. "Manic Depressive Psychosis"
30 58. "Bipolar Mood Disorder"
31 59. "Bipolar Mood Disorders"
32 60. "Disorder, Bipolar Mood"
33 61. "Mood Disorder, Bipolar"
34 62. "Affective Psychosis, Bipolar"
35 63. "Bipolar Affective Psychosis"
36 64. "Psychoses, Bipolar Affective"
37 65. "Psychosis, Bipolar Affective"
38 66. "Bipolar Disorder Type 1"
39 67. "Type 1 Bipolar Disorder"
40 68. "Manic Depression"
41 69. "Depression, Manic"
42 70. "Depressions, Manic"
43 71. "Depression, Bipolar"
44 72. "Bipolar Depression"
45 73. "Bipolar Disorder Type 2"
46 74. "Type 2 Bipolar Disorder" OR
47 75. "Manic Disorder"
48 76. "Disorder, Manic"
49 77. "Manic Disorders"
50 78. "Anxiety Disorder**"
51 79. "Disorder, Anxiety"
52 80. "Disorders, Anxiety"
53 81. "Neuroses, Anxiety"
54 82. "Anxiety Neuroses"
55 83. "Anxiety States, Neurotic"
56 84. "Anxiety State, Neurotic"
57 85. "Neurotic Anxiety State"
58 86. "Neurotic Anxiety States"

- 1
2
3 87. "State, Neurotic Anxiety"
4 88. "States, Neurotic Anxiety"
5 89. "Phobia, Social" OR "Social Phobia**"
6 90. "Social Evaluation Phobia"
7 91. "Phobia, Social Evaluation"
8 92. "Social Evaluation Phobias"
9 93. "Social Anxiety Disorder"
10 94. "Anxiety Disorder, Social"
11 95. "Disorder, Social Anxiety"
12 96. "Social Anxiety Disorders"
13 97. Sociophobia*
14 98. "Fear of Social Evaluation"
15 99. "Evaluation Fear, Social"
16 100. "Social Evaluation Fear"
17 101. "Feeding and Eating Disorders"
18 102. "Eating and Feeding Disorders"
19 103. "Feeding Disorders"
20 104. "Disorder, Feeding"
21 105. "Disorders, Feeding"
22 106. "Feeding Disorder"
23 107. "Eating Disorders"
24 108. "Disorder, Eating"
25 109. "Disorders, Eating"
26 110. "Eating Disorder"
27 111. "Appetite Disorders"
28 112. "Appetite Disorder"
29 113. "Anorexia Nervosa"
30 114. "Anorexia Nervosas"
31 115. "Nervosa, Anorexia"
32 116. "Nervosas, Anorexia"
33 117. "Bulimia Nervosa"
34 118. "Nervosa, Bulimia"
35 119. "Substance-Related Disorder**"
36 120. "Disorder, Substance Related"
37 121. "Disorders, Substance Related"
38 122. "Related Disorder, Substance"
39 123. "Related Disorders, Substance"
40 124. "Drug Use Disorders"
41 125. "Drug Use Disorder"
42 126. "Disorder, Drug Use"
43 127. "Organic Mental Disorders, Substance-Induced"
44 128. "Organic Mental Disorders, Substance Induced"
45 129. "Substance Abuse"
46 130. "Abuse, Substance"
47 131. "Substance Abuses"
48 132. "Substance Dependence"
49 133. "Dependence, Substance"
50 134. "Substance Addiction"
51 135. "Addiction, Substance"
52 136. "Chemical Dependence"
53 137. "Chemical Dependences"
54 138. "Dependence, Chemical"
55 139. "Dependences, Chemical"
56 140. "Drug Dependence"
57 141. "Dependence, Drug"
58 142. "Drug Addiction"

1
2
3 143. "Addiction, Drug"
4 144. "Prescription Drug Abuse"
5 145. "Abuse, Prescription Drug"
6 146. "Drug Abuse, Prescription"
7 147. "Substance Use"
8 148. "Substance Uses"
9 149. "Use, Substance"
10 150. "Drug Abuse"
11 151. "Abuse, Drug"
12 152. "Drug Habituation"
13 153. "Habituation, Drug"
14 154. "Substance Use Disorders"
15 155. "Disorder, Substance Use"
16 156. "Substance Use Disorder"
17 157. or/1-157
18 158. "Mass Screening"
19 159. "Mass Screenings"
20 160. "Screening, Mass"
21 161. "Screenings, Mass"
22 162. Screening*
23
24 163. "Diagnostic Screening Programs"
25 164. "Diagnostic Screening Program"
26 165. "Program, Diagnostic Screening"
27 166. "Programs, Diagnostic Screening"
28 167. "Screening Program, Diagnostic"
29 168. "Screening Programs, Diagnostic"
30 169. or/158-168
31 170. COSMIN filter for identifying studies on the development of health measurement
32 instruments
33 171. #157 AND #169 AND 170
34
35
36
37

COSMIN filter

38 (instrumentation[sh] OR methods[sh] OR "Validation Studies"[pt] OR "Comparative Study"[pt]
39 OR "psychometrics"[MeSH] OR psychometr*[tiab] OR clinimetr*[tw] OR clinometr*[tw] OR
40 "outcome assessment (health care)"[MeSH] OR "outcome assessment"[tiab] OR "outcome
41 measure*"[tw] OR "observer variation"[MeSH] OR "observer variation"[tiab] OR "Health Status
42 Indicators"[Mesh] OR "reproducibility of results"[MeSH] OR reproducib*[tiab] OR "discriminant
43 analysis"[MeSH] OR reliab*[tiab] OR unreliab*[tiab] OR valid*[tiab] OR "coefficient of
44 variation"[tiab] OR coefficient[tiab] OR homogeneity[tiab] OR homogeneous[tiab] OR "internal
45 consistency"[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND
46 (correlation*[tiab] OR selection*[tiab] OR reduction*[tiab])) OR agreement[tw] OR precision[tw]
47 OR imprecision[tw] OR "precise values"[tw] OR test-retest[tiab] OR (test[tiab] AND retest[tiab])
48 OR (reliab*[tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-
49 rater[tiab] OR intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR
50 intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer[tiab] OR
51 intraobserver[tiab] OR intra-observer[tiab] OR intertechnician[tiab] OR inter-technician[tiab] OR
52 intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-examiner[tiab] OR
53 intraexaminer[tiab] OR intra-examiner[tiab] OR interassay[tiab] OR inter-assay[tiab] OR
54 intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-individual[tiab] OR
55 intraindividual[tiab] OR intra-individual[tiab] OR interparticipant[tiab] OR inter-participant[tiab]
56 OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa's[tiab] OR
57 kappas[tiab] OR repeatab*[tw] OR ((replicab*[tw] OR repeated[tw]) AND (measure[tw] OR
58 measures[tw] OR findings[tw] OR result[tw] OR results[tw] OR test[tw] OR tests[tw])) OR
59 generaliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND
60

1
2
3 correlation*[tiab] OR discriminative[tiab] OR "known group"[tiab] OR "factor analysis"[tiab] OR
4 "factor analyses"[tiab] OR "factor structure"[tiab] OR "factor structures"[tiab] OR dimension*[tiab]
5 OR subscale*[tiab] OR (multitrait[tiab] AND scaling[tiab] AND (analysis[tiab] OR analyses[tiab]))
6 OR "item discriminant"[tiab] OR "interscale correlation*[tiab] OR error[tiab] OR errors[tiab] OR
7 "individual variability"[tiab] OR "interval variability"[tiab] OR "rate variability"[tiab] OR
8 (variability[tiab] AND (analysis[tiab] OR values[tiab])) OR (uncertainty[tiab] AND
9 (measurement[tiab] OR measuring[tiab])) OR "standard error of measurement"[tiab] OR
10 sensitiv*[tiab] OR responsive*[tiab] OR (limit[tiab] AND detection[tiab]) OR "minimal detectable
11 concentration"[tiab] OR interpretab*[tiab] OR ((minimal[tiab] OR minimally[tiab] OR clinical[tiab]
12 OR clinically[tiab]) AND (important[tiab] OR significant[tiab] OR detectable[tiab])) AND
13 (change[tiab] OR difference[tiab])) OR (small*[tiab] AND (real[tiab] OR detectable[tiab])) AND
14 (change[tiab] OR difference[tiab])) OR "meaningful change"[tiab] OR "ceiling effect"[tiab] OR
15 "floor effect"[tiab] OR "Item response model"[tiab] OR IRT[tiab] OR Rasch[tiab] OR "Differential
16 item functioning"[tiab] OR DIF[tiab] OR "computer adaptive testing"[tiab] OR "item bank"[tiab]
17 OR "cross-cultural equivalence"[tiab])
18
19

20 **#4 exclusie**

21 NOT ('delphi-technique'[ti] OR cross-sectional[ti] OR "addresses"[Publication Type] OR
22 "biography"[Publication Type] OR "case reports"[Publication Type] OR "comment"[Publication
23 Type] OR "directory"[Publication Type] OR "editorial"[Publication Type] OR
24 "festschrift"[Publication Type] OR "interview"[Publication Type] OR "lectures"[Publication Type]
25 OR "legal cases"[Publication Type] OR "legislation"[Publication Type] OR "letter"[Publication
26 Type] OR "news"[Publication Type] OR "newspaper article"[Publication Type] OR "patient
27 education handout"[Publication Type] OR "popular works"[Publication Type] OR
28 "congresses"[Publication Type] OR "consensus development conference"[Publication Type] OR
29 "consensus development conference, nih"[Publication Type] OR "practice guideline"[Publication
30 Type]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Screening Instruments for Mental Disorders in Primary Health Care: a scoping review protocol (SCREENING-MD)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-084612.R2
Article Type:	Protocol
Date Submitted by the Author:	10-Jul-2024
Complete List of Authors:	Lopes, Luis; Universidade da Sorocaba; State University of Rio de Janeiro Biomedical Centre, Instituto de Medicina Social Santos, Danielle Maria; University of Sorocaba; Federal University of Rio de Janeiro Silva, Jéssica Cumpian; University of Sorocaba Bergamaschi, Cristiane; University of Sorocaba, Pharmaceutical Science Moura, Mariana ; University of Sorocaba, Department of Pharmaceutical Sciences Okuyama, Julia; Universidade de Sorocaba, Post-Graduate Program of Pharmaceutical Science Lopes, Luciane; Universidade de Sorocaba, Pharmaceutical Science
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Epidemiology, Public health
Keywords:	Primary Health Care, MENTAL HEALTH, Mass Screening

SCHOLARONE™
Manuscripts

1 1 **Screening Instruments for Mental Disorders in Primary Health Care: a**
2 2 **scoping review protocol (SCREENING-MD)**

3 3 **Luis Phillippe Nagem Lopes**

4 4 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
5 5 Sorocaba, São Paulo, Brazil
6 6 Institute of Social Medicine, State University of Rio de Janeiro, Rio de Janeiro,
7 7 Brazil.
8 8 Email: luis.pharma20161@gmail.com

9 9 **Danielle Maria de Souza Serio dos Santos, PhD**

10 10 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
11 11 Sorocaba, São Paulo, Brazil
12 12 Institute of Pharmaceutical Sciences, Multidisciplinary Center. Federal
13 13 University of Rio de Janeiro, Macaé, Rio de Janeiro, Brazil.
14 14 Email: dani.farma84@gmail.com

15 15 **Jéssica Cumpian Silva, PhD**

16 16 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
17 17 Sorocaba, São Paulo, Brazil
18 18 Email: jesscumpian@gmail.com

19 19 **Mariana Del Grossi, PhD**

20 20 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
21 21 Sorocaba, São Paulo, Brazil
22 22 Email: maridelgrossi@gmail.com

23 23 **Cristiane de Cássia Bergamaschi, PhD**

24 24 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
25 25 Sorocaba, São Paulo, Brazil
26 26 E-mail: cristiane.motta@prof.uniso.br

27 27 **Julia Hiromi Hori Okuyama, PhD**

28 28 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
29 29 Sorocaba, São Paulo, Brazil
30 30 Email: jhhokuyama@gmail.com

31 31 **Luciane Cruz Lopes, PhD**

32 32 Graduate Course in Pharmaceutical Sciences, University of Sorocaba,
33 33 Sorocaba, São Paulo, Brazil

35 35 ***Corresponding author:**

36 36 Luciane Cruz Lopes – luciane.lopes@prof.uniso.br; luslopesbr@gmail.com
37 37 Graduate Course in Pharmaceutical Sciences, University of Sorocaba, UNISO,
38 38 Brazil
39 39 Rodovia Raposo Tavares, KM 92,5 - Sorocaba, São Paulo, Brazil
40 40 ZIP Code: 18023-000
41 41 Phone: 55 19 99781-8441 Fax: 55 15 2101-7074

1
2
3
4
43

ABSTRACT

5
6
7
8
9
10
11
12
13
44 **Introduction:** When mental disorders go undetected until later stages, they can
45 result in poorer health outcomes for patients. Primary Health Care (PHC) stands
46 as a strategic setting for the early identification and management of these mental
47 disorders, given its role as the primary care environment for health service users.
48 This scoping review has the objective of mapping and assessing screening
49 instruments validated for mental disorders that are applicable in PHC, particularly
50 regarding their measurement properties.

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
51 **Methods and Analysis:** This scoping review will include studies that have
52 developed and validated screening instruments for mental disorders in the PHC
53 context, irrespective of the age group. Searches will be conducted in Medline,
54 Embase, Lilacs, CINAHL, and PsycINFO, without imposing restrictions on
55 publication status, publication year, or language. Additionally, we will scrutinize
56 the references cited in the selected studies. Our inclusion criteria encompass
57 studies examining any measurement property recommended by the Consensus-
58 based Standards for the selection of health Measurement Instruments (COSMIN)
59 taxonomy. The selection process, data extraction, and quality assessment of
60 studies will be performed independently by pairs of reviewers. To evaluate the
61 risk of bias within the selected studies, we will employ the COSMIN Risk of Bias
62 2 tools. The collected data will undergo analysis using descriptive statistics and
63 will be presented in an evidence gap map format for each specific mental
64 disorder.

32
33
34
35
36
37
38
65 **Ethics and dissemination:** The findings from this review will be discussed
66 through deliberative dialogue with stakeholders and disseminated through peer-
67 reviewed publications and conference presentations. The project was approved
68 by the Ethics Committee for Research at the University of Sorocaba (number:
69 66993323.9.0000.5500).

39
40
70 **Protocol Registration:** Open Science Framework – 10.17605/OSF.IO/Z6T5M

41
71 **Keywords:** Mental Disorders. Primary Health Care. Screening. Scoping Review.

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

72 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 73 • This scoping review will employ systematic procedures based on
74 important methodological guidelines such as those provided by the
75 Joanna Briggs Institute and the Consensus-based Standards for the
76 Selection of Health Measurement Instruments (COSMIN);
77 • Stakeholders were involved in the development of this study protocol;
78 • This review will include only screening instruments for mental disorders
79 that are validated and published in the indexed literature;
80 • Heterogeneous reporting in psychometric studies and instances of missing
81 data might restrict the outcomes of this study.

1 2 82 INTRODUCTION 3 4

5
6 83 One out of every eight individuals worldwide has received a diagnosis of a mental
7 84 disorder, amounting to 970 million people [1]. In 2020, the estimates surged by
8 85 over 20%, primarily for anxiety and depressive disorders, due to the impact of the
9 86 COVID-19 pandemic [1]. Currently, even after the pandemic, statistics on mental
10 87 disorders remain high [2]. The significant global prevalence of these and other
11 88 mental disorders, such as eating disorders [3], substance use disorders [4], and
12 89 psychotic disorders [5], has mobilized important research agendas for
13 90 appropriate screening and identification [6]. Despite the existence of treatment
14 91 options for these conditions, their recognition remains challenging, primarily due
15 92 to stigma, insufficient professional training, and a shortage of validated screening
16 93 instruments [7].
17
18

19
20 94 Primary Health Care (PHC) serves as the primary entry point into health systems,
21 95 typically where patients seek care most often, playing a crucial role in ensuring
22 96 universal healthcare, accessible, and equitable for the population [8,9]. When it
23 97 comes to mental health, PHC has been instrumental in reducing the stigma and
24 98 discrimination associated with mental disorders, enhancing healthcare access,
25 99 reducing the long-term impact of mental disorders, and promoting social
26 100 integration [10]. As a result, PHC stands as a vital setting for the implementation
27 101 of mental disorder screening.
28
29

30
31 102 Screening for mental disorders in PHC has been encouraged because late
32 103 identification leads to poorer health outcomes [11]. It's important to note,
33 104 however, that PHC lacks systematic methods for tracking mental disorders,
34 105 leading to inaccuracies in results primarily due to missed or incorrect diagnoses,
35 106 owing to the complexity of mental disorders [12,13]. Screening for mental
36 107 disorders in primary care environments, when conducted, is often done
37 108 subjectively and without a systematic process, lacking the use of validated
38 109 instruments and professional training. This observation was made in a qualitative
39 110 study by Loeb and colleagues, based on the perspective of primary care medical
40 111 professionals. This finding was further corroborated by the study conducted by
41 112 Rogers and collaborators (2021), who also noted the scarcity of systematized
42 113 screening processes incorporating validated strategies [12,13]. Therefore,
43
44

1
2
3 114 implementing suitable instruments is the initial step towards integrating mental
4 disorder screening into the existing PHC services.
5
6

7 116 Instruments that are validated and consistent are crucial for the implementation
8 of screening in PHC. In recent years, many screening instruments for mental
9 disorders have been developed, but little is known about the measurement
10 properties that have been evaluated [14]. Moreover, when it comes to low- and
11 middle-income countries, there are concerns about whether the development
12 process of these instruments is suitable for this population. A recent systematic
13 review recommended that the instruments designed for screening mental
14 disorders are validated in local contexts, and these validations leave gaps in the
15 applicability of these instruments in other countries, particularly those with low
16 and middle incomes [15].
17
18

19 126 This scoping review has the objective of both mapping and assessing screening
20 instruments for mental disorders that are applicable in PHC, particularly regarding
21 their measurement properties.
22
23

24 129 **METHODS**
25
26

27 130 **Study design and registry**
28
29

30 131 **Figure 1** illustrates the steps to be undertaken in this scoping review. Our scoping
31 review will adhere to the guidelines by Joanna Briggs and the Consensus-based
32 Standards for the selection of health Measurement Instruments (COSMIN)
33 systematic reviews manual [16,17]. The study's protocol is accessible on the
34 Open Science Framework [18]. The protocol was documented following the
35 Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension
36 for Scoping Reviews (PRISMA-ScR) Checklist (adapted for protocol)
37 for Scoping Reviews (PRISMA-ScR) Checklist (adapted for protocol)
38 (**Supplementary Material 1**) [19]. This study will begin in July 2024 and end in
39 September 2025.
40
41

42 140 **[Figure 1. Flow of conducting the scoping review]**
43
44

45 141 **Eligibility criteria**
46
47

48 142 The research question was structured following the key components typically
49 used in reviews of health measurement instruments [17], including:
50
51

1
2 **144 Construct**

3
4
5 145 We will consider studies that primarily focus on the screening of specific mental
6 disorders, including eating disorders (ICD F50), anxiety disorders (ICD F40-41),
7 mood disorders (ICD F30-39), substance use disorders (ICD F10-19), and
8 psychotic disorders (ICD F20-29). These disorders were selected due to their
9 higher prevalence.
10
11
12
13

14
15 **150 Population**
16

17
18 151 We will include studies involving individuals of various age groups, genders, and
19 geographic locations who exhibit one or more risk factors for mental disorders,
20 including eating disorders (ICD F50), anxiety disorders (ICD F40-41), mood
21 disorders (ICD F30-39), substance use disorders (ICD F10-19), and psychotic
22 disorders (ICD F20-29).
23
24
25

26
27 **156 Types of Instruments and Measurement Properties of Interest**
28

29
30 157 Studies will be considered without restrictions on the specific measurement
31 property under examination or the method of administration. We will only include
32 studies focused on instrument development (methodological studies); studies
33 that just utilized the instrument will be excluded. Multidimensional instruments will
34 160 also be eligible for inclusion.
35
36

37
38 **162 Context**
39

40
41 163 Only studies conducted in PHC settings will be included, considering primary care
42 environments and population health levels [20]. As a result, instruments
43 developed and validated for specialized care or psychiatric inpatient settings will
44 be excluded.
45
46

47
48 **167 Information Sources**
49

50
51 168 The consulted databases will be MEDLINE (via PubMed), Embase, Lilacs (via
52 Virtual Health Library Portal), PsycINFO, and CINAHL. Other information sources
53 will also be consulted, including the reference lists of included studies. No
54 restrictions on language or year of publication will be applied. If necessary,
55 specialized translation services will be consulted for languages that are not
56 readable by the team.
57
58
59
60

1
2 174 **Search Strategy**

3
4 175 To validate the search strategy, double-checking will be conducted using Peer
5 176 Review of Electronic Search Strategies (PRESS) [21]. A specialized librarian will
6 177 validate it, and modifications will be made if necessary. **Supplementary Material**
7 178 **2** describes the search strategy for each information source. Given the substantial
8 179 volume of studies on screening instruments for mental disorders, we applied a
9 180 developed and validated methodological filter to identify instruments [22].
10

11
12 181 **Study selection and data extraction**

13
14 182 The selection process will involve pairs of reviewers, resolving any
15 183 disagreements through consensus. This process will occur in two stages: initially
16 184 screening based on title and abstract, followed by the assessment of full-text
17 185 articles using Rayyan software (Step 1) and Microsoft Excel 2016 (Step 2) [23].
18 186 Reviewer calibration will precede the selection process, which includes the initial
19 187 assessment of at least 50 randomly chosen titles and abstracts in the first stage,
20 188 followed by at least 10 full-text articles. This process will continue until the
21 189 standardization of included and excluded studies is achieved. The overlapping of
22 190 articles from the calibration exercise between reviewers will be adopted to assess
23 191 the reliability of the team [24,25]. A reviewer will be considered qualified if they
24 192 accurately select at least 75% of the calibration set, as recommended in the
25 193 manuals [16].
26

27
28 194 The data extraction process will similarly involve two independent reviewers, and
29 195 the calibration will follow a process akin to that previously described for selection.
30 196 At this stage, within an Excel spreadsheet, reviewers will extract the following
31 197 information:
32

33
34 198 Part 1. Study characteristics: author, year, country, number of participants;
35 199 number and percentage of female participants; average or median age and age
36 200 range; and whether the instrument was designed for use in primary care (yes/no);
37
38 201 Part 2. Characteristics of the instruments: name of the instrument; acronym or
39 202 abbreviation of the instrument; method of administration; administration time;
40 203 number of items; number of dimensions; whether cross-cultural adaptation was
41 204 performed (yes/no), if yes, specify the culture.
42

1
2
3 205 Part 3. Measurement properties: Studies will be categorized based on the
4 measurement properties outlined in the COSMIN taxonomy [26]. This taxonomy
5 categorizes studies according to the following properties: reliability, validity,
6 responsiveness, and interpretability.
7
8 208
9

10 209 **Risk of bias**
11
12

13 210 The risk of bias assessment will be conducted using the COSMIN Risk of Bias
14 checklist tool, which evaluates instruments based on their measurement
15 properties [27, 28]. The COSMIN Risk of Bias checklist tool assesses instruments
16 based on the methodological quality of the psychometric steps conducted in the
17 studies. In other words, when we utilize the COSMIN Risk of Bias checklist tool
18 to assess studies, we inherently appraise the psychometric properties of the
19 instrument. While it was primarily developed for Patient-Reported Outcome
20 Measures (PROM), it can also be employed for other psychometric instruments
21 [27]. Two reviewers will independently conduct the assessment, and any
22 discrepancies will be resolved through consensus.
23
24 219
25
26
27
28
29

30 31 220 **Data synthesis**
32
33

34 221 The data will be analyzed using descriptive statistics via Stata (version 14.2)
35 software. For better visualization, the results will be presented in bubble and heat
36 maps, categorizing them based on the methodological quality of instrument
37 development and the assessed measurement properties.
38
39 224
40

41 225 **PATIENT AND PUBLIC INVOLVEMENT**
42
43

44 226 We will conduct a deliberative dialogue with stakeholders to discuss barriers and
45 facilitators for implementing screening in PHC. A convenience sample of public
46 health professionals working in primary care, representatives from the Brazilian
47 Ministry of Health, and researchers will be recruited via email. The deliberative
48 dialogue will be held virtually, following the recommendations outlined in the
49 SUPPORT tools [29].
50
51 231
52

53 232 A plain language summary of the scoping review will be disseminated to
54 interested parties 15 days before the dialogue. The organization of the
55 deliberative dialogue will be as follows: the initial 15 minutes of the dialogue will
56 focus on presenting a thorough overview of the scoping review findings.
57
58 235
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

236 Subsequently, discussions will revolve around barriers, facilitators, and the
237 utilization of screening instruments in PHC in Brazil. After the deliberative
238 dialogue, interested parties will evaluate the scoping review using a checklist
239 developed by Lavis (2009) [29]. This checklist, utilizing both open and closed
240 questions, aims to explore the experience of stakeholders in deliberative
241 dialogue, the knowledge gained, and the insights identified from the evidence
242 synthesis. It also evaluates the participants' level of satisfaction with the
243 deliberative dialogue and the evidence summarized in the scoping review.

244 **ETHICS AND DISSEMINATION**

245 The project was approved by the Ethics Committee for Research at the University
246 of Sorocaba (number: 66993323.9.0000.5500). As the deliberative dialogue will
247 involve human participants, a free and informed consent form will be provided in
248 advance and completed by the research participants. This study's preliminary and
249 final results will be presented at conferences related to the topic and at seminars
250 organized by the Brazilian Ministry of Health.

31 **DISCUSSION**

32
33 251 This is the first scoping review to chart screening instruments for mental disorders
34 in PHC, involving their measurement properties and assessing bias risks. In this
35 context, this work, employing an innovative knowledge translation methodology
36 involving deliberative dialogue, holds the potential to assist healthcare
37 professionals, managers, and researchers in making evidence-informed
38 decisions regarding the implementation of validated screening instruments within
39 PHC. Furthermore, our findings will facilitate the identification of limitations in the
40 developed instruments, enabling the proposal of research agendas that prioritize
41 robust psychometric studies on screening instruments for mental disorders,
42 aiming to create instruments beneficial for clinical practice.

43
44 262 Although our work adhere to all methodological guidelines, potential limitations
45 may arise due to the heterogeneity in reporting concerning the development of
46 screening instruments for mental disorders. Consequently, reviewers may need
47 to conduct subjective assessments to evaluate the risk of bias and categorize
48 instruments, aligning with the guidelines outlined in the COSMIN Manual [17].
49 Furthermore, incomplete data, particularly concerning contextual information

1
2 268 about these instruments within care settings, can present challenges in data
3 269 extraction.
4
5

6
7 270 Therefore, the methodological rigor of our scoping review, combined with the
8 271 knowledge translation strategy employing deliberative dialogue, can promote the
9 272 integration of scientific evidence into clinical practice and the screening of mental
10 273 disorders in PHC. This will be possible through engaging interested parties and
11 274 the Brazilian government, ensuring that these individuals are sensitized to the
12 275 process of screening for mental disorders in Brazil's PHC. Moreover, the
13 276 identified research gaps can serve as a foundation for new studies on these
14 277 instruments. Additionally, utilizing COSMIN's international taxonomy and
15 278 methodological recommendations can raise awareness among researchers
16 279 about the effective utilization of these validated instruments for measuring
17 280 outcomes in the healthcare domain [26].
18
19

281 **AUTHOR CONTRIBUTIONS**

282 All authors (LPNL, DMSSS, JCS, MDG, CCB, JHHO, and LCL) made substantial
283 intellectual contributions to the development of this protocol. LCL is the guarantor
284 of the study. LPNL is the principal investigator, responsible for writing the draft
285 protocol. The review question was developed by LCL and refined by LPNL and
286 DMSSS. LPNL and JCS tested the search strategy. All authors (LPNL, DMSSS,
287 JCS, MDG, CCB, JHHO, and LCL) participated in writing the manuscript, critically
288 reviewed the content, approved the final manuscript, and agreed to be
289 responsible for the manuscript, ensuring the accuracy and integrity of the work.
290

44 **ACKNOWLEDGEMENTS**

45
46 291 The authors wish to express their gratitude to the health evidence team at the
47 292 Department of Science and Technology for their invaluable assistance in
48 293 formulating the research question and devising the search strategy. Additionally,
49 294 librarian Mabel Figueiró deserves appreciation for validating the search strategy
50 295 and making necessary corrections.
51
52

55 **FUNDING**

56
57 297 Our research was supported by funding from the Ministry of Health of Brazil
58 298 (MoH) and the National Council for Scientific and Technological Development
59
60

1
2
3 299 (CNPq), under grant number 408237/2022-8. Additionally, this project received
4 funding from the Coordination for the Improvement of Higher Education
5 Personnel (CAPES)—PROSUC—CAPES/UNISO. Unfortunately, no specific
6 grant number is applicable for this support.
7
8
9

10 303 **COMPETING INTERESTS**
11
12

13 304 None to declare.
14
15

16 305 **WORD COUNT**
17
18

19 306 1,723.
20
21


22 307 **References**
23
24

- 25 308 1 World Health Organization. Mental disorders. <https://www.who.int/news-room/fact-sheets/detail/mental-disorders> (accessed 23 November 2023)
26 310 2 McGrath JJ, Al-Hamzawi A, Alonso J, et al. Age of onset and cumulative
27 risk of mental disorders: a cross-national analysis of population surveys from 29
28 countries. *Lancet Psychiatry*. 2023;10:668–81.
29
30 313 3 Qian J, Wu Y, Liu F, et al. An update on the prevalence of eating
31 disorders in the general population: a systematic review and meta-analysis. *Eat
32 Weight Disord*. 2022;27:415–28.
33
34 316 4 Steel Z, Marnane C, Iranpour C, et al. The global prevalence of common
35 mental disorders: a systematic review and meta-analysis 1980–2013. *Int J
36 Epidemiol*. 2014;43:476–93.
37
38 319 5 Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders
39 and its association with methodological issues. A systematic review and meta-
40 analyses. *PLoS One*. 2018;13:e0195687.
41
42 322 6 Whitton AE, Hardy R, Cope K, et al. Mental Health Screening in General
43 Practices as a Means for Enhancing Uptake of Digital Mental Health
44 Interventions: Observational Cohort Study. *J Med Internet Res*.
45 325 2021;23:e28369.
46
47 326 7 Wakida EK, Talib ZM, Akena D, et al. Barriers and facilitators to the
48 integration of mental health services into primary health care: a systematic
49 review. *Syst Rev*. 2018;7:211.
50
51 329 8 Hall JJ, Taylor R. Health for all beyond 2000: the demise of the Alma-Ata
52 Declaration and primary health care in developing countries. *Med J Aust*.
53 331 2003;178:17–20.
54
55 332 9 World Health Organization. Primary health care.
56 333 <https://www.who.int/health-topics/primary-health-care> (accessed 28 April 2024)
57
58
59
60

- 1
2
3 334 10 Mulvaney-Day N, Marshall T, Downey Piscopo K, et al. Screening for
4 Behavioral Health Conditions in Primary Care Settings: A Systematic Review of
5 the Literature. *J Gen Intern Med.* 2018;33:335–46.
6
7 337 11 AACAP. Mental Health Screening in Primary Care.
8 [https://www.aacap.org/AACAP/Policy_Statements/2019/Mental-Health-](https://www.aacap.org/AACAP/Policy_Statements/2019/Mental-Health-Screening-Primary-Care.aspx)
9 [Screening-Primary-Care.aspx](https://www.aacap.org/AACAP/Policy_Statements/2019/Mental-Health-Screening-Primary-Care.aspx) (accessed 23 November 2023)
10
11 340 12 Loeb DF, Bayliss EA, Binswanger IA, et al. Primary care physician
12 perceptions on caring for complex patients with medical and mental illness. *J*
13 *Gen Intern Med.* 2012;27:945–52.
14
15 343 13 Rogers R, Hartigan SE, Sanders CE. Identifying Mental Disorders in
16 Primary Care: Diagnostic Accuracy of the Connected Mind Fast Check (CMFC)
17 Electronic Screen. *J Clin Psychol Med Settings.* 2021;28:882–96.
18
19 346 14 Fotheringham L, Paddick S-M, Barron Millar E, et al. Screening tools for
20 common mental disorders in older adults in South Asia: a systematic scoping
21 review. *Int Psychogeriatr.* 2022;34:427–38.
22
23 349 15 Ali G-C, Ryan G, De Silva MJ. Validated Screening Tools for Common
24 Mental Disorders in Low and Middle Income Countries: A Systematic Review.
25 *PLoS One.* 2016;11:e0156939.
26
27 352 16 Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil, H.
28 Scoping Reviews (2020). Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan
29 Z, editors. JBI Manual for Evidence Synthesis. [https://jbi-global-](https://jbi-global-wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews)
30 [wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews](https://jbi-global-wiki.refined.site/space/MANUAL/4687342/Chapter+11%3A+Scoping+reviews)
31 (accessed 4 January 2023)
32
33 357 17 Consensus-based Standards for the selection of health Measurement
34 Instruments (COSMIN). Guideline for Systematic Reviews of Outcome
35 Measurement Instruments • COSMIN. COSMIN.
36 [https://www.cosmin.nl/tools/guideline-conducting-systematic-review-outcome-](https://www.cosmin.nl/tools/guideline-conducting-systematic-review-outcome-measures/)
37 [measures/](https://www.cosmin.nl/tools/guideline-conducting-systematic-review-outcome-measures/) (accessed 24 November 2023)
38
39 362 18 Lopes LPN. SCREENING MD Study: protocol. Published Online First: 24
40 November 2023. <https://osf.io/z6t5m/> (accessed 5 April 2024)
41
42 364 19 Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping
43 Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.*
44 2018;169:467–73.
45
46 367 20 Muldoon LK, Hogg WE, Levitt M. Primary Care (PC) and Primary Health
47 Care (PHC). *Can J Public Health.* 2006;97:409–11.
48
49 369 21 McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of
50 Electronic Search Strategies: 2015 Guideline Statement. *Journal of Clinical*
51 *Epidemiology.* 2016;75:40–6.
52
53
54
55
56
57
58
59
60

- 1
2
3 372 22 Terwee CB, Jansma EP, Riphagen II, et al. Development of a
4 373 methodological PubMed search filter for finding studies on measurement
5 374 properties of measurement instruments. *Qual Life Res.* 2009;18:1115–23.
6
7 375 23 Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and
8 376 mobile app for systematic reviews. *Systematic Reviews.* 2016;5:210.
9
10 377 24 Lopes LPN, Oliveira JC de, Bergamaschi C de C, et al. Use of second-
11 378 generation antipsychotics in autism spectrum disorder: a systematic review and
12 379 meta-analysis protocol. *BMJ Open.* 2023;13:e069114.
13
14 380 25 de Oliveira JC, Alves MR, Lopes LPN, et al. Sex differences and adverse
15 381 events of antiretrovirals in people living with HIV/AIDS: a systematic review and
16 382 meta-analysis protocol. *BMJ Open.* 2022;12:e057094.
17
18 383 26 Mokkink LB, Terwee CB, Patrick DL, et al. The COSMIN study reached
19 384 international consensus on taxonomy, terminology, and definitions of
20 385 measurement properties for health-related patient-reported outcomes. *J Clin*
21 386 *Epidemiol.* 2010;63:737–45.
22
23 387 27 Mokkink LB, de Vet HCW, Prinsen C a. C, et al. COSMIN Risk of Bias
24 388 checklist for systematic reviews of Patient-Reported Outcome Measures. *Qual*
25 389 *Life Res.* 2018;27:1171–9.
26
27 390 28 Francis DO, McPheeetters ML, Noud M, et al. Checklist to operationalize
28 391 measurement characteristics of patient-reported outcome measures. *Syst Rev.*
29 392 2016;5:129.
30
31 393 29 Lavis JN, Oxman AD, Lewin S, et al. SUPPORT Tools for evidence-
32 394 informed health Policymaking (STP). *Health Res Policy Syst.* 2009;7 Suppl 1:I1.
33
34 395
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Flow of conducting the scoping review



Supplementary Material 1 Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

Adapted to protocol

SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
TITLE			
Title	1	Identify the report as a scoping review.	1
ABSTRACT			
Structured summary	2	Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach.	5-6
Objectives	4	Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives.	6
METHODS			
Protocol and registration	5	Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number.	6
Eligibility criteria	6	Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale.	6-7
Information sources*	7	Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed.	7
Search	8	Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated.	7 and Supplementary Material 2
Selection of sources of evidence†	9	State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review.	8
Data charting process‡	10	Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought and any assumptions and simplifications made.	8
Critical appraisal of individual	12	If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe	8



SECTION	ITEM	PRISMA-ScR CHECKLIST ITEM	REPORTED ON PAGE #
sources of evidence§		the methods used and how this information was used in any data synthesis (if appropriate).	
Synthesis of results	13	Describe the methods of handling and summarizing the data that were charted.	9

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation. Ann Intern Med. 2018;169:467–473. doi: [10.7326/M18-0850](https://doi.org/10.7326/M18-0850).



1
2
3 **Supplementary Material 2:** Search strategies employed in each consulted
4 database.
5

6 **MEDLINE (Via Pubmed)**
7

- 8 1. "Mental Disorder*"
9 2. "Psychiatric Illness**"
10 3. "Psychiatric* Disease"
11 4. "Mental Illness"
12 5. "Mental Illnesses"
13 6. "Psychiatric Disorder**"
14 7. "Behavior Disorders"
15 8. "Psychiatric Diagnosis"
16 9. "Severe Mental Disorder**"
17 10. "Psychotic Disorder**"
18 11. Psychos*
19 12. "Schizoaffective Disorder***"
20 13. "Schizophreniform Disorder**"
21 14. "Brief Reactive Psychos**"
22 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
23 16. "Schizophrenia, Paranoid"
24 17. "Paranoid Schizophrenias"
25 18. "Schizophrenias, Paranoid"
26 19. "Paranoid Schizophrenia"
27 20. "Delusional Disorder"
28 21. "Delusional Disorders"
29 22. "Disorder, Delusional"
30 23. "Disorders, Delusional"
31 24. "Schizophrenia, Disorganized"
32 25. "Disorganized Schizophrenia"
33 26. "Disorganized Schizophrenias"
34 27. "Schizophrenias, Disorganized"
35 28. "Hebephrenic Schizophrenia"
36 29. "Hebephrenic Schizophrenias"
37 30. "Schizophrenias, Hebephrenic"
38 31. "Schizophrenia, Hebephrenic"
39 32. "Schizophrenia, Catatonic"
40 33. "Catatonic Schizophrenia"
41 34. "Catatonic Schizophrenias"
42 35. "Schizophrenias, Catatonic""
43 36. "Mood Disorder**"
44 37. "Disorder, Mood"
45 38. "Disorders, Mood"
46 39. "Affective Disorder**"
47 40. "Disorder, Affective"
48 41. "Disorders, Affective"
49 42. Mania*
50 43. "Manic State"
51 44. "Hypomanic Episode"
52 45. "Hypomanic Episodes"
53 46. Hypomania*
54 47. "Manic Episode"
55 48. "Episode, Manic"
56 49. "Manic Episodes"
57 50. "Bipolar Disorder"
58 51. "Bipolar Disorders"

- 1
2
3 52. "Psychosis, Manic-Depressive"
4 53. "Psychosis, Manic Depressive"
5 54. "Psychoses, Manic-Depressive"
6 55. "Psychoses, Manic Depressive"
7 56. "Manic-Depressive Psychosis"
8 57. "Manic Depressive Psychosis"
9 58. "Bipolar Mood Disorder"
10 59. "Bipolar Mood Disorders"
11 60. "Disorder, Bipolar Mood"
12 61. "Mood Disorder, Bipolar"
13 62. "Affective Psychosis, Bipolar"
14 63. "Bipolar Affective Psychosis"
15 64. "Psychoses, Bipolar Affective"
16 65. "Psychosis, Bipolar Affective"
17 66. "Bipolar Disorder Type 1"
18 67. "Type 1 Bipolar Disorder"
19 68. "Manic Depression"
20 69. "Depression, Manic"
21 70. "Depressions, Manic"
22 71. "Depression, Bipolar"
23 72. "Bipolar Depression"
24 73. "Bipolar Disorder Type 2"
25 74. "Type 2 Bipolar Disorder" OR
26 75. "Manic Disorder"
27 76. "Disorder, Manic"
28 77. "Manic Disorders"
29 78. "Anxiety Disorder**"
30 79. "Disorder, Anxiety"
31 80. "Disorders, Anxiety"
32 81. "Neuroses, Anxiety"
33 82. "Anxiety Neuroses"
34 83. "Anxiety States, Neurotic"
35 84. "Anxiety State, Neurotic"
36 85. "Neurotic Anxiety State"
37 86. "Neurotic Anxiety States"
38 87. "State, Neurotic Anxiety"
39 88. "States, Neurotic Anxiety"
40 89. "Phobia, Social" OR "Social Phobia**"
41 90. "Social Evaluation Phobia"
42 91. "Phobia, Social Evaluation"
43 92. "Social Evaluation Phobias"
44 93. "Social Anxiety Disorder"
45 94. "Anxiety Disorder, Social"
46 95. "Disorder, Social Anxiety"
47 96. "Social Anxiety Disorders"
48 97. "Sociophobia"
49 98. "Fear of Social Evaluation"
50 99. "Evaluation Fear, Social"
51 100. "Social Evaluation Fear"
52 101. "Feeding and Eating Disorders"
53 102. "Eating and Feeding Disorders"
54 103. "Feeding Disorders"
55 104. "Disorder, Feeding"
56 105. "Disorders, Feeding"
57 106. "Feeding Disorder"
58 107. "Eating Disorders"

- 1
2
3 108. "Disorder, Eating"
4 109. "Disorders, Eating"
5 110. "Eating Disorder"
6 111. "Appetite Disorders"
7 112. "Appetite Disorder"
8 113. "Anorexia Nervosa"
9 114. "Anorexia Nervosas"
10 115. "Nervosa, Anorexia"
11 116. "Nervosas, Anorexia"
12 117. "Bulimia Nervosa"
13 118. "Nervosa, Bulimia"
14 119. "Substance-Related Disorder*"
15 120. "Disorder, Substance Related"
16 121. "Disorders, Substance Related"
17 122. "Related Disorder, Substance"
18 123. "Related Disorders, Substance"
19 124. "Drug Use Disorders"
20 125. "Drug Use Disorder"
21 126. "Disorder, Drug Use"
22 127. "Organic Mental Disorders, Substance-Induced"
23 128. "Organic Mental Disorders, Substance Induced"
24 129. "Substance Abuse"
25 130. "Abuse, Substance"
26 131. "Substance Abuses"
27 132. "Substance Dependence"
28 133. "Dependence, Substance"
29 134. "Substance Addiction"
30 135. "Addiction, Substance"
31 136. "Chemical Dependence"
32 137. "Chemical Dependences"
33 138. "Dependence, Chemical"
34 139. "Dependences, Chemical"
35 140. "Drug Dependence"
36 141. "Dependence, Drug"
37 142. "Drug Addiction"
38 143. "Addiction, Drug"
39 144. "Prescription Drug Abuse"
40 145. "Abuse, Prescription Drug"
41 146. "Drug Abuse, Prescription"
42 147. "Substance Use"
43 148. "Substance Uses"
44 149. "Use, Substance"
45 150. "Drug Abuse"
46 151. "Abuse, Drug"
47 152. "Drug Habituation"
48 153. "Habituation, Drug"
49 154. "Substance Use Disorders"
50 155. "Disorder, Substance Use"
51 156. "Substance Use Disorder"
52 157. or/1-157
53 158. "Mass Screening"
54 159. "Mass Screenings"
55 160. "Screening, Mass"
56 161. "Screenings, Mass"
57 162. "Screening*"
58 163. "Diagnostic Screening Programs"

- 1
2
3 164. "Diagnostic Screening Program"
4 165. "Program, Diagnostic Screening"
5 166. "Programs, Diagnostic Screening"
6 167. "Screening Program, Diagnostic"
7 168. "Screening Programs, Diagnostic"
8 169. or/158-168
9 170. COSMIN filter for identifying studies on the development of health measurement
10 instruments
11 171. #157 AND #169 AND 170
12

13 **EMBASE**

- 14
15 1. 'Mental Disorder*'
16 2. 'Psychiatric Illness*'
17 3. 'Psychiatric* Disease'
18 4. 'Mental Illness'
19 5. 'Mental Illnesses'
20 6. 'Psychiatric Disorder*'
21 7. 'Behavior Disorders'
22 8. 'Psychiatric Diagnosis'
23 9. 'Severe Mental Disorder*'
24 10. 'Psychotic Disorder**'
25 11. Psychos*
26 12. 'Schizoaffective Disorder***'
27 13. 'Schizophreniform Disorder*'
28 14. 'Brief Reactive Psychos*'
29 15. 'Schizophrenia Spectrum and Other Psychotic Disorders'
30 16. 'Schizophrenia, Paranoid'
31 17. 'Paranoid Schizophrenias'
32 18. 'Schizophrenias, Paranoid'
33 19. 'Paranoid Schizophrenia'
34 20. 'Delusional Disorder'
35 21. 'Delusional Disorders'
36 22. 'Disorder, Delusional'
37 23. 'Disorders, Delusional'
38 24. 'Schizophrenia, Disorganized'
39 25. 'Disorganized Schizophrenia'
40 26. 'Disorganized Schizophrenias'
41 27. 'Schizophrenias, Disorganized'
42 28. 'Hebephrenic Schizophrenia'
43 29. 'Hebephrenic Schizophrenias'
44 30. 'Schizophrenias, Hebephrenic'
45 31. 'Schizophrenia, Hebephrenic'
46 32. 'Schizophrenia, Catatonic'
47 33. 'Catatonic Schizophrenia'
48 34. 'Catatonic Schizophrenias'
49 35. 'Schizophrenias, Catatonic"
50 36. 'Mood Disorder*'
51 37. 'Disorder, Mood'
52 38. 'Disorders, Mood'
53 39. 'Affective Disorder*'
54 40. 'Disorder, Affective'
55 41. 'Disorders, Affective'
56 42. Mania*
57 43. 'Manic State'
58 44. 'Hypomanic Episode'
59 45. 'Hypomanic Episodes'
60

- 1
2
3 46. Hypomania*
4 47. 'Manic Episode'
5 48. 'Episode, Manic'
6 49. 'Manic Episodes'
7 50. 'Bipolar Disorder'
8 51. 'Bipolar Disorders'
9 52. 'Psychosis, Manic-Depressive'
10 53. 'Psychosis, Manic Depressive'
11 54. 'Psychoses, Manic-Depressive'
12 55. 'Psychoses, Manic Depressive'
13 56. 'Manic-Depressive Psychosis'
14 57. 'Manic Depressive Psychosis'
15 58. 'Bipolar Mood Disorder'
16 59. 'Bipolar Mood Disorders'
17 60. 'Disorder, Bipolar Mood'
18 61. 'Mood Disorder, Bipolar'
19 62. 'Affective Psychosis, Bipolar'
20 63. 'Bipolar Affective Psychosis'
21 64. 'Psychoses, Bipolar Affective'
22 65. 'Psychosis, Bipolar Affective'
23 66. 'Bipolar Disorder Type 1'
24 67. 'Type 1 Bipolar Disorder'
25 68. 'Manic Depression'
26 69. 'Depression, Manic'
27 70. 'Depressions, Manic'
28 71. 'Depression, Bipolar'
29 72. 'Bipolar Depression'
30 73. 'Bipolar Disorder Type 2'
31 74. 'Type 2 Bipolar Disorder' OR
32 75. 'Manic Disorder'
33 76. 'Disorder, Manic'
34 77. 'Manic Disorders'
35 78. 'Anxiety Disorder*'
36 79. 'Disorder, Anxiety'
37 80. 'Disorders, Anxiety'
38 81. 'Neuroses, Anxiety'
39 82. 'Anxiety Neuroses'
40 83. 'Anxiety States, Neurotic'
41 84. 'Anxiety State, Neurotic'
42 85. 'Neurotic Anxiety State'
43 86. 'Neurotic Anxiety States'
44 87. 'State, Neurotic Anxiety'
45 88. 'States, Neurotic Anxiety'
46 89. 'Phobia, Social' OR 'Social Phobia*'
47 90. 'Social Evaluation Phobia'
48 91. 'Phobia, Social Evaluation'
49 92. 'Social Evaluation Phobias'
50 93. 'Social Anxiety Disorder'
51 94. 'Anxiety Disorder, Social'
52 95. 'Disorder, Social Anxiety'
53 96. 'Social Anxiety Disorders'
54 97. Sociophobia*
55 98. 'Fear of Social Evaluation'
56 99. 'Evaluation Fear, Social'
57 100. 'Social Evaluation Fear'
58 101. 'Feeding and Eating Disorders'

- 1
2
3 102. 'Eating and Feeding Disorders'
4 103. 'Feeding Disorders'
5 104. 'Disorder, Feeding'
6 105. 'Disorders, Feeding'
7 106. 'Feeding Disorder'
8 107. 'Eating Disorders'
9 108. 'Disorder, Eating'
10 109. 'Disorders, Eating'
11 110. 'Eating Disorder'
12 111. 'Appetite Disorders'
13 112. 'Appetite Disorder'
14 113. 'Anorexia Nervosa'
15 114. 'Anorexia Nervosas'
16 115. 'Nervosa, Anorexia'
17 116. 'Nervosas, Anorexia'
18 117. 'Bulimia Nervosa'
19 118. 'Nervosa, Bulimia'
20 119. 'Substance-Related Disorder*'
21 120. 'Disorder, Substance Related'
22 121. 'Disorders, Substance Related'
23 122. 'Related Disorder, Substance'
24 123. 'Related Disorders, Substance'
25 124. 'Drug Use Disorders'
26 125. 'Drug Use Disorder'
27 126. 'Disorder, Drug Use'
28 127. 'Organic Mental Disorders, Substance-Induced'
29 128. 'Organic Mental Disorders, Substance Induced'
30 129. 'Substance Abuse'
31 130. 'Abuse, Substance'
32 131. 'Substance Abuses'
33 132. 'Substance Dependence'
34 133. 'Dependence, Substance'
35 134. 'Substance Addiction'
36 135. 'Addiction, Substance'
37 136. 'Chemical Dependence'
38 137. 'Chemical Dependences'
39 138. 'Dependence, Chemical'
40 139. 'Dependences, Chemical'
41 140. 'Drug Dependence'
42 141. 'Dependence, Drug'
43 142. 'Drug Addiction'
44 143. 'Addiction, Drug'
45 144. 'Prescription Drug Abuse'
46 145. 'Abuse, Prescription Drug'
47 146. 'Drug Abuse, Prescription'
48 147. 'Substance Use'
49 148. 'Substance Uses'
50 149. 'Use, Substance'
51 150. 'Drug Abuse'
52 151. 'Abuse, Drug'
53 152. 'Drug Habituation'
54 153. 'Habituation, Drug'
55 154. 'Substance Use Disorders'
56 155. 'Disorder, Substance Use'
57 156. 'Substance Use Disorder'
58 157. or/1-157

- 1
2
3 158. 'Mass Screening'
4 159. 'Mass Screenings'
5 160. 'Screening, Mass'
6 161. 'Screenings, Mass'
7 162. Screening*
8 163. 'Diagnostic Screening Programs'
9 164. 'Diagnostic Screening Program'
10 165. 'Program, Diagnostic Screening'
11 166. 'Programs, Diagnostic Screening'
12 167. 'Screening Program, Diagnostic'
13 168. 'Screening Programs, Diagnostic'
14 169. or/158-168
15 170. COSMIN filter for identifying studies on the development of health measurement
16 instruments
17 171. #157 AND #169 AND 170
18

19 **PsycINFO**
20

- 21 1. "Mental Disorder*"
22 2. "Psychiatric Illness**"
23 3. "Psychiatric* Disease"
24 4. "Mental Illness"
25 5. "Mental Illnesses"
26 6. "Psychiatric Disorder*"
27 7. "Behavior Disorders"
28 8. "Psychiatric Diagnosis"
29 9. "Severe Mental Disorder*"
30 10. "Psychotic Disorder*"
31 11. Psychos*
32 12. "Schizoaffective Disorder***"
33 13. "Schizophreniform Disorder*"
34 14. "Brief Reactive Psychos*"
35 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
36 16. "Schizophrenia, Paranoid"
37 17. "Paranoid Schizophrenias"
38 18. "Schizophrenias, Paranoid"
39 19. "Paranoid Schizophrenia"
40 20. "Delusional Disorder"
41 21. "Delusional Disorders"
42 22. "Disorder, Delusional"
43 23. "Disorders, Delusional"
44 24. "Schizophrenia, Disorganized"
45 25. "Disorganized Schizophrenia"
46 26. "Disorganized Schizophrenias"
47 27. "Schizophrenias, Disorganized"
48 28. "Hebephrenic Schizophrenia"
49 29. "Hebephrenic Schizophrenias"
50 30. "Schizophrenias, Hebephrenic"
51 31. "Schizophrenia, Hebephrenic"
52 32. "Schizophrenia, Catatonic"
53 33. "Catatonic Schizophrenia"
54 34. "Catatonic Schizophrenias"
55 35. "Schizophrenias, Catatonic""
56 36. "Mood Disorder*"
57 37. "Disorder, Mood"
58 38. "Disorders, Mood"
59 39. "Affective Disorder**"

- 1
2
3 40. "Disorder, Affective"
4 41. "Disorders, Affective"
5 42. Mania*
6 43. "Manic State"
7 44. "Hypomanic Episode"
8 45. "Hypomanic Episodes"
9 46. Hypomania*
10 47. "Manic Episode"
11 48. "Episode, Manic"
12 49. "Manic Episodes"
13 50. "Bipolar Disorder"
14 51. "Bipolar Disorders"
15 52. "Psychosis, Manic-Depressive"
16 53. "Psychosis, Manic Depressive"
17 54. "Psychoses, Manic-Depressive"
18 55. "Psychoses, Manic Depressive"
19 56. "Manic-Depressive Psychosis"
20 57. "Manic Depressive Psychosis"
21 58. "Bipolar Mood Disorder"
22 59. "Bipolar Mood Disorders"
23 60. "Disorder, Bipolar Mood"
24 61. "Mood Disorder, Bipolar"
25 62. "Affective Psychosis, Bipolar"
26 63. "Bipolar Affective Psychosis"
27 64. "Psychoses, Bipolar Affective"
28 65. "Psychosis, Bipolar Affective"
29 66. "Bipolar Disorder Type 1"
30 67. "Type 1 Bipolar Disorder"
31 68. "Manic Depression"
32 69. "Depression, Manic"
33 70. "Depressions, Manic"
34 71. "Depression, Bipolar"
35 72. "Bipolar Depression"
36 73. "Bipolar Disorder Type 2"
37 74. "Type 2 Bipolar Disorder" OR
38 75. "Manic Disorder"
39 76. "Disorder, Manic"
40 77. "Manic Disorders"
41 78. "Anxiety Disorder**"
42 79. "Disorder, Anxiety"
43 80. "Disorders, Anxiety"
44 81. "Neuroses, Anxiety"
45 82. "Anxiety Neuroses"
46 83. "Anxiety States, Neurotic"
47 84. "Anxiety State, Neurotic"
48 85. "Neurotic Anxiety State"
49 86. "Neurotic Anxiety States"
50 87. "State, Neurotic Anxiety"
51 88. "States, Neurotic Anxiety"
52 89. "Phobia, Social" OR "Social Phobia**"
53 90. "Social Evaluation Phobia"
54 91. "Phobia, Social Evaluation"
55 92. "Social Evaluation Phobias"
56 93. "Social Anxiety Disorder"
57 94. "Anxiety Disorder, Social"
58 95. "Disorder, Social Anxiety"

- 1
2
3 96. "Social Anxiety Disorders"
4 97. Sociophobia*
5 98. "Fear of Social Evaluation"
6 99. "Evaluation Fear, Social"
7 100. "Social Evaluation Fear"
8 101. "Feeding and Eating Disorders"
9 102. "Eating and Feeding Disorders"
10 103. "Feeding Disorders"
11 104. "Disorder, Feeding"
12 105. "Disorders, Feeding"
13 106. "Feeding Disorder"
14 107. "Eating Disorders"
15 108. "Disorder, Eating"
16 109. "Disorders, Eating"
17 110. "Eating Disorder"
18 111. "Appetite Disorders"
19 112. "Appetite Disorder"
20 113. "Anorexia Nervosa"
21 114. "Anorexia Nervosas"
22 115. "Nervosa, Anorexia"
23 116. "Nervosas, Anorexia"
24 117. "Bulimia Nervosa"
25 118. "Nervosa, Bulimia"
26 119. "Substance-Related Disorder*"
27 120. "Disorder, Substance Related"
28 121. "Disorders, Substance Related"
29 122. "Related Disorder, Substance"
30 123. "Related Disorders, Substance"
31 124. "Drug Use Disorders"
32 125. "Drug Use Disorder"
33 126. "Disorder, Drug Use"
34 127. "Organic Mental Disorders, Substance-Induced"
35 128. "Organic Mental Disorders, Substance Induced"
36 129. "Substance Abuse"
37 130. "Abuse, Substance"
38 131. "Substance Abuses"
39 132. "Substance Dependence"
40 133. "Dependence, Substance"
41 134. "Substance Addiction"
42 135. "Addiction, Substance"
43 136. "Chemical Dependence"
44 137. "Chemical Dependences"
45 138. "Dependence, Chemical"
46 139. "Dependences, Chemical"
47 140. "Drug Dependence"
48 141. "Dependence, Drug"
49 142. "Drug Addiction"
50 143. "Addiction, Drug"
51 144. "Prescription Drug Abuse"
52 145. "Abuse, Prescription Drug"
53 146. "Drug Abuse, Prescription"
54 147. "Substance Use"
55 148. "Substance Uses"
56 149. "Use, Substance"
57 150. "Drug Abuse"
58 151. "Abuse, Drug"

- 1
2
3 152. "Drug Habituation"
4 153. "Habituation, Drug"
5 154. "Substance Use Disorders"
6 155. "Disorder, Substance Use"
7 156. "Substance Use Disorder"
8 157. or/1-157
9 158. "Mass Screening"
10 159. "Mass Screenings"
11 160. "Screening, Mass"
12 161. "Screenings, Mass"
13 162. Screening*
14 163. "Diagnostic Screening Programs"
15 164. "Diagnostic Screening Program"
16 165. "Program, Diagnostic Screening"
17 166. "Programs, Diagnostic Screening"
18 167. "Screening Program, Diagnostic"
19 168. "Screening Programs, Diagnostic"
20 169. or/158-168
21 170. COSMIN filter for identifying studies on the development of health measurement
22 instruments
23 171. #157 AND #169 AND 170

24
25 **LILACS**
26

- 27 1. "Transtornos Mentais"
28 2. "Diagnóstico Psiquiátrico"
29 3. "Distúrbios Psiquiátricos"
30 4. "Doença Mental"
31 5. "Doença Psiquiátrica"
32 6. "Doenças Psiquiátricas"
33 7. Insanidade
34 8. "Transtorno do Comportamento"
35 9. "Transtornos do Comportamento"
36 10. "Transtornos Mentais Graves"
37 11. "Transtornos Mentais Severos"
38 12. "Transtornos Psiquiátricos"
39 13. "Trastornos Mentales"
40 14. "Enfermedad Mental"
41 15. "Enfermedad Psiquiátrica"
42 16. "Enfermedades Psiquiátricas"
43 17. Insanidad
44 18. "Transtornos Mentales Severos"
45 19. "Trastorno del Comportamiento"
46 20. "Trastorno Mental"
47 21. "Trastornos del Comportamiento"
48 22. "Trastornos Mentales Graves"
49 23. "Trastornos Psiquiátricos"
50 24. "Mental Disorder**"
51 25. "Psychiatric Illness**"
52 26. "Psychiatric* Disease"
53 27. "Mental Illness"
54 28. "Mental Illnesses"
55 29. "Psychiatric Disorder**"
56 30. "Behavior Disorders"
57 31. "Psychiatric Diagnosis"
58 32. "Severe Mental Disorder**"
59 33. "Psychotic Disorder**"

- 1
2
3 34. Psychos*
4 35. "Schizoaffective Disorder*"
5 36. "Schizophreniform Disorder*"
6 37. "Brief Reactive Psychos*"
7 38. "Schizophrenia Spectrum and Other Psychotic Disorders"
8 39. "Schizophrenia, Paranoid"
9 40. "Paranoid Schizophrenias"
10 41. "Schizophrenias, Paranoid"
11 42. "Paranoid Schizophrenia"
12 43. "Delusional Disorder"
13 44. "Delusional Disorders"
14 45. "Disorder, Delusional"
15 46. "Disorders, Delusional"
16 47. "Schizophrenia, Disorganized"
17 48. "Disorganized Schizophrenia"
18 49. "Disorganized Schizophrenias"
19 50. "Schizophrenias, Disorganized"
20 51. "Hebephrenic Schizophrenia"
21 52. "Hebephrenic Schizophrenias"
22 53. "Schizophrenias, Hebephrenic"
23 54. "Schizophrenia, Hebephrenic"
24 55. "Schizophrenia, Catatonic"
25 56. "Catatonic Schizophrenia"
26 57. "Catatonic Schizophrenias"
27 58. "Schizophrenias, Catatonic"
28 59. "Transtornos Psicóticos"
29 60. "Psicose Reativa Breve"
30 61. Psicoses
31 62. "Transtorno Esquizoafetivo"
32 63. "Transtornos Esquizofreniformes"
33 64. "Espectro da Esquizofrenia e Outros Transtornos Psicóticos"
34 65. "Esquizofrenia e Transtornos com Características Psicóticas"
35 66. "Esquizofrenia Paranoide"
36 67. "Transtorno Delirante"
37 68. "Esquizofrenia Hebefrênica"
38 69. "Esquizofrenia Catatônica"
39 70. "Transtornos Psicóticos"
40 71. Psicosis OR "Psicosis Reactiva Breve"
41 72. "Transtorno Esquizoafetivo"
42 73. "Transtornos Esquizofreniformes"
43 74. "Esquizofrenia Hebefrénica"
44 75. "Esquizofrenia Catatónica"
45 76. "Mood Disorder*"
46 77. "Disorder, Mood"
47 78. "Disorders, Mood"
48 79. "Affective Disorder*"
49 80. "Disorder, Affective"
50 81. "Disorders, Affective"
51 82. Mania*
52 83. "Manic State"
53 84. "Hypomanic Episode"
54 85. "Hypomanic Episodes"
55 86. Hypomania*
56 87. "Manic Episode"
57 88. "Episode, Manic"
58 89. "Manic Episodes"

- 1
2
3 90. "Bipolar Disorder"
4 91. "Bipolar Disorders"
5 92. "Psychosis, Manic-Depressive"
6 93. "Psychosis, Manic Depressive"
7 94. "Psychoses, Manic-Depressive"
8 95. "Psychoses, Manic Depressive"
9 96. "Manic-Depressive Psychosis"
10 97. "Manic Depressive Psychosis"
11 98. "Bipolar Mood Disorder"
12 99. "Bipolar Mood Disorders"
13 100. "Disorder, Bipolar Mood"
14 101. "Mood Disorder, Bipolar"
15 102. "Affective Psychosis, Bipolar"
16 103. "Bipolar Affective Psychosis"
17 104. "Psychoses, Bipolar Affective"
18 105. "Psychosis, Bipolar Affective"
19 106. "Bipolar Disorder Type 1"
20 107. "Type 1 Bipolar Disorder"
21 108. "Manic Depression"
22 109. "Depression, Manic"
23 110. "Depressions, Manic"
24 111. "Depression, Bipolar"
25 112. "Bipolar Depression"
26 113. "Bipolar Disorder Type 2"
27 114. "Type 2 Bipolar Disorder" OR
28 115. "Manic Disorder"
29 116. "Disorder, Manic"
30 117. "Manic Disorders"
31 118. "Transtornos do Humor"
32 119. "Transtornos Afetivos"
33 120. "Trastornos del Humor"
34 121. Mania
35 122. "Episódio Hipomaníaco"
36 123. "Episódio Maníaco"
37 124. "Estado Maníaco"
38 125. "Estado de Loucura"
39 126. hipomania
40 127. "episodio hipomaníaco"
41 128. "episodio maníaco"
42 129. "estado maníaco"
43 130. "hipomanía"
44 131. "Anxiety Disorder*"
45 132. "Disorder, Anxiety"
46 133. "Disorders, Anxiety"
47 134. "Neuroses, Anxiety"
48 135. "Anxiety Neuroses"
49 136. "Anxiety States, Neurotic"
50 137. "Anxiety State, Neurotic"
51 138. "Neurotic Anxiety State"
52 139. "Neurotic Anxiety States"
53 140. "State, Neurotic Anxiety"
54 141. "States, Neurotic Anxiety"
55 142. "Phobia, Social" OR "Social Phobia*"
56 143. "Social Evaluation Phobia"
57 144. "Phobia, Social Evaluation"
58 145. "Social Evaluation Phobias"

- 1
2
3 146. "Social Anxiety Disorder"
4 147. "Anxiety Disorder, Social"
5 148. "Disorder, Social Anxiety"
6 149. "Social Anxiety Disorders"
7 150. Sociophobia*
8 151. "Transtornos de Ansiedade"
9 152. "Distúrbios de Ansiedade"
10 153. "Estados de Ansiedade Neurótica"
11 154. "Neurose de Ansiedade"
12 155. "Transtornos Ansiosos"
13 156. "Transtornos de Angústia"
14 157. Agorafobia
15 158. Demofobia
16 159. Enoclofobia
17 160. "Fobia de Espaços Abertos"
18 161. "Fobia de Multidão"
19 162. "Fobia de Multidões"
20 163. Oclofobia*
21 164. "Transtorno de Pânico"
22 165. "Ataques de Pânico"
23 166. "trastornos de ansiedad"
24 167. "estados de ansiedad neuróticos"
25 168. "neurosis de ansiedad"
26 169. "fobia a las multitudes"
27 170. "fobia a los espacios abiertos"
28 171. "trastorno de pánico"
29 172. "ataques de pánico"
30 173. "Fear of Social Evaluation"
31 174. "Evaluation Fear, Social"
32 175. "Social Evaluation Fear"
33 176. "Feeding and Eating Disorders"
34 177. "Eating and Feeding Disorders"
35 178. "Feeding Disorders"
36 179. "Disorder, Feeding"
37 180. "Disorders, Feeding"
38 181. "Feeding Disorder"
39 182. "Eating Disorders"
40 183. "Disorder, Eating"
41 184. "Disorders, Eating"
42 185. "Eating Disorder"
43 186. "Appetite Disorders"
44 187. "Appetite Disorder"
45 188. "Anorexia Nervosa"
46 189. "Anorexia Nervosas"
47 190. "Nervosa, Anorexia"
48 191. "Nervosas, Anorexia"
49 192. "Bulimia Nervosa"
50 193. "Nervosa, Bulimia"
51 194. "Transtornos da Alimentação"
52 195. "Transtornos da Ingestão de Alimentos"
53 196. "Transtornos do Apetite"
54 197. "Transtorno da Compulsão Alimentar"
55 198. "Compulsão Alimentar"
56 199. "Anorexia Nervosa"
57 200. "Bulimia Nervosa"
58 201. "Trastornos de Alimentación y de la Ingestión de Alimentos"

- 1
2
3 202. "Trastorno Alimentario"
4 203. "Trastornos Alimentarios"
5 204. "Trastornos Alimentarios y de la Ingestión de Alimentos"
6 205. "Trastornos de Alimentación"
7 206. "Trastornos de la Conducta Alimentaria"
8 207. "Trastornos de la Ingesta de Alimentos"
9 208. "Trastornos de la Ingestión de Alimentos"
10 209. "Trastornos del Apetito"
11 210. "Trastorno por Atracón"
12 211. "trastorno de hiperfagia compulsiva"
13 212. "trastorno de atracones"
14 213. "Anorexia Nerviosa"
15 214. "anorexia nerviosa"
16 215. "Bulimia Nerviosa"
17 216. "Substance-Related Disorder*"
18 217. "Disorder, Substance Related"
19 218. "Disorders, Substance Related"
20 219. "Related Disorder, Substance"
21 220. "Related Disorders, Substance"
22 221. "Drug Use Disorders"
23 222. "Drug Use Disorder"
24 223. "Disorder, Drug Use"
25 224. "Organic Mental Disorders, Substance-Induced"
26 225. "Organic Mental Disorders, Substance Induced"
27 226. "Substance Abuse"
28 227. "Abuse, Substance"
29 228. "Substance Abuses"
30 229. "Substance Dependence"
31 230. "Dependence, Substance"
32 231. "Substance Addiction"
33 232. "Addiction, Substance"
34 233. "Chemical Dependence"
35 234. "Chemical Dependences"
36 235. "Dependence, Chemical"
37 236. "Dependences, Chemical"
38 237. "Drug Dependence"
39 238. "Dependence, Drug"
40 239. "Drug Addiction"
41 240. "Addiction, Drug"
42 241. "Prescription Drug Abuse"
43 242. "Abuse, Prescription Drug"
44 243. "Drug Abuse, Prescription"
45 244. "Substance Use"
46 245. "Substance Uses"
47 246. "Use, Substance"
48 247. "Drug Abuse"
49 248. "Abuse, Drug"
50 249. "Drug Habituation"
51 250. "Habituation, Drug"
52 251. "Substance Use Disorders"
53 252. "Disorder, Substance Use"
54 253. "Substance Use Disorder"
55 254. "Transtornos Relacionados ao Uso de Substâncias"
56 255. "Abuso de Drogas"
57 256. "Abuso de Medicamentos sob Prescrição"
58 257. "Abuso de Substâncias"

- 1
2
3 258. "Abuso de Substâncias Psicoativas"
4 259. "Abuso de Substâncias que Produzem Dependência"
5 260. "Abuso de Substâncias que não Produzem Dependência"
6 261. "Adição a Drogas"
7 262. "Dependência Física de Substâncias"
8 263. "Dependência Psíquica de Substâncias"
9 264. "Dependência Química"
10 265. "Dependência de Agentes Químicos"
11 266. "Dependência de Drogas"
12 267. "Dependência de Substâncias"
13 268. "Dependência de Substâncias Psicoativas"
14 269. Drogadicção
15 270. Drogadição
16 271. Farmacodependência
17 272. "Habituação a Drogas"
18 273. Toxicomania
19 274. "Transtorno Relacionado ao Uso de Substâncias"
20 275. "Transtornos Induzidos por Uso de Substâncias"
21 276. "Transtornos Mentais Orgânicos Induzidos por Substâncias"
22 277. "Transtornos Mentais Orgânicos Induzidos por Substâncias Psicoativas"
23 278. "Transtornos Relacionados ao Uso de Substâncias Psicoativas"
24 279. "Transtornos por Uso de Drogas"
25 280. "Transtornos por Uso de Substâncias"
26 281. "Transtornos por Uso de Substâncias Psicoativas"
27 282. "Uso Indevido de Drogas"
28 283. "Uso Indevido de Substâncias"
29 284. "Uso de Substâncias"
30 285. "Trastornos Relacionados con Sustancias"
31 286. "adicción a sustancias"
32 287. drogadicción
33 288. drogodependencia
34 289. "habituación a drogas"
35 290. "habituación a sustancias"
36 291. "trastorno por consumo de sustancias"
37 292. "trastorno relacionado con sustancias"
38 293. "trastornos inducidos por consumo de sustancias"
39 294. "trastornos inducidos por uso de sustancias"
40 295. "trastornos mentales orgánicos inducidos por sustancias"
41 296. "trastornos por consumo de drogas"
42 297. "trastornos por consumo de sustancias"
43 298. "trastornos por consumo de sustancias psicoactivas"
44 299. "trastornos por uso de drogas"
45 300. "trastornos por uso de sustancias"
46 301. "trastornos por uso de sustancias psicoactivas"
47 302. "trastornos relacionados con el consumo de sustancias psicoactivas"
48 303. "trastornos relacionados con el uso de sustancias psicoactivas"
49 304. or/1-303
50 305. "Mass Screening"
51 306. "Mass Screenings"
52 307. "Screening, Mass"
53 308. "Screenings, Mass"
54 309. Screening*
55 310. "Diagnostic Screening Programs"
56 311. "Diagnostic Screening Program"
57 312. "Program, Diagnostic Screening"
58 313. "Programs, Diagnostic Screening"

- 1
2
3 314. "Screening Program, Diagnostic"
4 315. "Screening Programs, Diagnostic"
5 316. "Programas de Rastreamento"
6 317. "Exame Coletivo"
7 318. "Identificação Sistêmica"
8 319. "Programas de Triagem Diagnóstica"
9 320. Rastreamento
10 321. Rastreio
11 322. "Triagem de Massa"
12 323. "Tamizaje Masivo"
13 324. "cribado sistemático"
14 325. cribado "cribado masivo"
15 326. "detección selectiva"
16 327. "detección sistemática"
17 328. "examen colectivo"
18 329. "identificación sistemática"
19 330. screening OR "screening masivo"
20 331. "Programas de Detección Diagnóstica"
21 332. "programas de cribado diagnóstico"
22 333. "programa de cribado diagnóstico"
23 334. or/305-333
24 335. COSMIN filter for identifying studies on the development of health measurement
25 instruments
26 336. #304 AND #334 AND 335
27
28
29

CINAHL

- 30 1. "Mental Disorder**"
31 2. "Psychiatric Illness**"
32 3. "Psychiatric* Disease"
33 4. "Mental Illness"
34 5. "Mental Illnesses"
35 6. "Psychiatric Disorder**"
36 7. "Behavior Disorders"
37 8. "Psychiatric Diagnosis"
38 9. "Severe Mental Disorder**"
39 10. "Psychotic Disorder**"
40 11. Psychos*
41 12. "Schizoaffective Disorder***"
42 13. "Schizophreniform Disorder**"
43 14. "Brief Reactive Psychos**"
44 15. "Schizophrenia Spectrum and Other Psychotic Disorders"
45 16. "Schizophrenia, Paranoid"
46 17. "Paranoid Schizophrenias"
47 18. "Schizophrenias, Paranoid"
48 19. "Paranoid Schizophrenia"
49 20. "Delusional Disorder"
50 21. "Delusional Disorders"
51 22. "Disorder, Delusional"
52 23. "Disorders, Delusional"
53 24. "Schizophrenia, Disorganized"
54 25. "Disorganized Schizophrenia"
55 26. "Disorganized Schizophrenias"
56 27. "Schizophrenias, Disorganized"
57 28. "Hebephrenic Schizophrenia"
58 29. "Hebephrenic Schizophrenias"
59 30. "Schizophrenias, Hebephrenic"
60

- 1
2
3 31. "Schizophrenia, Hebephrenic"
4 32. "Schizophrenia, Catatonic"
5 33. "Catatonic Schizophrenia"
6 34. "Catatonic Schizophrenias"
7 35. "Schizophrenias, Catatonic""
8 36. "Mood Disorder**"
9 37. "Disorder, Mood"
10 38. "Disorders, Mood"
11 39. "Affective Disorder**"
12 40. "Disorder, Affective"
13 41. "Disorders, Affective"
14 42. Mania*
15 43. "Manic State"
16 44. "Hypomanic Episode"
17 45. "Hypomanic Episodes"
18 46. Hypomania*
19 47. "Manic Episode"
20 48. "Episode, Manic"
21 49. "Manic Episodes"
22 50. "Bipolar Disorder"
23 51. "Bipolar Disorders"
24 52. "Psychosis, Manic-Depressive"
25 53. "Psychosis, Manic Depressive"
26 54. "Psychoses, Manic-Depressive"
27 55. "Psychoses, Manic Depressive"
28 56. "Manic-Depressive Psychosis"
29 57. "Manic Depressive Psychosis"
30 58. "Bipolar Mood Disorder"
31 59. "Bipolar Mood Disorders"
32 60. "Disorder, Bipolar Mood"
33 61. "Mood Disorder, Bipolar"
34 62. "Affective Psychosis, Bipolar"
35 63. "Bipolar Affective Psychosis"
36 64. "Psychoses, Bipolar Affective"
37 65. "Psychosis, Bipolar Affective"
38 66. "Bipolar Disorder Type 1"
39 67. "Type 1 Bipolar Disorder"
40 68. "Manic Depression"
41 69. "Depression, Manic"
42 70. "Depressions, Manic"
43 71. "Depression, Bipolar"
44 72. "Bipolar Depression"
45 73. "Bipolar Disorder Type 2"
46 74. "Type 2 Bipolar Disorder" OR
47 75. "Manic Disorder"
48 76. "Disorder, Manic"
49 77. "Manic Disorders"
50 78. "Anxiety Disorder**"
51 79. "Disorder, Anxiety"
52 80. "Disorders, Anxiety"
53 81. "Neuroses, Anxiety"
54 82. "Anxiety Neuroses"
55 83. "Anxiety States, Neurotic"
56 84. "Anxiety State, Neurotic"
57 85. "Neurotic Anxiety State"
58 86. "Neurotic Anxiety States"

- 1
2
3 87. "State, Neurotic Anxiety"
4 88. "States, Neurotic Anxiety"
5 89. "Phobia, Social" OR "Social Phobia**"
6 90. "Social Evaluation Phobia"
7 91. "Phobia, Social Evaluation"
8 92. "Social Evaluation Phobias"
9 93. "Social Anxiety Disorder"
10 94. "Anxiety Disorder, Social"
11 95. "Disorder, Social Anxiety"
12 96. "Social Anxiety Disorders"
13 97. Sociophobia*
14 98. "Fear of Social Evaluation"
15 99. "Evaluation Fear, Social"
16 100. "Social Evaluation Fear"
17 101. "Feeding and Eating Disorders"
18 102. "Eating and Feeding Disorders"
19 103. "Feeding Disorders"
20 104. "Disorder, Feeding"
21 105. "Disorders, Feeding"
22 106. "Feeding Disorder"
23 107. "Eating Disorders"
24 108. "Disorder, Eating"
25 109. "Disorders, Eating"
26 110. "Eating Disorder"
27 111. "Appetite Disorders"
28 112. "Appetite Disorder"
29 113. "Anorexia Nervosa"
30 114. "Anorexia Nervosas"
31 115. "Nervosa, Anorexia"
32 116. "Nervosas, Anorexia"
33 117. "Bulimia Nervosa"
34 118. "Nervosa, Bulimia"
35 119. "Substance-Related Disorder**"
36 120. "Disorder, Substance Related"
37 121. "Disorders, Substance Related"
38 122. "Related Disorder, Substance"
39 123. "Related Disorders, Substance"
40 124. "Drug Use Disorders"
41 125. "Drug Use Disorder"
42 126. "Disorder, Drug Use"
43 127. "Organic Mental Disorders, Substance-Induced"
44 128. "Organic Mental Disorders, Substance Induced"
45 129. "Substance Abuse"
46 130. "Abuse, Substance"
47 131. "Substance Abuses"
48 132. "Substance Dependence"
49 133. "Dependence, Substance"
50 134. "Substance Addiction"
51 135. "Addiction, Substance"
52 136. "Chemical Dependence"
53 137. "Chemical Dependences"
54 138. "Dependence, Chemical"
55 139. "Dependences, Chemical"
56 140. "Drug Dependence"
57 141. "Dependence, Drug"
58 142. "Drug Addiction"

1
2
3 143. "Addiction, Drug"
4 144. "Prescription Drug Abuse"
5 145. "Abuse, Prescription Drug"
6 146. "Drug Abuse, Prescription"
7 147. "Substance Use"
8 148. "Substance Uses"
9 149. "Use, Substance"
10 150. "Drug Abuse"
11 151. "Abuse, Drug"
12 152. "Drug Habituation"
13 153. "Habituation, Drug"
14 154. "Substance Use Disorders"
15 155. "Disorder, Substance Use"
16 156. "Substance Use Disorder"
17 157. or/1-157
18 158. "Mass Screening"
19 159. "Mass Screenings"
20 160. "Screening, Mass"
21 161. "Screenings, Mass"
22 162. Screening*
23 163. "Diagnostic Screening Programs"
24 164. "Diagnostic Screening Program"
25 165. "Program, Diagnostic Screening"
26 166. "Programs, Diagnostic Screening"
27 167. "Screening Program, Diagnostic"
28 168. "Screening Programs, Diagnostic"
29 169. or/158-168
30 170. COSMIN filter for identifying studies on the development of health measurement
31 instruments
32 171. #157 AND #169 AND 170
33
34
35
36
37

COSMIN filter

38 (instrumentation[sh] OR methods[sh] OR "Validation Studies"[pt] OR "Comparative Study"[pt]
39 OR "psychometrics"[MeSH] OR psychometr*[tiab] OR clinimetr*[tw] OR clinometr*[tw] OR
40 "outcome assessment (health care)"[MeSH] OR "outcome assessment"[tiab] OR "outcome
41 measure*"[tw] OR "observer variation"[MeSH] OR "observer variation"[tiab] OR "Health Status
42 Indicators"[Mesh] OR "reproducibility of results"[MeSH] OR reproducib*[tiab] OR "discriminant
43 analysis"[MeSH] OR reliab*[tiab] OR unreliab*[tiab] OR valid*[tiab] OR "coefficient of
44 variation"[tiab] OR coefficient[tiab] OR homogeneity[tiab] OR homogeneous[tiab] OR "internal
45 consistency"[tiab] OR (cronbach*[tiab] AND (alpha[tiab] OR alphas[tiab])) OR (item[tiab] AND
46 (correlation*[tiab] OR selection*[tiab] OR reduction*[tiab])) OR agreement[tw] OR precision[tw]
47 OR imprecision[tw] OR "precise values"[tw] OR test-retest[tiab] OR (test[tiab] AND retest[tiab])
48 OR (reliab*[tiab] AND (test[tiab] OR retest[tiab])) OR stability[tiab] OR interrater[tiab] OR inter-
49 rater[tiab] OR intrarater[tiab] OR intra-rater[tiab] OR intertester[tiab] OR inter-tester[tiab] OR
50 intratester[tiab] OR intra-tester[tiab] OR interobserver[tiab] OR inter-observer[tiab] OR
51 intraobserver[tiab] OR intra-observer[tiab] OR intertechnician[tiab] OR inter-technician[tiab] OR
52 intratechnician[tiab] OR intra-technician[tiab] OR interexaminer[tiab] OR inter-examiner[tiab] OR
53 intraexaminer[tiab] OR intra-examiner[tiab] OR interassay[tiab] OR inter-assay[tiab] OR
54 intraassay[tiab] OR intra-assay[tiab] OR interindividual[tiab] OR inter-individual[tiab] OR
55 intraindividual[tiab] OR intra-individual[tiab] OR interparticipant[tiab] OR inter-participant[tiab]
56 OR intraparticipant[tiab] OR intra-participant[tiab] OR kappa[tiab] OR kappa's[tiab] OR
57 kappas[tiab] OR repeatab*[tw] OR ((replicab*[tw] OR repeated[tw]) AND (measure[tw] OR
58 measures[tw] OR findings[tw] OR result[tw] OR results[tw] OR test[tw] OR tests[tw])) OR
59 generaliza*[tiab] OR generalisa*[tiab] OR concordance[tiab] OR (intraclass[tiab] AND
60

1
2
3 correlation*[tiab] OR discriminative[tiab] OR "known group"[tiab] OR "factor analysis"[tiab] OR
4 "factor analyses"[tiab] OR "factor structure"[tiab] OR "factor structures"[tiab] OR dimension*[tiab]
5 OR subscale*[tiab] OR (multitrait[tiab] AND scaling[tiab] AND (analysis[tiab] OR analyses[tiab]))
6 OR "item discriminant"[tiab] OR "interscale correlation*[tiab] OR error[tiab] OR errors[tiab] OR
7 "individual variability"[tiab] OR "interval variability"[tiab] OR "rate variability"[tiab] OR
8 (variability[tiab] AND (analysis[tiab] OR values[tiab])) OR (uncertainty[tiab] AND
9 (measurement[tiab] OR measuring[tiab])) OR "standard error of measurement"[tiab] OR
10 sensitiv*[tiab] OR responsive*[tiab] OR (limit[tiab] AND detection[tiab]) OR "minimal detectable
11 concentration"[tiab] OR interpretab*[tiab] OR ((minimal[tiab] OR minimally[tiab] OR clinical[tiab]
12 OR clinically[tiab]) AND (important[tiab] OR significant[tiab] OR detectable[tiab])) AND
13 (change[tiab] OR difference[tiab])) OR (small*[tiab] AND (real[tiab] OR detectable[tiab])) AND
14 (change[tiab] OR difference[tiab])) OR "meaningful change"[tiab] OR "ceiling effect"[tiab] OR
15 "floor effect"[tiab] OR "Item response model"[tiab] OR IRT[tiab] OR Rasch[tiab] OR "Differential
16 item functioning"[tiab] OR DIF[tiab] OR "computer adaptive testing"[tiab] OR "item bank"[tiab]
17 OR "cross-cultural equivalence"[tiab])
18
19

20 **#4 exclusie**

21 NOT ('delphi-technique'[ti] OR cross-sectional[ti] OR "addresses"[Publication Type] OR
22 "biography"[Publication Type] OR "case reports"[Publication Type] OR "comment"[Publication
23 Type] OR "directory"[Publication Type] OR "editorial"[Publication Type] OR
24 "festschrift"[Publication Type] OR "interview"[Publication Type] OR "lectures"[Publication Type]
25 OR "legal cases"[Publication Type] OR "legislation"[Publication Type] OR "letter"[Publication
26 Type] OR "news"[Publication Type] OR "newspaper article"[Publication Type] OR "patient
27 education handout"[Publication Type] OR "popular works"[Publication Type] OR
28 "congresses"[Publication Type] OR "consensus development conference"[Publication Type] OR
29 "consensus development conference, nih"[Publication Type] OR "practice guideline"[Publication
30 Type]) NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60